{"id": "209_419_1_275", "text": "Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death.", "text_with_entity_marker": "Mutations in [E1]LRRK2[/E1] increase phosphorylation of [E2]peroxiredoxin 3[/E2] exacerbating oxidative stress-induced neuronal death.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LRRK2", "entity_1_idx": [[13, 18]], "entity_1_idx_in_text_with_entity_marker": [17, 22], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "peroxiredoxin 3", "entity_2_idx": [[47, 62]], "entity_2_idx_in_text_with_entity_marker": [60, 75], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "209_420_3_276", "text": "Here, we show that LRRK2 interacts with human peroxiredoxin 3 (PRDX3), a mitochondrial member of the antioxidant family of thioredoxin (Trx) peroxidases", "text_with_entity_marker": "Here, we show that [E1]LRRK2[/E1] interacts with [E2]human peroxiredoxin 3 (PRDX3)[/E2], a mitochondrial member of the antioxidant family of thioredoxin (Trx) peroxidases", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LRRK2", "entity_1_idx": [[19, 24]], "entity_1_idx_in_text_with_entity_marker": [23, 28], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "human peroxiredoxin 3 (PRDX3)", "entity_2_idx": [[40, 69]], "entity_2_idx_in_text_with_entity_marker": [53, 82], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "178_358_4_227", "text": "The N-terminal (BIR1) and C-terminal (BIR3) BIR domains of cIAP1 were determined to be necessary and sufficient for binding TRAF2 and SMAC, respectively", "text_with_entity_marker": "The N-terminal ([E1]BIR1[/E1]) and C-terminal (BIR3) BIR domains of cIAP1 were determined to be necessary and sufficient for binding [E2]TRAF2[/E2] and SMAC, respectively", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "BIR1", "entity_1_idx": [[16, 20]], "entity_1_idx_in_text_with_entity_marker": [20, 24], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "TRAF2", "entity_2_idx": [[124, 129]], "entity_2_idx_in_text_with_entity_marker": [137, 142], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "178_358_4_228", "text": "The N-terminal (BIR1) and C-terminal (BIR3) BIR domains of cIAP1 were determined to be necessary and sufficient for binding TRAF2 and SMAC, respectively", "text_with_entity_marker": "The N-terminal ([E1]BIR1[/E1]) and C-terminal (BIR3) BIR domains of cIAP1 were determined to be necessary and sufficient for binding TRAF2 and [E2]SMAC[/E2], respectively", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "BIR1", "entity_1_idx": [[16, 20]], "entity_1_idx_in_text_with_entity_marker": [20, 24], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "SMAC", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "178_358_4_229", "text": "The N-terminal (BIR1) and C-terminal (BIR3) BIR domains of cIAP1 were determined to be necessary and sufficient for binding TRAF2 and SMAC, respectively", "text_with_entity_marker": "The N-terminal (BIR1) and C-terminal ([E1]BIR3[/E1]) BIR domains of cIAP1 were determined to be necessary and sufficient for binding [E2]TRAF2[/E2] and SMAC, respectively", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "BIR3", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "TRAF2", "entity_2_idx": [[124, 129]], "entity_2_idx_in_text_with_entity_marker": [137, 142], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "178_358_4_230", "text": "The N-terminal (BIR1) and C-terminal (BIR3) BIR domains of cIAP1 were determined to be necessary and sufficient for binding TRAF2 and SMAC, respectively", "text_with_entity_marker": "The N-terminal (BIR1) and C-terminal ([E1]BIR3[/E1]) BIR domains of cIAP1 were determined to be necessary and sufficient for binding TRAF2 and [E2]SMAC[/E2], respectively", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "BIR3", "entity_1_idx": [[38, 42]], "entity_1_idx_in_text_with_entity_marker": [42, 46], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "SMAC", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "179_360_4_231", "text": "Here we show that upon hyperphosphorylation, hDlg interacts with the beta-TrCP ubiquitin ligase receptor through a DSGLPS motif within its Src homology 3 domain", "text_with_entity_marker": "Here we show that upon hyperphosphorylation, [E1]hDlg[/E1] interacts with the [E2]beta-TrCP ubiquitin ligase receptor[/E2] through a DSGLPS motif within its Src homology 3 domain", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "hDlg", "entity_1_idx": [[45, 49]], "entity_1_idx_in_text_with_entity_marker": [49, 53], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "beta-TrCP ubiquitin ligase receptor", "entity_2_idx": [[69, 104]], "entity_2_idx_in_text_with_entity_marker": [82, 117], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "170_342_1_221", "text": "We have previously shown that casein kinase (CK) Ialpha from mammalian brain phosphorylates 14-3-3 zeta and tau isoforms on residue 233", "text_with_entity_marker": "We have previously shown that [E1]casein kinase (CK) Ialpha[/E1] from mammalian brain phosphorylates [E2]14-3-3[/E2] zeta and tau isoforms on residue 233", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "casein kinase (CK) Ialpha", "entity_1_idx": [[30, 55]], "entity_1_idx_in_text_with_entity_marker": [34, 59], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "14-3-3", "entity_2_idx": [[92, 98]], "entity_2_idx_in_text_with_entity_marker": [105, 111], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "263_528_3_352", "text": "By immunoprecipitation experiments, we show that LMP1 interacts with Ubc9, the single reported SUMO-conjugating enzyme", "text_with_entity_marker": "By immunoprecipitation experiments, we show that [E1]LMP1[/E1] interacts with [E2]Ubc9[/E2], the single reported SUMO-conjugating enzyme", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "LMP1", "entity_1_idx": [[49, 53]], "entity_1_idx_in_text_with_entity_marker": [53, 57], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Ubc9", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "126_254_3_173", "text": "Using a functional screen of a cDNA expression library, we have identified two putative ligands of the WW domain of YAP, which we named WBP-1 and WBP-2", "text_with_entity_marker": "Using a functional screen of a cDNA expression library, we have identified two putative ligands of the WW domain of [E1]YAP[/E1], which we named [E2]WBP-1[/E2] and WBP-2", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "YAP", "entity_1_idx": [[116, 119]], "entity_1_idx_in_text_with_entity_marker": [120, 123], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "WBP-1", "entity_2_idx": [[136, 141]], "entity_2_idx_in_text_with_entity_marker": [149, 154], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "126_254_3_174", "text": "Using a functional screen of a cDNA expression library, we have identified two putative ligands of the WW domain of YAP, which we named WBP-1 and WBP-2", "text_with_entity_marker": "Using a functional screen of a cDNA expression library, we have identified two putative ligands of the WW domain of [E1]YAP[/E1], which we named WBP-1 and [E2]WBP-2[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "YAP", "entity_1_idx": [[116, 119]], "entity_1_idx_in_text_with_entity_marker": [120, 123], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "WBP-2", "entity_2_idx": [[146, 151]], "entity_2_idx_in_text_with_entity_marker": [159, 164], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "12_25_1_23", "text": "Autolytic activity of human calpain 7 is enhanced by ESCRT-III-related protein IST1 through MIT-MIM interaction.", "text_with_entity_marker": "Autolytic activity of human calpain 7 is enhanced by ESCRT-III-related protein [E1]IST1[/E1][E2]calpain 7[/E2] is enhanced by ESCRT-III-related protein IST1 through MIT-MIM interaction.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IST1", "entity_1_idx": [[79, 83]], "entity_1_idx_in_text_with_entity_marker": [83, 87], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "calpain 7", "entity_2_idx": [[28, 37]], "entity_2_idx_in_text_with_entity_marker": [96, 105], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "12_26_4_24", "text": "In this study, we investigated the interaction between calpain 7 and a newly reported ESCRT-III family member, increased sodium tolerance-1 (IST1), which possesses two different types of MIT-interacting motifs (MIM1 and MIM2)", "text_with_entity_marker": "In this study, we investigated the interaction between calpain 7 and a newly reported ESCRT-III family member, increased sodium tolerance-1 ([E1]IST1[/E1][E2]calpain 7[/E2] and a newly reported ESCRT-III family member, increased sodium tolerance-1 (IST1), which possesses two different types of MIT-interacting motifs (MIM1 and MIM2)", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IST1", "entity_1_idx": [[141, 145]], "entity_1_idx_in_text_with_entity_marker": [145, 149], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "calpain 7", "entity_2_idx": [[55, 64]], "entity_2_idx_in_text_with_entity_marker": [158, 167], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "89_179_1_118", "text": "Deletion of Phe508 in the first nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator increases its affinity for the heat shock cognate 70 chaperone.", "text_with_entity_marker": "Deletion of Phe508 in the first nucleotide-binding domain of the [E1]cystic fibrosis transmembrane conductance regulator[/E1] increases its affinity for the [E2]heat shock cognate 70[/E2] chaperone.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cystic fibrosis transmembrane conductance regulator", "entity_1_idx": [[65, 116]], "entity_1_idx_in_text_with_entity_marker": [69, 120], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "heat shock cognate 70", "entity_2_idx": [[148, 169]], "entity_2_idx_in_text_with_entity_marker": [161, 182], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "89_180_3_119", "text": "We recently proposed that the ERQC proceeds along several checkpoints, the first of which, utilizing the chaperone heat shock cognate 70 (Hsc70), is the major one directing F508del-CFTR for proteolysis", "text_with_entity_marker": "We recently proposed that the ERQC proceeds along several checkpoints, the first of which, utilizing the chaperone [E1]heat shock cognate 70 (Hsc70)[/E1], is the major one directing [E2]F508del-CFTR[/E2] for proteolysis", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "heat shock cognate 70 (Hsc70)", "entity_1_idx": [[115, 144]], "entity_1_idx_in_text_with_entity_marker": [119, 148], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "F508del-CFTR", "entity_2_idx": [[173, 185]], "entity_2_idx_in_text_with_entity_marker": [186, 198], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "112_225_1_150", "text": "Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function.", "text_with_entity_marker": "Bone overgrowth-associated mutations in the [E1]LRP4[/E1] gene impair [E2]sclerostin[/E2] facilitator function.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "LRP4", "entity_1_idx": [[44, 48]], "entity_1_idx_in_text_with_entity_marker": [48, 52], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "sclerostin", "entity_2_idx": [[61, 71]], "entity_2_idx_in_text_with_entity_marker": [74, 84], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "112_226_11_151", "text": "Together these data indicate that the interaction of sclerostin with LRP4 is required to mediate the inhibitory function of sclerostin on bone formation, thus identifying a novel role for LRP4 in bone.", "text_with_entity_marker": "Together these data indicate that the interaction of sclerostin with [E1]LRP4[/E1][E2]sclerostin[/E2] with LRP4 is required to mediate the inhibitory function of sclerostin on bone formation, thus identifying a novel role for LRP4 in bone.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "LRP4", "entity_1_idx": [[69, 73]], "entity_1_idx_in_text_with_entity_marker": [73, 77], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "sclerostin", "entity_2_idx": [[53, 63]], "entity_2_idx_in_text_with_entity_marker": [86, 96], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "24_49_1_46", "text": "A major mutation of KIF21A associated with congenital fibrosis of the extraocular muscles type 1 (CFEOM1) enhances translocation of Kank1 to the membrane.", "text_with_entity_marker": "A major mutation of [E1]KIF21A[/E1] associated with congenital fibrosis of the extraocular muscles type 1 (CFEOM1) enhances translocation of [E2]Kank1[/E2] to the membrane.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "KIF21A", "entity_1_idx": [[20, 26]], "entity_1_idx_in_text_with_entity_marker": [24, 30], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Kank1", "entity_2_idx": [[132, 137]], "entity_2_idx_in_text_with_entity_marker": [145, 150], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "24_50_6_47", "text": "These results suggest that KIF21A regulates the distribution of Kank1 and that KIF21A mutations associated with CFEOM1 enhanced the accumulation of Kank1 in the membrane fraction", "text_with_entity_marker": "These results suggest that [E1]KIF21A[/E1] regulates the distribution of [E2]Kank1[/E2] and that KIF21A mutations associated with CFEOM1 enhanced the accumulation of Kank1 in the membrane fraction", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "KIF21A", "entity_1_idx": [[27, 33]], "entity_1_idx_in_text_with_entity_marker": [31, 37], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Kank1", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "221_444_8_292", "text": "Our findings suggest a possible functional association of SMN with RNase P and RNase MRP complexes.", "text_with_entity_marker": "Our findings suggest a possible functional association of [E1]SMN[/E1] with [E2]RNase P[/E2] and RNase MRP complexes.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "SMN", "entity_1_idx": [[58, 61]], "entity_1_idx_in_text_with_entity_marker": [62, 65], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "RNase P", "entity_2_idx": [[67, 74]], "entity_2_idx_in_text_with_entity_marker": [80, 87], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "221_444_8_293", "text": "Our findings suggest a possible functional association of SMN with RNase P and RNase MRP complexes.", "text_with_entity_marker": "Our findings suggest a possible functional association of [E1]SMN[/E1] with RNase P and RNase [E2]MRP[/E2] complexes.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "SMN", "entity_1_idx": [[58, 61]], "entity_1_idx_in_text_with_entity_marker": [62, 65], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "MRP", "entity_2_idx": [[85, 88]], "entity_2_idx_in_text_with_entity_marker": [98, 101], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "157_316_2_209", "text": "In this report, we demonstrate that the cellular transcription factor Oct-1 cooperates with the EBV immediate-early protein BRLF1 (R, Rta) to induce lytic viral reactivation", "text_with_entity_marker": "In this report, we demonstrate that the cellular transcription factor [E1]Oct-1[/E1] cooperates with the EBV immediate-early protein [E2]BRLF1[/E2] (R, Rta) to induce lytic viral reactivation", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Oct-1", "entity_1_idx": [[70, 75]], "entity_1_idx_in_text_with_entity_marker": [74, 79], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "BRLF1", "entity_2_idx": [[124, 129]], "entity_2_idx_in_text_with_entity_marker": [137, 142], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "185_371_1_241", "text": "Structural basis for ARF1-mediated recruitment of ARHGAP21 to Golgi membranes.", "text_with_entity_marker": "Structural basis for [E1]ARF1[/E1]-mediated recruitment of [E2]ARHGAP21[/E2] to Golgi membranes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "ARF1", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "ARHGAP21", "entity_2_idx": [[50, 58]], "entity_2_idx_in_text_with_entity_marker": [63, 71], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "185_372_2_242", "text": "ARHGAP21 is recruited to the Golgi by binding to another small GTPase, ARF1", "text_with_entity_marker": "ARHGAP21 is recruited to the Golgi by binding to another small GTPase, [E1]ARF1[/E1][E2]ARHGAP21[/E2] is recruited to the Golgi by binding to another small GTPase, ARF1", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "ARF1", "entity_1_idx": [[71, 75]], "entity_1_idx_in_text_with_entity_marker": [75, 79], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "ARHGAP21", "entity_2_idx": [[0, 8]], "entity_2_idx_in_text_with_entity_marker": [88, 96], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "42_86_1_66", "text": "p47, a p97-binding protein, functions in Golgi membrane fusion together with p97 and VCIP135, another p97-binding protein", "text_with_entity_marker": "[E1]p47[/E1], a [E2]p97[/E2]-binding protein, functions in Golgi membrane fusion together with p97 and VCIP135, another p97-binding protein", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "p47", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "p97", "entity_2_idx": [[7, 10]], "entity_2_idx_in_text_with_entity_marker": [20, 23], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "42_86_1_67", "text": "p47, a p97-binding protein, functions in Golgi membrane fusion together with p97 and VCIP135, another p97-binding protein", "text_with_entity_marker": "p47, a [E1]p97[/E1]-binding protein, functions in Golgi membrane fusion together with p97 and [E2]VCIP135[/E2], another p97-binding protein", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "p97", "entity_1_idx": [[7, 10]], "entity_1_idx_in_text_with_entity_marker": [11, 14], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "VCIP135", "entity_2_idx": [[85, 92]], "entity_2_idx_in_text_with_entity_marker": [98, 105], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "36_73_1_63", "text": "Independent and interdependent functions of LAF1 and HFR1 in phytochrome A signaling.", "text_with_entity_marker": "Independent and interdependent functions of [E1]LAF1[/E1] and [E2]HFR1[/E2] in phytochrome A signaling.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LAF1", "entity_1_idx": [[44, 48]], "entity_1_idx_in_text_with_entity_marker": [48, 52], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "HFR1", "entity_2_idx": [[53, 57]], "entity_2_idx_in_text_with_entity_marker": [66, 70], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "29_60_7_53", "text": "The slower migrating species of IkappaBalpha from pervanadate-treated cells was tyrosine-phosphorylated as revealed by cross-reactivity with anti-phosphotyrosine antibodies, by the ability of the specific tyrosine phosphatase PTP1B to dephosphorylate it, and by phosphoamino acid analysis of IkappaBalpha immunoprecipitated from 32P-labeled cells", "text_with_entity_marker": "The slower migrating species of IkappaBalpha from pervanadate-treated cells was tyrosine-phosphorylated as revealed by cross-reactivity with anti-phosphotyrosine antibodies, by the ability of the specific tyrosine phosphatase [E1]PTP1B[/E1][E2]IkappaBalpha[/E2] from pervanadate-treated cells was tyrosine-phosphorylated as revealed by cross-reactivity with anti-phosphotyrosine antibodies, by the ability of the specific tyrosine phosphatase PTP1B to dephosphorylate it, and by phosphoamino acid analysis of IkappaBalpha immunoprecipitated from 32P-labeled cells", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "PTP1B", "entity_1_idx": [[226, 231]], "entity_1_idx_in_text_with_entity_marker": [230, 235], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "IkappaBalpha", "entity_2_idx": [[32, 44]], "entity_2_idx_in_text_with_entity_marker": [244, 256], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "114_229_1_153", "text": "LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth.", "text_with_entity_marker": "[E1]LRRK2[/E1] phosphorylates tubulin-associated [E2]tau[/E2] but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LRRK2", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "tau", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "114_230_3_154", "text": "These results provide direct proof that tau is a physiological substrate for LRRK2", "text_with_entity_marker": "These results provide direct proof that tau is a physiological substrate for [E1]LRRK2[/E1][E2]tau[/E2] is a physiological substrate for LRRK2", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LRRK2", "entity_1_idx": [[77, 82]], "entity_1_idx_in_text_with_entity_marker": [81, 86], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "tau", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [95, 98], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "122_245_1_171", "text": "Yeast epiarginase regulation, an enzyme-enzyme activity control: identification of residues of ornithine carbamoyltransferase and arginase responsible for enzyme catalytic and regulatory activities.", "text_with_entity_marker": "Yeast epiarginase regulation, an enzyme-enzyme activity control: identification of residues of [E1]ornithine carbamoyltransferase[/E1][E2]arginase[/E2] regulation, an enzyme-enzyme activity control: identification of residues of ornithine carbamoyltransferase and arginase responsible for enzyme catalytic and regulatory activities.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "ornithine carbamoyltransferase", "entity_1_idx": [[95, 125]], "entity_1_idx_in_text_with_entity_marker": [99, 129], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "arginase", "entity_2_idx": [[9, 17]], "entity_2_idx_in_text_with_entity_marker": [138, 146], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "122_246_1_172", "text": "In the presence of ornithine and arginine, ornithine carbamoyltransferase (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active", "text_with_entity_marker": "In the presence of ornithine and arginine, [E1]ornithine carbamoyltransferase (OTCase)[/E1] and [E2]arginase[/E2] form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "ornithine carbamoyltransferase (OTCase)", "entity_1_idx": [[43, 82]], "entity_1_idx_in_text_with_entity_marker": [47, 86], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "arginase", "entity_2_idx": [[87, 95]], "entity_2_idx_in_text_with_entity_marker": [100, 108], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "280_561_1_376", "text": "Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2.", "text_with_entity_marker": "Physical and functional interactions among [E1]AP-2[/E1] transcription factors, [E2]p300/CREB-binding protein[/E2], and CITED2.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "AP-2", "entity_1_idx": [[43, 47]], "entity_1_idx_in_text_with_entity_marker": [47, 51], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "p300/CREB-binding protein", "entity_2_idx": [[71, 96]], "entity_2_idx_in_text_with_entity_marker": [84, 109], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "280_561_1_377", "text": "Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2.", "text_with_entity_marker": "Physical and functional interactions among [E1]AP-2[/E1] transcription factors, p300/CREB-binding protein, and [E2]CITED2[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "AP-2", "entity_1_idx": [[43, 47]], "entity_1_idx_in_text_with_entity_marker": [47, 51], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "CITED2", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "280_561_1_378", "text": "Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2.", "text_with_entity_marker": "Physical and functional interactions among AP-2 transcription factors, [E1]p300/CREB-binding protein[/E1], and [E2]CITED2[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p300/CREB-binding protein", "entity_1_idx": [[71, 96]], "entity_1_idx_in_text_with_entity_marker": [75, 100], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "CITED2", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "280_562_12_379", "text": "Our results suggest a model wherein interactions among TFAP2A, CITED2, and p300/CBP are necessary for TFAP2A-mediated transcriptional activation and for normal neural tube and cardiac development.", "text_with_entity_marker": "Our results suggest a model wherein interactions among [E1]TFAP2A[/E1], [E2]CITED2[/E2], and p300/CBP are necessary for TFAP2A-mediated transcriptional activation and for normal neural tube and cardiac development.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TFAP2A", "entity_1_idx": [[55, 61]], "entity_1_idx_in_text_with_entity_marker": [59, 65], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "CITED2", "entity_2_idx": [[63, 69]], "entity_2_idx_in_text_with_entity_marker": [76, 82], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "280_562_12_380", "text": "Our results suggest a model wherein interactions among TFAP2A, CITED2, and p300/CBP are necessary for TFAP2A-mediated transcriptional activation and for normal neural tube and cardiac development.", "text_with_entity_marker": "Our results suggest a model wherein interactions among [E1]TFAP2A[/E1], CITED2, and [E2]p300/CBP[/E2] are necessary for TFAP2A-mediated transcriptional activation and for normal neural tube and cardiac development.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TFAP2A", "entity_1_idx": [[55, 61]], "entity_1_idx_in_text_with_entity_marker": [59, 65], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "p300/CBP", "entity_2_idx": [[75, 83]], "entity_2_idx_in_text_with_entity_marker": [88, 96], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "280_562_12_381", "text": "Our results suggest a model wherein interactions among TFAP2A, CITED2, and p300/CBP are necessary for TFAP2A-mediated transcriptional activation and for normal neural tube and cardiac development.", "text_with_entity_marker": "Our results suggest a model wherein interactions among TFAP2A, [E1]CITED2[/E1], and [E2]p300/CBP[/E2] are necessary for TFAP2A-mediated transcriptional activation and for normal neural tube and cardiac development.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CITED2", "entity_1_idx": [[63, 69]], "entity_1_idx_in_text_with_entity_marker": [67, 73], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "p300/CBP", "entity_2_idx": [[75, 83]], "entity_2_idx_in_text_with_entity_marker": [88, 96], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "130_261_1_176", "text": "Cdc42 regulation of kinase activity and signaling by the yeast p21-activated kinase Ste20.", "text_with_entity_marker": "Cdc42 regulation of kinase activity and signaling by the yeast [E1]p21[/E1]-activated kinase [E2]Ste20[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p21", "entity_1_idx": [[63, 66]], "entity_1_idx_in_text_with_entity_marker": [67, 70], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Ste20", "entity_2_idx": [[84, 89]], "entity_2_idx_in_text_with_entity_marker": [97, 102], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "130_261_1_177", "text": "Cdc42 regulation of kinase activity and signaling by the yeast p21-activated kinase Ste20.", "text_with_entity_marker": "[E1]Cdc42[/E1] regulation of kinase activity and signaling by the yeast p21-activated kinase [E2]Ste20[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Cdc42", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Ste20", "entity_2_idx": [[84, 89]], "entity_2_idx_in_text_with_entity_marker": [97, 102], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "130_262_9_178", "text": "In total, our observations indicate that Cdc42 converts Ste20 to an active form, while pathway stimuli regulate the ability of this active Ste20 to trigger signaling through a particular pathway.", "text_with_entity_marker": "In total, our observations indicate that [E1]Cdc42[/E1] converts [E2]Ste20[/E2] to an active form, while pathway stimuli regulate the ability of this active Ste20 to trigger signaling through a particular pathway.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Cdc42", "entity_1_idx": [[41, 46]], "entity_1_idx_in_text_with_entity_marker": [45, 50], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "Ste20", "entity_2_idx": [[56, 61]], "entity_2_idx_in_text_with_entity_marker": [69, 74], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "194_389_1_255", "text": "Interaction of CarD with RNA polymerase mediates Mycobacterium tuberculosis viability, rifampin resistance, and pathogenesis.", "text_with_entity_marker": "Interaction of [E1]CarD[/E1] with [E2]RNA polymerase[/E2] mediates Mycobacterium tuberculosis viability, rifampin resistance, and pathogenesis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CarD", "entity_1_idx": [[15, 19]], "entity_1_idx_in_text_with_entity_marker": [19, 23], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "RNA polymerase", "entity_2_idx": [[25, 39]], "entity_2_idx_in_text_with_entity_marker": [38, 52], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "194_390_5_256", "text": "CarD associates with the RNA polymerase (RNAP), but it has been unknown which of the diverse functions of CarD are mediated through the RNAP; this question must be answered to understand the CarD mechanism of action", "text_with_entity_marker": "[E1]CarD[/E1] associates with the [E2]RNA polymerase (RNAP)[/E2], but it has been unknown which of the diverse functions of CarD are mediated through the RNAP; this question must be answered to understand the CarD mechanism of action", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CarD", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "RNA polymerase (RNAP)", "entity_2_idx": [[25, 46]], "entity_2_idx_in_text_with_entity_marker": [38, 59], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "265_532_15_354", "text": "Mutation of conserved residues in ropporin or RII prevents binding to AKAP110", "text_with_entity_marker": "Mutation of conserved residues in [E1]ropporin[/E1] or RII prevents binding to [E2]AKAP[/E2]110", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "ropporin", "entity_1_idx": [[34, 42]], "entity_1_idx_in_text_with_entity_marker": [38, 46], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "AKAP", "entity_2_idx": [[70, 74]], "entity_2_idx_in_text_with_entity_marker": [83, 87], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "227_456_2_297", "text": "Here, we demonstrate that a tripartite nexus between Bcl-xL, cytoplasmic p53, and PUMA coordinates these distinct p53 functions", "text_with_entity_marker": "Here, we demonstrate that a tripartite nexus between [E1]Bcl-xL[/E1], cytoplasmic p53, and [E2]PUMA[/E2] coordinates these distinct p53 functions", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Bcl-xL", "entity_1_idx": [[53, 59]], "entity_1_idx_in_text_with_entity_marker": [57, 63], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "PUMA", "entity_2_idx": [[82, 86]], "entity_2_idx_in_text_with_entity_marker": [95, 99], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "227_456_2_298", "text": "Here, we demonstrate that a tripartite nexus between Bcl-xL, cytoplasmic p53, and PUMA coordinates these distinct p53 functions", "text_with_entity_marker": "Here, we demonstrate that a tripartite nexus between [E1]Bcl-xL[/E1], cytoplasmic [E2]p53[/E2], and PUMA coordinates these distinct p53 functions", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Bcl-xL", "entity_1_idx": [[53, 59]], "entity_1_idx_in_text_with_entity_marker": [57, 63], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "302_606_2_417", "text": "c-Kit binds specifically to the 10th PDZ domain of MUPP-1 via its C-terminal sequence", "text_with_entity_marker": "[E1]c-Kit[/E1] binds specifically to the 10th PDZ domain of [E2]MUPP-1[/E2] via its C-terminal sequence", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Kit", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "MUPP-1", "entity_2_idx": [[51, 57]], "entity_2_idx_in_text_with_entity_marker": [64, 70], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "143_287_1_199", "text": "Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3.", "text_with_entity_marker": "Regulation of MDMX nuclear import and degradation by [E1]Chk2[/E1][E2]MDMX[/E2] nuclear import and degradation by Chk2 and 14-3-3.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Chk2", "entity_1_idx": [[53, 57]], "entity_1_idx_in_text_with_entity_marker": [57, 61], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "MDMX", "entity_2_idx": [[14, 18]], "entity_2_idx_in_text_with_entity_marker": [70, 74], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "143_287_1_200", "text": "Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3.", "text_with_entity_marker": "Regulation of MDMX nuclear import and degradation by Chk2 and [E1]14-3-3[/E1][E2]MDMX[/E2] nuclear import and degradation by Chk2 and 14-3-3.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "14-3-3", "entity_1_idx": [[62, 68]], "entity_1_idx_in_text_with_entity_marker": [66, 72], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "MDMX", "entity_2_idx": [[14, 18]], "entity_2_idx_in_text_with_entity_marker": [81, 85], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "143_288_7_201", "text": "Chk2 and 14-3-3 cooperatively stimulate MDMX ubiquitination and overcome the inhibition of p53 by MDMX", "text_with_entity_marker": "[E1]Chk2[/E1] and 14-3-3 cooperatively stimulate [E2]MDMX[/E2] ubiquitination and overcome the inhibition of p53 by MDMX", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Chk2", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "MDMX", "entity_2_idx": [[40, 44]], "entity_2_idx_in_text_with_entity_marker": [53, 57], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "143_288_7_202", "text": "Chk2 and 14-3-3 cooperatively stimulate MDMX ubiquitination and overcome the inhibition of p53 by MDMX", "text_with_entity_marker": "Chk2 and [E1]14-3-3[/E1] cooperatively stimulate [E2]MDMX[/E2] ubiquitination and overcome the inhibition of p53 by MDMX", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "14-3-3", "entity_1_idx": [[9, 15]], "entity_1_idx_in_text_with_entity_marker": [13, 19], "entity_1_type": "gene", "entity_1_type_id": 0, "entity_2": "MDMX", "entity_2_idx": [[40, 44]], "entity_2_idx_in_text_with_entity_marker": [53, 57], "entity_2_type": "gene", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1428_AIMed.d169.s1428.p0", "text": "We have cloned a cDNA encoding an IL-13 binding protein (IL-13R) from the Caki-1 human renal carcinoma cell line.", "text_with_entity_marker": "We have cloned a cDNA encoding an [E1]IL-13[/E1] binding protein ([E2]IL-13R[/E2]) from the Caki-1 human renal carcinoma cell line.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-13", "entity_1_idx": [[34, 39]], "entity_1_idx_in_text_with_entity_marker": [38, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13R", "entity_2_idx": [[57, 63]], "entity_2_idx_in_text_with_entity_marker": [70, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d169.s1431_AIMed.d169.s1431.p0", "text": "COS-7 cells transfected with the IL-13R cDNA bind IL-13 with high affinity but do not bind IL-4.", "text_with_entity_marker": "COS-7 cells transfected with the [E1]IL-13R[/E1] cDNA bind [E2]IL-13[/E2] with high affinity but do not bind IL-4.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-13R", "entity_1_idx": [[33, 39]], "entity_1_idx_in_text_with_entity_marker": [37, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-13", "entity_2_idx": [[50, 55]], "entity_2_idx_in_text_with_entity_marker": [63, 68], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1675_AIMed.d197.s1675.p1", "text": "Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction.", "text_with_entity_marker": "Analysis of the human [E1]interleukin-6[/E1]/human [E2]interleukin-6 receptor[/E2] binding interface at the amino acid level: proposed mechanism of interaction.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "interleukin-6", "entity_1_idx": [[22, 35]], "entity_1_idx_in_text_with_entity_marker": [26, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-6 receptor", "entity_2_idx": [[42, 64]], "entity_2_idx_in_text_with_entity_marker": [55, 77], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p2", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between [E1]interleukin-6[/E1] (IL-6) and [E2]IL-6 receptor[/E2] (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "interleukin-6", "entity_1_idx": [[24, 37]], "entity_1_idx_in_text_with_entity_marker": [28, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6 receptor", "entity_2_idx": [[49, 62]], "entity_2_idx_in_text_with_entity_marker": [62, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p3", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between [E1]interleukin-6[/E1] (IL-6) and IL-6 receptor ([E2]IL-6R[/E2]) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "interleukin-6", "entity_1_idx": [[24, 37]], "entity_1_idx_in_text_with_entity_marker": [28, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p6", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between interleukin-6 ([E1]IL-6[/E1]) and [E2]IL-6 receptor[/E2] (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[39, 43]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6 receptor", "entity_2_idx": [[49, 62]], "entity_2_idx_in_text_with_entity_marker": [62, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1676_AIMed.d197.s1676.p10", "text": "The interaction between interleukin-6 (IL-6) and IL-6 receptor (IL-6R) is the initial and most specific step in the IL-6 signaling pathway.", "text_with_entity_marker": "The interaction between interleukin-6 (IL-6) and [E1]IL-6[/E1] receptor ([E2]IL-6R[/E2]) is the initial and most specific step in the IL-6 signaling pathway.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[49, 53]], "entity_1_idx_in_text_with_entity_marker": [53, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1678_AIMed.d197.s1678.p1", "text": "We studied the human IL-6 (hIL-6)/hIL-6R binding interface by a combination of molecular modelling and site-directed mutagenesis.", "text_with_entity_marker": "We studied the human [E1]IL-6[/E1] (hIL-6)/[E2]hIL-6R[/E2] binding interface by a combination of molecular modelling and site-directed mutagenesis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-6R", "entity_2_idx": [[34, 40]], "entity_2_idx_in_text_with_entity_marker": [47, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1678_AIMed.d197.s1678.p2", "text": "We studied the human IL-6 (hIL-6)/hIL-6R binding interface by a combination of molecular modelling and site-directed mutagenesis.", "text_with_entity_marker": "We studied the human IL-6 ([E1]hIL-6[/E1])/[E2]hIL-6R[/E2] binding interface by a combination of molecular modelling and site-directed mutagenesis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "hIL-6", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-6R", "entity_2_idx": [[34, 40]], "entity_2_idx_in_text_with_entity_marker": [47, 53], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1681_AIMed.d197.s1681.p0", "text": "Following this hypothesis, we altered in hIL-6 and hIL-6R residues predicted to reside in the contact region and to interact with each other.", "text_with_entity_marker": "Following this hypothesis, we altered in [E1]hIL-6[/E1] and [E2]hIL-6R[/E2] residues predicted to reside in the contact region and to interact with each other.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "hIL-6", "entity_1_idx": [[41, 46]], "entity_1_idx_in_text_with_entity_marker": [45, 50], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hIL-6R", "entity_2_idx": [[51, 57]], "entity_2_idx_in_text_with_entity_marker": [64, 70], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d197.s1682_AIMed.d197.s1682.p0", "text": "We studied the capacity of these mutants to form an IL-6/IL-6R complex and their ability to transduce the signal.", "text_with_entity_marker": "We studied the capacity of these mutants to form an [E1]IL-6[/E1]/[E2]IL-6R[/E2] complex and their ability to transduce the signal.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-6R", "entity_2_idx": [[57, 62]], "entity_2_idx_in_text_with_entity_marker": [70, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1665_AIMed.d196.s1665.p0", "text": "HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint.", "text_with_entity_marker": "[E1]HOX11[/E1] interacts with protein phosphatases [E2]PP2A[/E2] and PP1 and disrupts a G2/M cell-cycle checkpoint.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP2A", "entity_2_idx": [[42, 46]], "entity_2_idx_in_text_with_entity_marker": [55, 59], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1665_AIMed.d196.s1665.p1", "text": "HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint.", "text_with_entity_marker": "[E1]HOX11[/E1] interacts with protein phosphatases PP2A and [E2]PP1[/E2] and disrupts a G2/M cell-cycle checkpoint.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP1", "entity_2_idx": [[51, 54]], "entity_2_idx_in_text_with_entity_marker": [64, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p1", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein [E1]HOX11[/E1] interacted with protein [E2]serine-threonine phosphatase 2A catalytic subunit[/E2] (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "serine-threonine phosphatase 2A catalytic subunit", "entity_2_idx": [[59, 108]], "entity_2_idx_in_text_with_entity_marker": [72, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p2", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein [E1]HOX11[/E1] interacted with protein serine-threonine phosphatase 2A catalytic subunit ([E2]PP2AC[/E2]), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP2AC", "entity_2_idx": [[110, 115]], "entity_2_idx_in_text_with_entity_marker": [123, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p3", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein [E1]HOX11[/E1] interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as [E2]protein phosphatase 1[/E2] (PP1C) in mammalian cells.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein phosphatase 1", "entity_2_idx": [[129, 150]], "entity_2_idx_in_text_with_entity_marker": [142, 163], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1669_AIMed.d196.s1669.p4", "text": "We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 (PP1C) in mammalian cells.", "text_with_entity_marker": "We observed that the protein [E1]HOX11[/E1] interacted with protein serine-threonine phosphatase 2A catalytic subunit (PP2AC), as well as protein phosphatase 1 ([E2]PP1C[/E2]) in mammalian cells.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP1C", "entity_2_idx": [[152, 156]], "entity_2_idx_in_text_with_entity_marker": [165, 169], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1673_AIMed.d196.s1673.p0", "text": "Thus HOX11 is a cellular oncogene that targets PP2A and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters.", "text_with_entity_marker": "Thus [E1]HOX11[/E1] is a cellular oncogene that targets [E2]PP2A[/E2] and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[5, 10]], "entity_1_idx_in_text_with_entity_marker": [9, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP2A", "entity_2_idx": [[47, 51]], "entity_2_idx_in_text_with_entity_marker": [60, 64], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d196.s1673_AIMed.d196.s1673.p1", "text": "Thus HOX11 is a cellular oncogene that targets PP2A and PP1, both of which are targets for oncogenic viruses and chemical tumour promoters.", "text_with_entity_marker": "Thus [E1]HOX11[/E1] is a cellular oncogene that targets PP2A and [E2]PP1[/E2], both of which are targets for oncogenic viruses and chemical tumour promoters.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "HOX11", "entity_1_idx": [[5, 10]], "entity_1_idx_in_text_with_entity_marker": [9, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PP1", "entity_2_idx": [[56, 59]], "entity_2_idx_in_text_with_entity_marker": [69, 72], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s852_AIMed.d101.s852.p1", "text": "The bZIP domains of Fos and Jun mediate a physical association with the TATA box-binding protein.", "text_with_entity_marker": "The bZIP domains of [E1]Fos[/E1] and Jun mediate a physical association with the [E2]TATA box-binding protein[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Fos", "entity_1_idx": [[20, 23]], "entity_1_idx_in_text_with_entity_marker": [24, 27], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA box-binding protein", "entity_2_idx": [[72, 96]], "entity_2_idx_in_text_with_entity_marker": [85, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s852_AIMed.d101.s852.p2", "text": "The bZIP domains of Fos and Jun mediate a physical association with the TATA box-binding protein.", "text_with_entity_marker": "The bZIP domains of Fos and [E1]Jun[/E1] mediate a physical association with the [E2]TATA box-binding protein[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Jun", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA box-binding protein", "entity_2_idx": [[72, 96]], "entity_2_idx_in_text_with_entity_marker": [85, 109], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s853_AIMed.d101.s853.p0", "text": "Fos and Jun oncoproteins form a complex that regulates transcription from promoters containing AP-1 binding sites.", "text_with_entity_marker": "[E1]Fos[/E1] and [E2]Jun[/E2] oncoproteins form a complex that regulates transcription from promoters containing AP-1 binding sites.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Fos", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Jun", "entity_2_idx": [[8, 11]], "entity_2_idx_in_text_with_entity_marker": [21, 24], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s855_AIMed.d101.s855.p1", "text": "The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "text_with_entity_marker": "The ability of [E1]c-Fos[/E1] and c-Jun proteins to interact directly with the [E2]TATA box-binding protein[/E2] (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Fos", "entity_1_idx": [[15, 20]], "entity_1_idx_in_text_with_entity_marker": [19, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA box-binding protein", "entity_2_idx": [[70, 94]], "entity_2_idx_in_text_with_entity_marker": [83, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s855_AIMed.d101.s855.p2", "text": "The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "text_with_entity_marker": "The ability of [E1]c-Fos[/E1] and c-Jun proteins to interact directly with the TATA box-binding protein ([E2]TBP[/E2]), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Fos", "entity_1_idx": [[15, 20]], "entity_1_idx_in_text_with_entity_marker": [19, 24], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[96, 99]], "entity_2_idx_in_text_with_entity_marker": [109, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s855_AIMed.d101.s855.p3", "text": "The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "text_with_entity_marker": "The ability of c-Fos and [E1]c-Jun[/E1] proteins to interact directly with the [E2]TATA box-binding protein[/E2] (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[25, 30]], "entity_1_idx_in_text_with_entity_marker": [29, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TATA box-binding protein", "entity_2_idx": [[70, 94]], "entity_2_idx_in_text_with_entity_marker": [83, 107], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s855_AIMed.d101.s855.p4", "text": "The ability of c-Fos and c-Jun proteins to interact directly with the TATA box-binding protein (TBP), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "text_with_entity_marker": "The ability of c-Fos and [E1]c-Jun[/E1] proteins to interact directly with the TATA box-binding protein ([E2]TBP[/E2]), the general transcription factor required for initiating the assembly of transcription complexes, was investigated.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[25, 30]], "entity_1_idx_in_text_with_entity_marker": [29, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[96, 99]], "entity_2_idx_in_text_with_entity_marker": [109, 112], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p1", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both [E1]c-Fos[/E1] and c-Jun bind specifically and stably to [E2]TBP[/E2].Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Fos", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p5", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and [E1]c-Jun[/E1] bind specifically and stably to [E2]TBP[/E2].Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[97, 102]], "entity_1_idx_in_text_with_entity_marker": [101, 106], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[135, 138]], "entity_2_idx_in_text_with_entity_marker": [148, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p13", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of [E1]c-Fos[/E1] and c-Jun are necessary and sufficient for stable association with [E2]TBP[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Fos", "entity_1_idx": [[229, 234]], "entity_1_idx_in_text_with_entity_marker": [233, 238], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[302, 305]], "entity_2_idx_in_text_with_entity_marker": [315, 318], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s856_AIMed.d101.s856.p14", "text": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and c-Jun are necessary and sufficient for stable association with TBP.", "text_with_entity_marker": "Using co-immunoprecipitation and protein-protein association assays, we show that both c-Fos and c-Jun bind specifically and stably to TBP.Mutational analysis demonstrates that both the basic region and leucine zipper domains of c-Fos and [E1]c-Jun[/E1] are necessary and sufficient for stable association with [E2]TBP[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[239, 244]], "entity_1_idx_in_text_with_entity_marker": [243, 248], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[302, 305]], "entity_2_idx_in_text_with_entity_marker": [315, 318], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s857_AIMed.d101.s857.p0", "text": "A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.", "text_with_entity_marker": "A 51-residue region from the conserved C-terminal region of [E1]TBP[/E1], previously shown to be the binding site for the viral activator protein [E2]E1A[/E2], interacts with c-Fos and c-Jun proteins.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TBP", "entity_1_idx": [[60, 63]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1A", "entity_2_idx": [[137, 140]], "entity_2_idx_in_text_with_entity_marker": [150, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s857_AIMed.d101.s857.p1", "text": "A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.", "text_with_entity_marker": "A 51-residue region from the conserved C-terminal region of [E1]TBP[/E1], previously shown to be the binding site for the viral activator protein E1A, interacts with [E2]c-Fos[/E2] and c-Jun proteins.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TBP", "entity_1_idx": [[60, 63]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Fos", "entity_2_idx": [[157, 162]], "entity_2_idx_in_text_with_entity_marker": [170, 175], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s857_AIMed.d101.s857.p2", "text": "A 51-residue region from the conserved C-terminal region of TBP, previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and c-Jun proteins.", "text_with_entity_marker": "A 51-residue region from the conserved C-terminal region of [E1]TBP[/E1], previously shown to be the binding site for the viral activator protein E1A, interacts with c-Fos and [E2]c-Jun[/E2] proteins.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TBP", "entity_1_idx": [[60, 63]], "entity_1_idx_in_text_with_entity_marker": [64, 67], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[167, 172]], "entity_2_idx_in_text_with_entity_marker": [180, 185], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s858_AIMed.d101.s858.p1", "text": "We propose that c-Fos and c-Jun proteins function as transcriptional activators, in part by recruiting TBP to form complexes to initiate RNA synthesis.", "text_with_entity_marker": "We propose that [E1]c-Fos[/E1] and c-Jun proteins function as transcriptional activators, in part by recruiting [E2]TBP[/E2] to form complexes to initiate RNA synthesis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Fos", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[103, 106]], "entity_2_idx_in_text_with_entity_marker": [116, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d101.s858_AIMed.d101.s858.p2", "text": "We propose that c-Fos and c-Jun proteins function as transcriptional activators, in part by recruiting TBP to form complexes to initiate RNA synthesis.", "text_with_entity_marker": "We propose that c-Fos and [E1]c-Jun[/E1] proteins function as transcriptional activators, in part by recruiting [E2]TBP[/E2] to form complexes to initiate RNA synthesis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[26, 31]], "entity_1_idx_in_text_with_entity_marker": [30, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TBP", "entity_2_idx": [[103, 106]], "entity_2_idx_in_text_with_entity_marker": [116, 119], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1023_AIMed.d121.s1023.p0", "text": "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.", "text_with_entity_marker": "Several hydrophobic amino acids in the [E1]p53[/E1] amino-terminal domain are required for transcriptional activation, binding to [E2]mdm-2[/E2] and the adenovirus 5 E1B 55-kD protein.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mdm-2", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1023_AIMed.d121.s1023.p2", "text": "Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.", "text_with_entity_marker": "Several hydrophobic amino acids in the [E1]p53[/E1] amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus [E2]5 E1B[/E2] 55-kD protein.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "5 E1B", "entity_2_idx": [[146, 151]], "entity_2_idx_in_text_with_entity_marker": [159, 164], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1025_AIMed.d121.s1025.p0", "text": "The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.", "text_with_entity_marker": "The acidic amino terminus of the [E1]p53[/E1] protein has been shown to contain this trans-activation activity as well as the domains for [E2]mdm-2[/E2] and adenovirus 5 E1B 55-kD protein binding.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[33, 36]], "entity_1_idx_in_text_with_entity_marker": [37, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mdm-2", "entity_2_idx": [[129, 134]], "entity_2_idx_in_text_with_entity_marker": [142, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1025_AIMed.d121.s1025.p2", "text": "The acidic amino terminus of the p53 protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus 5 E1B 55-kD protein binding.", "text_with_entity_marker": "The acidic amino terminus of the [E1]p53[/E1] protein has been shown to contain this trans-activation activity as well as the domains for mdm-2 and adenovirus [E2]5 E1B[/E2] 55-kD protein binding.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[33, 36]], "entity_1_idx_in_text_with_entity_marker": [37, 40], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "5 E1B", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1028_AIMed.d121.s1028.p0", "text": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.", "text_with_entity_marker": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human [E1]p53[/E1] are both required for trans-activation activity, binding to the adenovirus [E2]E1B[/E2] 55-kD protein and the human mdm-2-p53 protein in vitro.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[71, 74]], "entity_1_idx_in_text_with_entity_marker": [75, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "E1B", "entity_2_idx": [[150, 153]], "entity_2_idx_in_text_with_entity_marker": [163, 166], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1028_AIMed.d121.s1028.p5", "text": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human mdm-2-p53 protein in vitro.", "text_with_entity_marker": "Rather, the hydrophobic amino acid residues Leu-22 and Trp-23 of human p53 are both required for trans-activation activity, binding to the adenovirus E1B 55-kD protein and the human [E1]mdm-2[/E1]-[E2]p53[/E2] protein in vitro.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "mdm-2", "entity_1_idx": [[182, 187]], "entity_1_idx_in_text_with_entity_marker": [186, 191], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[188, 191]], "entity_2_idx_in_text_with_entity_marker": [201, 204], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1029_AIMed.d121.s1029.p0", "text": "In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between p53 and human mdm-2 (hdm-2).", "text_with_entity_marker": "In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between [E1]p53[/E1] and human [E2]mdm-2[/E2] (hdm-2).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[93, 96]], "entity_1_idx_in_text_with_entity_marker": [97, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "mdm-2", "entity_2_idx": [[107, 112]], "entity_2_idx_in_text_with_entity_marker": [120, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d121.s1029_AIMed.d121.s1029.p1", "text": "In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between p53 and human mdm-2 (hdm-2).", "text_with_entity_marker": "In addition, hydrophobic residues Leu-14 and Phe-19 are crucial for the interactions between [E1]p53[/E1] and human mdm-2 ([E2]hdm-2[/E2]).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p53", "entity_1_idx": [[93, 96]], "entity_1_idx_in_text_with_entity_marker": [97, 100], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "hdm-2", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s682_AIMed.d80.s682.p0", "text": "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis.", "text_with_entity_marker": "[E1]FADD[/E1], a novel death domain-containing protein, interacts with the death domain of [E2]Fas[/E2] and initiates apoptosis.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "FADD", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[82, 85]], "entity_2_idx_in_text_with_entity_marker": [95, 98], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p9", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, [E1]FADD[/E1], which binds [E2]Fas[/E2] and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "FADD", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[134, 137]], "entity_2_idx_in_text_with_entity_marker": [147, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p10", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, [E1]FADD[/E1], which binds Fas and [E2]Fas[/E2]-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "FADD", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[142, 145]], "entity_2_idx_in_text_with_entity_marker": [155, 158], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s683_AIMed.d80.s683.p11", "text": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, FADD, which binds Fas and Fas-FD5, a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "text_with_entity_marker": "Using the cytoplasmic domain of Fas in the yeast two-hybrid system, we have identified a novel interacting protein, [E1]FADD[/E1], which binds Fas and Fas-[E2]FD5[/E2], a mutant of Fas possessing enhanced killing activity, but not the functionally inactive mutants Fas-LPR and Fas-FD8.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "FADD", "entity_1_idx": [[116, 120]], "entity_1_idx_in_text_with_entity_marker": [120, 124], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FD5", "entity_2_idx": [[146, 149]], "entity_2_idx_in_text_with_entity_marker": [159, 162], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s685_AIMed.d80.s685.p1", "text": "A point mutation in FADD, analogous to the lpr mutation of Fas, abolishes its ability to bind Fas, suggesting a death domain to death domain interaction.", "text_with_entity_marker": "A point mutation in [E1]FADD[/E1], analogous to the lpr mutation of Fas, abolishes its ability to bind [E2]Fas[/E2], suggesting a death domain to death domain interaction.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "FADD", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[94, 97]], "entity_2_idx_in_text_with_entity_marker": [107, 110], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s686_AIMed.d80.s686.p8", "text": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by CrmA, a specific inhibitor of the interleukin-1 beta-converting enzyme.", "text_with_entity_marker": "Overexpression of FADD in MCF7 and BJAB cells induces apoptosis, which, like Fas-induced apoptosis, is blocked by [E1]CrmA[/E1], a specific inhibitor of the [E2]interleukin-1 beta-converting enzyme[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CrmA", "entity_1_idx": [[114, 118]], "entity_1_idx_in_text_with_entity_marker": [118, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "interleukin-1 beta-converting enzyme", "entity_2_idx": [[148, 184]], "entity_2_idx_in_text_with_entity_marker": [161, 197], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1074_AIMed.d126.s1074.p2", "text": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.", "text_with_entity_marker": "Using immunoprecipitation techniques, we have determined the rates at which [E1]rhodanese[/E1] and glutamine synthetase (GS) are released from [E2]groEL[/E2] in a form committed to refold to active enzyme.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "rhodanese", "entity_1_idx": [[76, 85]], "entity_1_idx_in_text_with_entity_marker": [80, 89], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1074_AIMed.d126.s1074.p4", "text": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.", "text_with_entity_marker": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and [E1]glutamine synthetase[/E1] (GS) are released from [E2]groEL[/E2] in a form committed to refold to active enzyme.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "glutamine synthetase", "entity_1_idx": [[90, 110]], "entity_1_idx_in_text_with_entity_marker": [94, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1074_AIMed.d126.s1074.p5", "text": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase (GS) are released from groEL in a form committed to refold to active enzyme.", "text_with_entity_marker": "Using immunoprecipitation techniques, we have determined the rates at which rhodanese and glutamine synthetase ([E1]GS[/E1]) are released from [E2]groEL[/E2] in a form committed to refold to active enzyme.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "GS", "entity_1_idx": [[112, 114]], "entity_1_idx_in_text_with_entity_marker": [116, 118], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[134, 139]], "entity_2_idx_in_text_with_entity_marker": [147, 152], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1075_AIMed.d126.s1075.p1", "text": "Rhodanese and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable \"folding arrested\" complexes with groEL.", "text_with_entity_marker": "[E1]Rhodanese[/E1] and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable \"folding arrested\" complexes with [E2]groEL[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Rhodanese", "entity_1_idx": [[0, 9]], "entity_1_idx_in_text_with_entity_marker": [4, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[195, 200]], "entity_2_idx_in_text_with_entity_marker": [208, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1075_AIMed.d126.s1075.p2", "text": "Rhodanese and glutamine synthetase were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable \"folding arrested\" complexes with groEL.", "text_with_entity_marker": "Rhodanese and [E1]glutamine synthetase[/E1] were chosen as substrates because they exhibit different solution requirements for the chaperonin system and they form stable \"folding arrested\" complexes with [E2]groEL[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "glutamine synthetase", "entity_1_idx": [[14, 34]], "entity_1_idx_in_text_with_entity_marker": [18, 38], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[195, 200]], "entity_2_idx_in_text_with_entity_marker": [208, 213], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d126.s1081_AIMed.d126.s1081.p0", "text": "This suggests that rhodanese must interact with groEL throughout most of its folding reaction before it acquires a folding competent (groE independent) state.", "text_with_entity_marker": "This suggests that [E1]rhodanese[/E1] must interact with [E2]groEL[/E2] throughout most of its folding reaction before it acquires a folding competent (groE independent) state.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "rhodanese", "entity_1_idx": [[19, 28]], "entity_1_idx_in_text_with_entity_marker": [23, 32], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "groEL", "entity_2_idx": [[48, 53]], "entity_2_idx_in_text_with_entity_marker": [61, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s525_AIMed.d60.s525.p2", "text": "Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro.", "text_with_entity_marker": "Activation of [E1]mitogen-activated protein kinase kinase[/E1] by [E2]v-Raf[/E2] in NIH 3T3 cells and in vitro.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "mitogen-activated protein kinase kinase", "entity_1_idx": [[14, 53]], "entity_1_idx_in_text_with_entity_marker": [18, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "v-Raf", "entity_2_idx": [[57, 62]], "entity_2_idx_in_text_with_entity_marker": [70, 75], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s527_AIMed.d60.s527.p0", "text": "MAP kinase and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the c-Raf-1 protein kinase.", "text_with_entity_marker": "[E1]MAP kinase[/E1] and the protein kinase that activates it ([E2]MAP kinase kinase[/E2]) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the c-Raf-1 protein kinase.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "MAP kinase", "entity_1_idx": [[0, 10]], "entity_1_idx_in_text_with_entity_marker": [4, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase kinase", "entity_2_idx": [[53, 70]], "entity_2_idx_in_text_with_entity_marker": [66, 83], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s527_AIMed.d60.s527.p1", "text": "MAP kinase and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the c-Raf-1 protein kinase.", "text_with_entity_marker": "[E1]MAP kinase[/E1] and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the [E2]c-Raf-1[/E2] protein kinase.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "MAP kinase", "entity_1_idx": [[0, 10]], "entity_1_idx_in_text_with_entity_marker": [4, 14], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Raf-1", "entity_2_idx": [[207, 214]], "entity_2_idx_in_text_with_entity_marker": [220, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s527_AIMed.d60.s527.p2", "text": "MAP kinase and the protein kinase that activates it (MAP kinase kinase) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the c-Raf-1 protein kinase.", "text_with_entity_marker": "MAP kinase and the protein kinase that activates it ([E1]MAP kinase kinase[/E1]) were constitutively activated in NIH 3T3 cells infected with viruses containing either of two oncogenic forms (p35EC12, p3722W) of the [E2]c-Raf-1[/E2] protein kinase.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "MAP kinase kinase", "entity_1_idx": [[53, 70]], "entity_1_idx_in_text_with_entity_marker": [57, 74], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Raf-1", "entity_2_idx": [[207, 214]], "entity_2_idx_in_text_with_entity_marker": [220, 227], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s528_AIMed.d60.s528.p1", "text": "The v-Raf proteins purified from cells infected with EC12 or 22W viruses activated MAP kinase kinase from skeletal muscle in vitro.", "text_with_entity_marker": "The [E1]v-Raf[/E1] proteins purified from cells infected with EC12 or 22W viruses activated [E2]MAP kinase kinase[/E2] from skeletal muscle in vitro.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "v-Raf", "entity_1_idx": [[4, 9]], "entity_1_idx_in_text_with_entity_marker": [8, 13], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase kinase", "entity_2_idx": [[83, 100]], "entity_2_idx_in_text_with_entity_marker": [96, 113], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s530_AIMed.d60.s530.p1", "text": "These findings suggest that one function of c-Raf-1 in mitogenic signaling is to phosphorylate and activate MAP kinase kinase.", "text_with_entity_marker": "These findings suggest that one function of [E1]c-Raf-1[/E1] in mitogenic signaling is to phosphorylate and activate [E2]MAP kinase kinase[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Raf-1", "entity_1_idx": [[44, 51]], "entity_1_idx_in_text_with_entity_marker": [48, 55], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase kinase", "entity_2_idx": [[108, 125]], "entity_2_idx_in_text_with_entity_marker": [121, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d150.s1273_AIMed.d150.s1273.p2", "text": "Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein.", "text_with_entity_marker": "Regulation of the Ets-related transcription factor [E1]Elf-1[/E1] by binding to the [E2]retinoblastoma[/E2] protein.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Elf-1", "entity_1_idx": [[51, 56]], "entity_1_idx_in_text_with_entity_marker": [55, 60], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "retinoblastoma", "entity_2_idx": [[75, 89]], "entity_2_idx_in_text_with_entity_marker": [88, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d95.s802_AIMed.d95.s802.p0", "text": "Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.", "text_with_entity_marker": "Mechanism of CDK activation revealed by the structure of a [E1]cyclinA[/E1]-[E2]CDK2[/E2] complex.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclinA", "entity_1_idx": [[59, 66]], "entity_1_idx_in_text_with_entity_marker": [63, 70], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[67, 71]], "entity_2_idx_in_text_with_entity_marker": [80, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d95.s803_AIMed.d95.s803.p0", "text": "The crystal structure of the human cyclinA-cyclin-dependent kinase2 (CDK2)-ATP complex has been determined at 2.3 A resolution.", "text_with_entity_marker": "The crystal structure of the human [E1]cyclinA[/E1]-[E2]cyclin-dependent kinase2[/E2] (CDK2)-ATP complex has been determined at 2.3 A resolution.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclinA", "entity_1_idx": [[35, 42]], "entity_1_idx_in_text_with_entity_marker": [39, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin-dependent kinase2", "entity_2_idx": [[43, 67]], "entity_2_idx_in_text_with_entity_marker": [56, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d95.s803_AIMed.d95.s803.p1", "text": "The crystal structure of the human cyclinA-cyclin-dependent kinase2 (CDK2)-ATP complex has been determined at 2.3 A resolution.", "text_with_entity_marker": "The crystal structure of the human [E1]cyclinA[/E1]-cyclin-dependent kinase2 ([E2]CDK2[/E2])-ATP complex has been determined at 2.3 A resolution.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclinA", "entity_1_idx": [[35, 42]], "entity_1_idx_in_text_with_entity_marker": [39, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CDK2", "entity_2_idx": [[69, 73]], "entity_2_idx_in_text_with_entity_marker": [82, 86], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d30.s250_AIMed.d30.s250.p0", "text": "Isolation of human delta-catenin and its binding specificity with presenilin 1.", "text_with_entity_marker": "Isolation of human [E1]delta-catenin[/E1] and its binding specificity with [E2]presenilin 1[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "delta-catenin", "entity_1_idx": [[19, 32]], "entity_1_idx_in_text_with_entity_marker": [23, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "presenilin 1", "entity_2_idx": [[66, 78]], "entity_2_idx_in_text_with_entity_marker": [79, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d30.s251_AIMed.d30.s251.p0", "text": "We screened proteins for interaction with presenilin (PS) 1, and cloned the full-length cDNA of human delta-catenin, which encoded 1225 amino acids.", "text_with_entity_marker": "We screened proteins for interaction with [E1]presenilin (PS) 1[/E1], and cloned the full-length cDNA of human [E2]delta-catenin[/E2], which encoded 1225 amino acids.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "presenilin (PS) 1", "entity_1_idx": [[42, 59]], "entity_1_idx_in_text_with_entity_marker": [46, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "delta-catenin", "entity_2_idx": [[102, 115]], "entity_2_idx_in_text_with_entity_marker": [115, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d30.s252_AIMed.d30.s252.p0", "text": "Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that delta-catenin interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of PS1, but not with that of PS-2.", "text_with_entity_marker": "Yeast two-hybrid assay, GST binding assay and immunoprecipitation demonstrated that [E1]delta-catenin[/E1] interacted with a hydrophilic loop region in the endoproteolytic C-terminal fragment of [E2]PS1[/E2], but not with that of PS-2.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "delta-catenin", "entity_1_idx": [[84, 97]], "entity_1_idx_in_text_with_entity_marker": [88, 101], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "PS1", "entity_2_idx": [[186, 189]], "entity_2_idx_in_text_with_entity_marker": [199, 202], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d51.s455_AIMed.d51.s455.p0", "text": "Here we report the crystal structure of the FGFR2 ectodomain in a dimeric form that is induced by simultaneous binding to FGF1 and a heparin decasaccharide.", "text_with_entity_marker": "Here we report the crystal structure of the [E1]FGFR2[/E1] ectodomain in a dimeric form that is induced by simultaneous binding to [E2]FGF1[/E2] and a heparin decasaccharide.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "FGFR2", "entity_1_idx": [[44, 49]], "entity_1_idx_in_text_with_entity_marker": [48, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGF1", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d51.s458_AIMed.d51.s458.p0", "text": "The structure of the FGF1-FGFR2-heparin ternary complex provides a structural basis for the essential role of heparan sulphate in FGF signalling.", "text_with_entity_marker": "The structure of the [E1]FGF1[/E1]-[E2]FGFR2[/E2]-heparin ternary complex provides a structural basis for the essential role of heparan sulphate in FGF signalling.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "FGF1", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "FGFR2", "entity_2_idx": [[26, 31]], "entity_2_idx_in_text_with_entity_marker": [39, 44], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1603_AIMed.d189.s1603.p2", "text": "Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "text_with_entity_marker": "Associations of [E1]UBE2I[/E1] with RAD52, UBL1, [E2]p53[/E2], and RAD51 proteins in a yeast two-hybrid system.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[40, 43]], "entity_2_idx_in_text_with_entity_marker": [53, 56], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1603_AIMed.d189.s1603.p3", "text": "Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.", "text_with_entity_marker": "Associations of [E1]UBE2I[/E1] with RAD52, UBL1, p53, and [E2]RAD51[/E2] proteins in a yeast two-hybrid system.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD51", "entity_2_idx": [[49, 54]], "entity_2_idx_in_text_with_entity_marker": [62, 67], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p12", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated [E1]UBE2I[/E1], that interacts with RAD52, [E2]RAD51[/E2], p53, and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[135, 140]], "entity_1_idx_in_text_with_entity_marker": [139, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RAD51", "entity_2_idx": [[169, 174]], "entity_2_idx_in_text_with_entity_marker": [182, 187], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d189.s1606_AIMed.d189.s1606.p13", "text": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.", "text_with_entity_marker": "Using the human RAD52 protein as the \"bait\" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated [E1]UBE2I[/E1], that interacts with RAD52, RAD51, [E2]p53[/E2], and a ubiquitin-like protein UBL1.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UBE2I", "entity_1_idx": [[135, 140]], "entity_1_idx_in_text_with_entity_marker": [139, 144], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p53", "entity_2_idx": [[176, 179]], "entity_2_idx_in_text_with_entity_marker": [189, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d69.s586_AIMed.d69.s586.p0", "text": "Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity.", "text_with_entity_marker": "Activation of [E1]protein kinase C[/E1] decreases phosphorylation of [E2]c-Jun[/E2] at sites that negatively regulate its DNA-binding activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "protein kinase C", "entity_1_idx": [[14, 30]], "entity_1_idx_in_text_with_entity_marker": [18, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[60, 65]], "entity_2_idx_in_text_with_entity_marker": [73, 78], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d69.s587_AIMed.d69.s587.p0", "text": "In resting human epithelial and fibroblastic cells, c-Jun is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by glycogen synthase kinase 3 (GSK-3).", "text_with_entity_marker": "In resting human epithelial and fibroblastic cells, [E1]c-Jun[/E1] is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by [E2]glycogen synthase kinase 3[/E2] (GSK-3).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "glycogen synthase kinase 3", "entity_2_idx": [[161, 187]], "entity_2_idx_in_text_with_entity_marker": [174, 200], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d69.s587_AIMed.d69.s587.p1", "text": "In resting human epithelial and fibroblastic cells, c-Jun is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by glycogen synthase kinase 3 (GSK-3).", "text_with_entity_marker": "In resting human epithelial and fibroblastic cells, [E1]c-Jun[/E1] is phosphorylated on serine and threonine at five sites, three of which are phosphorylated in vitro by glycogen synthase kinase 3 ([E2]GSK-3[/E2]).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[52, 57]], "entity_1_idx_in_text_with_entity_marker": [56, 61], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GSK-3", "entity_2_idx": [[189, 194]], "entity_2_idx_in_text_with_entity_marker": [202, 207], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d69.s589_AIMed.d69.s589.p0", "text": "Activation of protein kinase C results in rapid, site-specific dephosphorylation of c-Jun at one or more of these three sites and is coincident with increased AP-1-binding activity.", "text_with_entity_marker": "Activation of [E1]protein kinase C[/E1] results in rapid, site-specific dephosphorylation of [E2]c-Jun[/E2] at one or more of these three sites and is coincident with increased AP-1-binding activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "protein kinase C", "entity_1_idx": [[14, 30]], "entity_1_idx_in_text_with_entity_marker": [18, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "c-Jun", "entity_2_idx": [[84, 89]], "entity_2_idx_in_text_with_entity_marker": [97, 102], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d69.s590_AIMed.d69.s590.p0", "text": "Phosphorylation of recombinant human c-Jun proteins in vitro by GSK-3 decreases their DNA-binding activity.", "text_with_entity_marker": "Phosphorylation of recombinant human [E1]c-Jun[/E1] proteins in vitro by [E2]GSK-3[/E2] decreases their DNA-binding activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[37, 42]], "entity_1_idx_in_text_with_entity_marker": [41, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "GSK-3", "entity_2_idx": [[64, 69]], "entity_2_idx_in_text_with_entity_marker": [77, 82], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d69.s592_AIMed.d69.s592.p0", "text": "We propose that c-Jun is present in resting cells in a latent, phosphorylated form that can be activated by site-specific dephosphorylation in response to protein kinase C activation.", "text_with_entity_marker": "We propose that [E1]c-Jun[/E1] is present in resting cells in a latent, phosphorylated form that can be activated by site-specific dephosphorylation in response to [E2]protein kinase C[/E2] activation.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "c-Jun", "entity_1_idx": [[16, 21]], "entity_1_idx_in_text_with_entity_marker": [20, 25], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[155, 171]], "entity_2_idx_in_text_with_entity_marker": [168, 184], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p4", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, [E1]hTAFII32[/E1] interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator [E2]viral protein 16[/E2] (VP16) as well as with the general transcription factor TFIIB.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "hTAFII32", "entity_1_idx": [[93, 101]], "entity_1_idx_in_text_with_entity_marker": [97, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "viral protein 16", "entity_2_idx": [[193, 209]], "entity_2_idx_in_text_with_entity_marker": [206, 222], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p5", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, [E1]hTAFII32[/E1] interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 ([E2]VP16[/E2]) as well as with the general transcription factor TFIIB.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "hTAFII32", "entity_1_idx": [[93, 101]], "entity_1_idx_in_text_with_entity_marker": [97, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "VP16", "entity_2_idx": [[211, 215]], "entity_2_idx_in_text_with_entity_marker": [224, 228], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d91.s781_AIMed.d91.s781.p6", "text": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, hTAFII32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB.", "text_with_entity_marker": "In vitro protein-protein interaction assays reveal that as observed with Drosophila TAFII40, [E1]hTAFII32[/E1] interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor [E2]TFIIB[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "hTAFII32", "entity_1_idx": [[93, 101]], "entity_1_idx_in_text_with_entity_marker": [97, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TFIIB", "entity_2_idx": [[266, 271]], "entity_2_idx_in_text_with_entity_marker": [279, 284], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d130.s1112_AIMed.d130.s1112.p0", "text": "Cloning of the complete coding region for human protein phosphatase inhibitor 2 using the two hybrid system and expression of inhibitor 2 in E. coli.", "text_with_entity_marker": "Cloning of the complete coding region for human [E1]protein phosphatase inhibitor 2[/E1] using the two hybrid system and expression of [E2]inhibitor 2[/E2] in E. coli.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "protein phosphatase inhibitor 2", "entity_1_idx": [[48, 79]], "entity_1_idx_in_text_with_entity_marker": [52, 83], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "inhibitor 2", "entity_2_idx": [[126, 137]], "entity_2_idx_in_text_with_entity_marker": [139, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d73.s621_AIMed.d73.s621.p0", "text": "The extracellular cysteine-rich domain of the TNF-R is homologous to the nerve growth factor receptor and the B cell activation protein Bp50.", "text_with_entity_marker": "The extracellular cysteine-rich domain of the TNF-R is homologous to the nerve growth factor receptor and the [E1]B cell activation protein[/E1] [E2]Bp50[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "B cell activation protein", "entity_1_idx": [[110, 135]], "entity_1_idx_in_text_with_entity_marker": [114, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Bp50", "entity_2_idx": [[136, 140]], "entity_2_idx_in_text_with_entity_marker": [149, 153], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s684_AIMed.d80.s684.p0", "text": "FADD contains a death domain homologous to the death domains of Fas and TNFR-1.", "text_with_entity_marker": "[E1]FADD[/E1] contains a death domain homologous to the death domains of [E2]Fas[/E2] and TNFR-1.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FADD", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[64, 67]], "entity_2_idx_in_text_with_entity_marker": [77, 80], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s684_AIMed.d80.s684.p1", "text": "FADD contains a death domain homologous to the death domains of Fas and TNFR-1.", "text_with_entity_marker": "[E1]FADD[/E1] contains a death domain homologous to the death domains of Fas and [E2]TNFR-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FADD", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR-1", "entity_2_idx": [[72, 78]], "entity_2_idx_in_text_with_entity_marker": [85, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s684_AIMed.d80.s684.p2", "text": "FADD contains a death domain homologous to the death domains of Fas and TNFR-1.", "text_with_entity_marker": "FADD contains a death domain homologous to the death domains of [E1]Fas[/E1] and [E2]TNFR-1[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas", "entity_1_idx": [[64, 67]], "entity_1_idx_in_text_with_entity_marker": [68, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TNFR-1", "entity_2_idx": [[72, 78]], "entity_2_idx_in_text_with_entity_marker": [85, 91], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d80.s687_AIMed.d80.s687.p0", "text": "These findings suggest that FADD may play an important role in the proximal signal transduction of Fas.", "text_with_entity_marker": "These findings suggest that [E1]FADD[/E1] may play an important role in the proximal signal transduction of [E2]Fas[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "FADD", "entity_1_idx": [[28, 32]], "entity_1_idx_in_text_with_entity_marker": [32, 36], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Fas", "entity_2_idx": [[99, 102]], "entity_2_idx_in_text_with_entity_marker": [112, 115], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1509_AIMed.d178.s1509.p0", "text": "Although many different types of proliferating cells contain p27 protein, neither the interactions of p27 with cyclin/CDK complexes nor the consequences of this interaction during the mitotic cycle have been fully explored.", "text_with_entity_marker": "Although many different types of proliferating cells contain [E1]p27[/E1] protein, neither the interactions of [E2]p27[/E2] with cyclin/CDK complexes nor the consequences of this interaction during the mitotic cycle have been fully explored.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p27", "entity_1_idx": [[61, 64]], "entity_1_idx_in_text_with_entity_marker": [65, 68], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[102, 105]], "entity_2_idx_in_text_with_entity_marker": [115, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d178.s1512_AIMed.d178.s1512.p0", "text": "Furthermore, the amount of p27 is significantly lower than the amount of cyclin D3 in these cells.", "text_with_entity_marker": "Furthermore, the amount of [E1]p27[/E1] is significantly lower than the amount of [E2]cyclin D3[/E2] in these cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p27", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cyclin D3", "entity_2_idx": [[73, 82]], "entity_2_idx_in_text_with_entity_marker": [86, 95], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s529_AIMed.d60.s529.p0", "text": "Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p3722W) also activated MAP kinase kinase in vitro.", "text_with_entity_marker": "Furthermore, a bacterially expressed [E1]v-Raf[/E1] fusion protein (glutathione S-transferase-p3722W) also activated [E2]MAP kinase[/E2] kinase in vitro.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "v-Raf", "entity_1_idx": [[37, 42]], "entity_1_idx_in_text_with_entity_marker": [41, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase", "entity_2_idx": [[108, 118]], "entity_2_idx_in_text_with_entity_marker": [121, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s529_AIMed.d60.s529.p1", "text": "Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p3722W) also activated MAP kinase kinase in vitro.", "text_with_entity_marker": "Furthermore, a bacterially expressed [E1]v-Raf[/E1] fusion protein (glutathione S-transferase-p3722W) also activated [E2]MAP kinase kinase[/E2] in vitro.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "v-Raf", "entity_1_idx": [[37, 42]], "entity_1_idx_in_text_with_entity_marker": [41, 46], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase kinase", "entity_2_idx": [[108, 125]], "entity_2_idx_in_text_with_entity_marker": [121, 138], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d60.s529_AIMed.d60.s529.p2", "text": "Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p3722W) also activated MAP kinase kinase in vitro.", "text_with_entity_marker": "Furthermore, a bacterially expressed v-Raf fusion protein (glutathione S-transferase-p3722W) also activated [E1-E2]MAP kinase[/E1] kinase[/E2] in vitro.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MAP kinase", "entity_1_idx": [[108, 118]], "entity_1_idx_in_text_with_entity_marker": [115, 125], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MAP kinase[/E1] kinase", "entity_2_idx": [[108, 125]], "entity_2_idx_in_text_with_entity_marker": [115, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p0", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either [E1]Id3[/E1]/[E2]HLH462[/E2] or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Id3", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "HLH462", "entity_2_idx": [[42, 48]], "entity_2_idx_in_text_with_entity_marker": [55, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p1", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either [E1]Id3[/E1]/HLH462 or [E2]ITF-2b[/E2] effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Id3", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ITF-2b", "entity_2_idx": [[52, 58]], "entity_2_idx_in_text_with_entity_marker": [65, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p2", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either [E1]Id3[/E1]/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific [E2]creatine kinase[/E2] promoter by the myogenic transcription factor MyoD.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Id3", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "creatine kinase", "entity_2_idx": [[119, 134]], "entity_2_idx_in_text_with_entity_marker": [132, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p3", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either [E1]Id3[/E1]/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor [E2]MyoD[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Id3", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p4", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either Id3/[E1]HLH462[/E1] or [E2]ITF-2b[/E2] effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "HLH462", "entity_1_idx": [[42, 48]], "entity_1_idx_in_text_with_entity_marker": [46, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ITF-2b", "entity_2_idx": [[52, 58]], "entity_2_idx_in_text_with_entity_marker": [65, 71], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p5", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either Id3/[E1]HLH462[/E1] or ITF-2b effectively inhibited the activation of the muscle-specific [E2]creatine kinase[/E2] promoter by the myogenic transcription factor MyoD.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "HLH462", "entity_1_idx": [[42, 48]], "entity_1_idx_in_text_with_entity_marker": [46, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "creatine kinase", "entity_2_idx": [[119, 134]], "entity_2_idx_in_text_with_entity_marker": [132, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p6", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either Id3/[E1]HLH462[/E1] or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor [E2]MyoD[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "HLH462", "entity_1_idx": [[42, 48]], "entity_1_idx_in_text_with_entity_marker": [46, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p7", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either Id3/HLH462 or [E1]ITF-2b[/E1] effectively inhibited the activation of the muscle-specific [E2]creatine kinase[/E2] promoter by the myogenic transcription factor MyoD.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ITF-2b", "entity_1_idx": [[52, 58]], "entity_1_idx_in_text_with_entity_marker": [56, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "creatine kinase", "entity_2_idx": [[119, 134]], "entity_2_idx_in_text_with_entity_marker": [132, 147], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p8", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either Id3/HLH462 or [E1]ITF-2b[/E1] effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor [E2]MyoD[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ITF-2b", "entity_1_idx": [[52, 58]], "entity_1_idx_in_text_with_entity_marker": [56, 62], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1644_AIMed.d193.s1644.p9", "text": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific creatine kinase promoter by the myogenic transcription factor MyoD.", "text_with_entity_marker": "As expected, overexpression of either Id3/HLH462 or ITF-2b effectively inhibited the activation of the muscle-specific [E1]creatine kinase[/E1] promoter by the myogenic transcription factor [E2]MyoD[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "creatine kinase", "entity_1_idx": [[119, 134]], "entity_1_idx_in_text_with_entity_marker": [123, 138], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1646_AIMed.d193.s1646.p0", "text": "Moreover, while ITF-2b inhibited the creatine kinase promoter, it acted as a weak transactivator on an artificial promoter consisting of three tandem copies of the consensus myogenic factor DNA binding site.", "text_with_entity_marker": "Moreover, while [E1]ITF-2b[/E1] inhibited the [E2]creatine kinase[/E2] promoter, it acted as a weak transactivator on an artificial promoter consisting of three tandem copies of the consensus myogenic factor DNA binding site.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ITF-2b", "entity_1_idx": [[16, 22]], "entity_1_idx_in_text_with_entity_marker": [20, 26], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "creatine kinase", "entity_2_idx": [[37, 52]], "entity_2_idx_in_text_with_entity_marker": [50, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d193.s1648_AIMed.d193.s1648.p0", "text": "Additional analysis revealed the presence of transcripts for both the activating (ITF-2a) and inhibitory (ITF-2b) isoforms in differentiating C2C12 cultures, suggesting that both isoforms might participate in regulating the differentiation process.", "text_with_entity_marker": "Additional analysis revealed the presence of transcripts for both the activating ([E1]ITF-2a[/E1]) and inhibitory ([E2]ITF-2b[/E2]) isoforms in differentiating C2C12 cultures, suggesting that both isoforms might participate in regulating the differentiation process.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ITF-2a", "entity_1_idx": [[82, 88]], "entity_1_idx_in_text_with_entity_marker": [86, 92], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ITF-2b", "entity_2_idx": [[106, 112]], "entity_2_idx_in_text_with_entity_marker": [119, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s5_AIMed.d0.s5.p0", "text": "Cytokines measurements during IFN-alpha treatment showed a trend to decreasing levels of IL-4 at 4, 12, and 24 weeks.", "text_with_entity_marker": "Cytokines measurements during [E1]IFN-alpha[/E1] treatment showed a trend to decreasing levels of [E2]IL-4[/E2] at 4, 12, and 24 weeks.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IFN-alpha", "entity_1_idx": [[30, 39]], "entity_1_idx_in_text_with_entity_marker": [34, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[89, 93]], "entity_2_idx_in_text_with_entity_marker": [102, 106], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s6_AIMed.d0.s6.p0", "text": "Levels of IFN-gamma were slightly increased following IFN-alpha treatment (P = 0.09).", "text_with_entity_marker": "Levels of [E1]IFN-gamma[/E1] were slightly increased following [E2]IFN-alpha[/E2] treatment (P = 0.09).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IFN-gamma", "entity_1_idx": [[10, 19]], "entity_1_idx_in_text_with_entity_marker": [14, 23], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-alpha", "entity_2_idx": [[54, 63]], "entity_2_idx_in_text_with_entity_marker": [67, 76], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s7_AIMed.d0.s7.p0", "text": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "text_with_entity_marker": "In patients with a complete response to [E1]IFN-alpha[/E1], the levels of [E2]IFN-gamma[/E2] were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IFN-alpha", "entity_1_idx": [[40, 49]], "entity_1_idx_in_text_with_entity_marker": [44, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-gamma", "entity_2_idx": [[65, 74]], "entity_2_idx_in_text_with_entity_marker": [78, 87], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s7_AIMed.d0.s7.p1", "text": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "text_with_entity_marker": "In patients with a complete response to [E1]IFN-alpha[/E1], the levels of IFN-gamma were higher at 24 weeks following [E2]IFN-alpha[/E2] treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IFN-alpha", "entity_1_idx": [[40, 49]], "entity_1_idx_in_text_with_entity_marker": [44, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-alpha", "entity_2_idx": [[109, 118]], "entity_2_idx_in_text_with_entity_marker": [122, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s7_AIMed.d0.s7.p2", "text": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "text_with_entity_marker": "In patients with a complete response to [E1]IFN-alpha[/E1], the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of [E2]IL-4[/E2] decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IFN-alpha", "entity_1_idx": [[40, 49]], "entity_1_idx_in_text_with_entity_marker": [44, 53], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[186, 190]], "entity_2_idx_in_text_with_entity_marker": [199, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s7_AIMed.d0.s7.p3", "text": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "text_with_entity_marker": "In patients with a complete response to IFN-alpha, the levels of [E1]IFN-gamma[/E1] were higher at 24 weeks following [E2]IFN-alpha[/E2] treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IFN-gamma", "entity_1_idx": [[65, 74]], "entity_1_idx_in_text_with_entity_marker": [69, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IFN-alpha", "entity_2_idx": [[109, 118]], "entity_2_idx_in_text_with_entity_marker": [122, 131], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s7_AIMed.d0.s7.p4", "text": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "text_with_entity_marker": "In patients with a complete response to IFN-alpha, the levels of [E1]IFN-gamma[/E1] were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of [E2]IL-4[/E2] decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IFN-gamma", "entity_1_idx": [[65, 74]], "entity_1_idx_in_text_with_entity_marker": [69, 78], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[186, 190]], "entity_2_idx_in_text_with_entity_marker": [199, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d0.s7_AIMed.d0.s7.p5", "text": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following IFN-alpha treatment than that of pre-treatment (P = 0.04), and the levels of IL-4 decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "text_with_entity_marker": "In patients with a complete response to IFN-alpha, the levels of IFN-gamma were higher at 24 weeks following [E1]IFN-alpha[/E1] treatment than that of pre-treatment (P = 0.04), and the levels of [E2]IL-4[/E2] decreased markedly at 12 and 24 weeks (P = 0.02, 0.03, respectively). mRNA expression positively correlated with the level of Th1/Th2 type cytokines in the supernatant.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "IFN-alpha", "entity_1_idx": [[109, 118]], "entity_1_idx_in_text_with_entity_marker": [113, 122], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "IL-4", "entity_2_idx": [[186, 190]], "entity_2_idx_in_text_with_entity_marker": [199, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1819_AIMed.d210.s1819.p0", "text": "To further examine the function of the bHLHZip protein, USF, we screened for cellular proteins which could directly interact with USF using the yeast two-hybrid system.", "text_with_entity_marker": "To further examine the function of the bHLHZip protein, [E1]USF[/E1], we screened for cellular proteins which could directly interact with [E2]USF[/E2] using the yeast two-hybrid system.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "USF", "entity_1_idx": [[56, 59]], "entity_1_idx_in_text_with_entity_marker": [60, 63], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "USF", "entity_2_idx": [[130, 133]], "entity_2_idx_in_text_with_entity_marker": [143, 146], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1824_AIMed.d210.s1824.p0", "text": "Expression of exogenous USF led to a decrease in AP1-dependent transcription in F9 cells.", "text_with_entity_marker": "Expression of exogenous [E1]USF[/E1] led to a decrease in [E2]AP1[/E2]-dependent transcription in F9 cells.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "USF", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [28, 31], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AP1", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d210.s1825_AIMed.d210.s1825.p0", "text": "Co-expression of exogenous Fra1 restored the AP1 activity in a dose-dependent manner.", "text_with_entity_marker": "Co-expression of exogenous [E1]Fra1[/E1] restored the [E2]AP1[/E2] activity in a dose-dependent manner.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fra1", "entity_1_idx": [[27, 31]], "entity_1_idx_in_text_with_entity_marker": [31, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "AP1", "entity_2_idx": [[45, 48]], "entity_2_idx_in_text_with_entity_marker": [58, 61], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s578_AIMed.d68.s578.p0", "text": "Two previously unidentified human cdc25 genes have been isolated, cdc25A and cdc25B.", "text_with_entity_marker": "Two previously unidentified human [E1]cdc25[/E1] genes have been isolated, [E2]cdc25A[/E2] and cdc25B.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cdc25", "entity_1_idx": [[34, 39]], "entity_1_idx_in_text_with_entity_marker": [38, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc25A", "entity_2_idx": [[66, 72]], "entity_2_idx_in_text_with_entity_marker": [79, 85], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s578_AIMed.d68.s578.p1", "text": "Two previously unidentified human cdc25 genes have been isolated, cdc25A and cdc25B.", "text_with_entity_marker": "Two previously unidentified human [E1]cdc25[/E1] genes have been isolated, cdc25A and [E2]cdc25B[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cdc25", "entity_1_idx": [[34, 39]], "entity_1_idx_in_text_with_entity_marker": [38, 43], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc25B", "entity_2_idx": [[77, 83]], "entity_2_idx_in_text_with_entity_marker": [90, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s578_AIMed.d68.s578.p2", "text": "Two previously unidentified human cdc25 genes have been isolated, cdc25A and cdc25B.", "text_with_entity_marker": "Two previously unidentified human cdc25 genes have been isolated, [E1]cdc25A[/E1] and [E2]cdc25B[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cdc25A", "entity_1_idx": [[66, 72]], "entity_1_idx_in_text_with_entity_marker": [70, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc25B", "entity_2_idx": [[77, 83]], "entity_2_idx_in_text_with_entity_marker": [90, 96], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s582_AIMed.d68.s582.p0", "text": "These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase, but also activate the cdc25 tyrosine phosphatase, of which cdc2 is the physiological substrate.", "text_with_entity_marker": "These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the [E1]cdc2[/E1] protein kinase, but also activate the [E2]cdc25[/E2] tyrosine phosphatase, of which cdc2 is the physiological substrate.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cdc2", "entity_1_idx": [[129, 133]], "entity_1_idx_in_text_with_entity_marker": [133, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc25", "entity_2_idx": [[172, 177]], "entity_2_idx_in_text_with_entity_marker": [185, 190], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s582_AIMed.d68.s582.p1", "text": "These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase, but also activate the cdc25 tyrosine phosphatase, of which cdc2 is the physiological substrate.", "text_with_entity_marker": "These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the [E1]cdc2[/E1] protein kinase, but also activate the cdc25 tyrosine phosphatase, of which [E2]cdc2[/E2] is the physiological substrate.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cdc2", "entity_1_idx": [[129, 133]], "entity_1_idx_in_text_with_entity_marker": [133, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc2", "entity_2_idx": [[209, 213]], "entity_2_idx_in_text_with_entity_marker": [222, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d68.s582_AIMed.d68.s582.p2", "text": "These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase, but also activate the cdc25 tyrosine phosphatase, of which cdc2 is the physiological substrate.", "text_with_entity_marker": "These findings indicate that B-type cyclins are multifunctional proteins that not only act as M phase regulatory subunits of the cdc2 protein kinase, but also activate the [E1]cdc25[/E1] tyrosine phosphatase, of which [E2]cdc2[/E2] is the physiological substrate.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cdc25", "entity_1_idx": [[172, 177]], "entity_1_idx_in_text_with_entity_marker": [176, 181], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "cdc2", "entity_2_idx": [[209, 213]], "entity_2_idx_in_text_with_entity_marker": [222, 226], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p0", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of [E1]trkA[/E1] and [E2]p75[/E2] were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "trkA", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[42, 45]], "entity_2_idx_in_text_with_entity_marker": [55, 58], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p1", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of [E1]trkA[/E1] and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E2]NGF[/E2]-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "trkA", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[126, 129]], "entity_2_idx_in_text_with_entity_marker": [139, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p2", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of [E1]trkA[/E1] and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E2]NGF-receptor[/E2] complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "trkA", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF-receptor", "entity_2_idx": [[126, 138]], "entity_2_idx_in_text_with_entity_marker": [139, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p3", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of [E1]trkA[/E1] and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with [E2]trk[/E2]-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "trkA", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trk", "entity_2_idx": [[154, 157]], "entity_2_idx_in_text_with_entity_marker": [167, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p4", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of [E1]trkA[/E1] and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked [E2]p75[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "trkA", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[235, 238]], "entity_2_idx_in_text_with_entity_marker": [248, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p5", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and [E1]p75[/E1] were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E2]NGF[/E2]-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p75", "entity_1_idx": [[42, 45]], "entity_1_idx_in_text_with_entity_marker": [46, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF", "entity_2_idx": [[126, 129]], "entity_2_idx_in_text_with_entity_marker": [139, 142], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p6", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and [E1]p75[/E1] were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E2]NGF-receptor[/E2] complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p75", "entity_1_idx": [[42, 45]], "entity_1_idx_in_text_with_entity_marker": [46, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF-receptor", "entity_2_idx": [[126, 138]], "entity_2_idx_in_text_with_entity_marker": [139, 151], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p7", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and [E1]p75[/E1] were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with [E2]trk[/E2]-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p75", "entity_1_idx": [[42, 45]], "entity_1_idx_in_text_with_entity_marker": [46, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trk", "entity_2_idx": [[154, 157]], "entity_2_idx_in_text_with_entity_marker": [167, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p8", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and [E1]p75[/E1] were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked [E2]p75[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p75", "entity_1_idx": [[42, 45]], "entity_1_idx_in_text_with_entity_marker": [46, 49], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[235, 238]], "entity_2_idx_in_text_with_entity_marker": [248, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p9", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E1-E2]NGF[/E1]-receptor[/E2] complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NGF", "entity_1_idx": [[126, 129]], "entity_1_idx_in_text_with_entity_marker": [133, 136], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "NGF[/E1]-receptor", "entity_2_idx": [[126, 138]], "entity_2_idx_in_text_with_entity_marker": [133, 150], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p10", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E1]NGF[/E1]-receptor complexes with [E2]trk[/E2]-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NGF", "entity_1_idx": [[126, 129]], "entity_1_idx_in_text_with_entity_marker": [130, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trk", "entity_2_idx": [[154, 157]], "entity_2_idx_in_text_with_entity_marker": [167, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p11", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E1]NGF[/E1]-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked [E2]p75[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NGF", "entity_1_idx": [[126, 129]], "entity_1_idx_in_text_with_entity_marker": [130, 133], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[235, 238]], "entity_2_idx_in_text_with_entity_marker": [248, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p12", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E1]NGF-receptor[/E1] complexes with [E2]trk[/E2]-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NGF-receptor", "entity_1_idx": [[126, 138]], "entity_1_idx_in_text_with_entity_marker": [130, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "trk", "entity_2_idx": [[154, 157]], "entity_2_idx_in_text_with_entity_marker": [167, 170], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p13", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked [E1]NGF-receptor[/E1] complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked [E2]p75[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NGF-receptor", "entity_1_idx": [[126, 138]], "entity_1_idx_in_text_with_entity_marker": [130, 142], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[235, 238]], "entity_2_idx_in_text_with_entity_marker": [248, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d92.s788_AIMed.d92.s788.p14", "text": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with trk-specific antibodies resulted in selective immunoprecipitation of crosslinked p75.", "text_with_entity_marker": "Although multimeric complexes of trkA and p75 were not detected by affinity crosslinking, immunoprecipitation of cross-linked NGF-receptor complexes with [E1]trk[/E1]-specific antibodies resulted in selective immunoprecipitation of crosslinked [E2]p75[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "trk", "entity_1_idx": [[154, 157]], "entity_1_idx_in_text_with_entity_marker": [158, 161], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p75", "entity_2_idx": [[235, 238]], "entity_2_idx_in_text_with_entity_marker": [248, 251], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1562_AIMed.d184.s1562.p0", "text": "For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and CXCR-4, respectively, as well as the primary receptor CD4 (refs 1-6).", "text_with_entity_marker": "For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, [E1]CCR-5[/E1] and [E2]CXCR-4[/E2], respectively, as well as the primary receptor CD4 (refs 1-6).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "CCR-5", "entity_1_idx": [[174, 179]], "entity_1_idx_in_text_with_entity_marker": [178, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CXCR-4", "entity_2_idx": [[184, 190]], "entity_2_idx_in_text_with_entity_marker": [197, 203], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1562_AIMed.d184.s1562.p1", "text": "For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and CXCR-4, respectively, as well as the primary receptor CD4 (refs 1-6).", "text_with_entity_marker": "For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, [E1]CCR-5[/E1] and CXCR-4, respectively, as well as the primary receptor [E2]CD4[/E2] (refs 1-6).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "CCR-5", "entity_1_idx": [[174, 179]], "entity_1_idx_in_text_with_entity_marker": [178, 183], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[238, 241]], "entity_2_idx_in_text_with_entity_marker": [251, 254], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d184.s1562_AIMed.d184.s1562.p2", "text": "For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and CXCR-4, respectively, as well as the primary receptor CD4 (refs 1-6).", "text_with_entity_marker": "For efficient entry into target cells, primary macrophage-tropic and laboratory-adapted human immunodeficiency viruses type 1 (HIV-1) require particular chemokine receptors, CCR-5 and [E1]CXCR-4[/E1], respectively, as well as the primary receptor [E2]CD4[/E2] (refs 1-6).", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "CXCR-4", "entity_1_idx": [[184, 190]], "entity_1_idx_in_text_with_entity_marker": [188, 194], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "CD4", "entity_2_idx": [[238, 241]], "entity_2_idx_in_text_with_entity_marker": [251, 254], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d154.s1309_AIMed.d154.s1309.p0", "text": "We have cloned and characterized human acidic (alpha 1-) syntrophin and a second isoform of human basic (beta 2-) syntrophin.", "text_with_entity_marker": "We have cloned and characterized human [E1]acidic (alpha 1-) syntrophin[/E1] and a second isoform of human [E2]basic (beta 2-) syntrophin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "acidic (alpha 1-) syntrophin", "entity_1_idx": [[39, 67]], "entity_1_idx_in_text_with_entity_marker": [43, 71], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "basic (beta 2-) syntrophin", "entity_2_idx": [[98, 124]], "entity_2_idx_in_text_with_entity_marker": [111, 137], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d154.s1311_AIMed.d154.s1311.p0", "text": "The deduced amino acid sequences of human alpha 1- and beta 2-syntrophin are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like beta 1-syntrophin, human beta 2-syntrophin has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance.", "text_with_entity_marker": "The deduced amino acid sequences of human alpha 1- and [E1]beta 2-syntrophin[/E1] are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like [E2]beta 1-syntrophin[/E2], human beta 2-syntrophin has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta 2-syntrophin", "entity_1_idx": [[55, 72]], "entity_1_idx_in_text_with_entity_marker": [59, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 1-syntrophin", "entity_2_idx": [[209, 226]], "entity_2_idx_in_text_with_entity_marker": [222, 239], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d154.s1311_AIMed.d154.s1311.p1", "text": "The deduced amino acid sequences of human alpha 1- and beta 2-syntrophin are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like beta 1-syntrophin, human beta 2-syntrophin has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance.", "text_with_entity_marker": "The deduced amino acid sequences of human alpha 1- and [E1]beta 2-syntrophin[/E1] are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like beta 1-syntrophin, human [E2]beta 2-syntrophin[/E2] has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta 2-syntrophin", "entity_1_idx": [[55, 72]], "entity_1_idx_in_text_with_entity_marker": [59, 76], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 2-syntrophin", "entity_2_idx": [[234, 251]], "entity_2_idx_in_text_with_entity_marker": [247, 264], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d154.s1311_AIMed.d154.s1311.p2", "text": "The deduced amino acid sequences of human alpha 1- and beta 2-syntrophin are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like beta 1-syntrophin, human beta 2-syntrophin has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance.", "text_with_entity_marker": "The deduced amino acid sequences of human alpha 1- and beta 2-syntrophin are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like [E1]beta 1-syntrophin[/E1], human [E2]beta 2-syntrophin[/E2] has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta 1-syntrophin", "entity_1_idx": [[209, 226]], "entity_1_idx_in_text_with_entity_marker": [213, 230], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "beta 2-syntrophin", "entity_2_idx": [[234, 251]], "entity_2_idx_in_text_with_entity_marker": [247, 264], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d154.s1313_AIMed.d154.s1313.p0", "text": "Somatic cell hybrids and fluorescent in situ hybridization were both used to determine their chromosomal locations: beta 2-syntrophin to chromosome 16q22-23 and alpha 1-syntrophin to chromosome 20q11.2.", "text_with_entity_marker": "Somatic cell hybrids and fluorescent in situ hybridization were both used to determine their chromosomal locations: [E1]beta 2-syntrophin[/E1] to chromosome 16q22-23 and [E2]alpha 1-syntrophin[/E2] to chromosome 20q11.2.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta 2-syntrophin", "entity_1_idx": [[116, 133]], "entity_1_idx_in_text_with_entity_marker": [120, 137], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "alpha 1-syntrophin", "entity_2_idx": [[161, 179]], "entity_2_idx_in_text_with_entity_marker": [174, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1245_AIMed.d147.s1245.p0", "text": "The retinoblastoma gene product, pRB, regulates cell proliferation by binding to and inhibiting the activity of key growth promoting proteins.", "text_with_entity_marker": "The [E1]retinoblastoma[/E1] gene product, [E2]pRB[/E2], regulates cell proliferation by binding to and inhibiting the activity of key growth promoting proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "retinoblastoma", "entity_1_idx": [[4, 18]], "entity_1_idx_in_text_with_entity_marker": [8, 22], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "pRB", "entity_2_idx": [[33, 36]], "entity_2_idx_in_text_with_entity_marker": [46, 49], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1249_AIMed.d147.s1249.p0", "text": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "text_with_entity_marker": "The products of the [E1]RBP1[/E1] and [E2]RBP2[/E2] genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP1", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP2", "entity_2_idx": [[29, 33]], "entity_2_idx_in_text_with_entity_marker": [42, 46], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1249_AIMed.d147.s1249.p1", "text": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "text_with_entity_marker": "The products of the [E1]RBP1[/E1] and RBP2 genes are ubiquitously expressed, large (200 kDa for [E2]RBP1[/E2] and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP1", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP1", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1249_AIMed.d147.s1249.p2", "text": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "text_with_entity_marker": "The products of the [E1]RBP1[/E1] and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for [E2]RBP2[/E2]) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP1", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP2", "entity_2_idx": [[108, 112]], "entity_2_idx_in_text_with_entity_marker": [121, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1249_AIMed.d147.s1249.p3", "text": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "text_with_entity_marker": "The products of the RBP1 and [E1]RBP2[/E1] genes are ubiquitously expressed, large (200 kDa for [E2]RBP1[/E2] and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP2", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP1", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1249_AIMed.d147.s1249.p4", "text": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "text_with_entity_marker": "The products of the RBP1 and [E1]RBP2[/E1] genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for [E2]RBP2[/E2]) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP2", "entity_1_idx": [[29, 33]], "entity_1_idx_in_text_with_entity_marker": [33, 37], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP2", "entity_2_idx": [[108, 112]], "entity_2_idx_in_text_with_entity_marker": [121, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d147.s1249_AIMed.d147.s1249.p5", "text": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "text_with_entity_marker": "The products of the RBP1 and RBP2 genes are ubiquitously expressed, large (200 kDa for [E1]RBP1[/E1] and 195 kDa for [E2]RBP2[/E2]) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP1", "entity_1_idx": [[87, 91]], "entity_1_idx_in_text_with_entity_marker": [91, 95], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP2", "entity_2_idx": [[108, 112]], "entity_2_idx_in_text_with_entity_marker": [121, 125], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1586_AIMed.d187.s1586.p0", "text": "Aggregated amyloid beta-protein (A beta) is a key component of the amyloid depositions found in the brains of patients with Alzheimer's disease.", "text_with_entity_marker": "Aggregated [E1]amyloid beta-protein[/E1] ([E2]A beta[/E2]) is a key component of the amyloid depositions found in the brains of patients with Alzheimer's disease.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "amyloid beta-protein", "entity_1_idx": [[11, 31]], "entity_1_idx_in_text_with_entity_marker": [15, 35], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[33, 39]], "entity_2_idx_in_text_with_entity_marker": [46, 52], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1588_AIMed.d187.s1588.p0", "text": "The analysis of complexes of A beta with CSF proteins in a KBr gradient revealed an association of A beta only with free proteins and not with lipoprotein particles.", "text_with_entity_marker": "The analysis of complexes of [E1]A beta[/E1] with CSF proteins in a KBr gradient revealed an association of [E2]A beta[/E2] only with free proteins and not with lipoprotein particles.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "A beta", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[99, 105]], "entity_2_idx_in_text_with_entity_marker": [112, 118], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d187.s1590_AIMed.d187.s1590.p0", "text": "In physiological buffers and CSF, TTR exclusively decreased the level of A beta pentamers.", "text_with_entity_marker": "In physiological buffers and CSF, [E1]TTR[/E1] exclusively decreased the level of [E2]A beta[/E2] pentamers.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TTR", "entity_1_idx": [[34, 37]], "entity_1_idx_in_text_with_entity_marker": [38, 41], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "A beta", "entity_2_idx": [[73, 79]], "entity_2_idx_in_text_with_entity_marker": [86, 92], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d23.s189_AIMed.d23.s189.p0", "text": "In the present study, we examined the presence of glucocorticoid receptors (GRs) and cyclooxygenase-2 (COX-2) in the nasal polyps of nonallergic patients as compared with normal controls.", "text_with_entity_marker": "In the present study, we examined the presence of glucocorticoid receptors (GRs) and [E1]cyclooxygenase-2[/E1] ([E2]COX-2[/E2]) in the nasal polyps of nonallergic patients as compared with normal controls.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "cyclooxygenase-2", "entity_1_idx": [[85, 101]], "entity_1_idx_in_text_with_entity_marker": [89, 105], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "COX-2", "entity_2_idx": [[103, 108]], "entity_2_idx_in_text_with_entity_marker": [116, 121], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d23.s194_AIMed.d23.s194.p0", "text": "In contrast, in normal nasal tissues, COX-2 labeling was only found in the vascular wall, and the expression was weaker--a finding demonstrating that COX-2 is upregulated in nasal polyps.", "text_with_entity_marker": "In contrast, in normal nasal tissues, [E1]COX-2[/E1] labeling was only found in the vascular wall, and the expression was weaker--a finding demonstrating that [E2]COX-2[/E2] is upregulated in nasal polyps.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "COX-2", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "COX-2", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d23.s195_AIMed.d23.s195.p0", "text": "Therefore, 1) the presence of GRs and COX-2 in nasal polyps from nonallergic patients, as well as upregulation of COX-2 expression, suggests that inflammation may play an important role in the pathophysiology of nasal polyps; and 2) glucocorticoid could be a potential treatment method for suppressing inflammatory processes.", "text_with_entity_marker": "Therefore, 1) the presence of GRs and [E1]COX-2[/E1] in nasal polyps from nonallergic patients, as well as upregulation of [E2]COX-2[/E2] expression, suggests that inflammation may play an important role in the pathophysiology of nasal polyps; and 2) glucocorticoid could be a potential treatment method for suppressing inflammatory processes.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "COX-2", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "COX-2", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s17_AIMed.d2.s17.p0", "text": "The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "text_with_entity_marker": "The molar ratio of serum [E1]retinol-binding protein[/E1] ([E2]RBP[/E2]) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "retinol-binding protein", "entity_1_idx": [[25, 48]], "entity_1_idx_in_text_with_entity_marker": [29, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[50, 53]], "entity_2_idx_in_text_with_entity_marker": [63, 66], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s17_AIMed.d2.s17.p1", "text": "The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "text_with_entity_marker": "The molar ratio of serum [E1]retinol-binding protein[/E1] (RBP) to [E2]transthyretin[/E2] (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "retinol-binding protein", "entity_1_idx": [[25, 48]], "entity_1_idx_in_text_with_entity_marker": [29, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transthyretin", "entity_2_idx": [[58, 71]], "entity_2_idx_in_text_with_entity_marker": [71, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s17_AIMed.d2.s17.p2", "text": "The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "text_with_entity_marker": "The molar ratio of serum [E1]retinol-binding protein[/E1] (RBP) to transthyretin ([E2]TTR[/E2]) is not useful to assess vitamin A status during infection in hospitalised children.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "retinol-binding protein", "entity_1_idx": [[25, 48]], "entity_1_idx_in_text_with_entity_marker": [29, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s17_AIMed.d2.s17.p3", "text": "The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "text_with_entity_marker": "The molar ratio of serum retinol-binding protein ([E1]RBP[/E1]) to [E2]transthyretin[/E2] (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transthyretin", "entity_2_idx": [[58, 71]], "entity_2_idx_in_text_with_entity_marker": [71, 84], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s17_AIMed.d2.s17.p4", "text": "The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "text_with_entity_marker": "The molar ratio of serum retinol-binding protein ([E1]RBP[/E1]) to transthyretin ([E2]TTR[/E2]) is not useful to assess vitamin A status during infection in hospitalised children.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[50, 53]], "entity_1_idx_in_text_with_entity_marker": [54, 57], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s17_AIMed.d2.s17.p5", "text": "The molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) is not useful to assess vitamin A status during infection in hospitalised children.", "text_with_entity_marker": "The molar ratio of serum retinol-binding protein (RBP) to [E1]transthyretin[/E1] ([E2]TTR[/E2]) is not useful to assess vitamin A status during infection in hospitalised children.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "transthyretin", "entity_1_idx": [[58, 71]], "entity_1_idx_in_text_with_entity_marker": [62, 75], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[73, 76]], "entity_2_idx_in_text_with_entity_marker": [86, 89], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s18_AIMed.d2.s18.p0", "text": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "text_with_entity_marker": "OBJECTIVE: To assess the usefulness of the molar ratio of serum [E1]retinol-binding protein[/E1] ([E2]RBP[/E2]) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "retinol-binding protein", "entity_1_idx": [[64, 87]], "entity_1_idx_in_text_with_entity_marker": [68, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[89, 92]], "entity_2_idx_in_text_with_entity_marker": [102, 105], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s18_AIMed.d2.s18.p1", "text": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "text_with_entity_marker": "OBJECTIVE: To assess the usefulness of the molar ratio of serum [E1]retinol-binding protein[/E1] (RBP) to [E2]transthyretin[/E2] (TTR) to determine vitamin A (VA) status during infection.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "retinol-binding protein", "entity_1_idx": [[64, 87]], "entity_1_idx_in_text_with_entity_marker": [68, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transthyretin", "entity_2_idx": [[97, 110]], "entity_2_idx_in_text_with_entity_marker": [110, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s18_AIMed.d2.s18.p2", "text": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "text_with_entity_marker": "OBJECTIVE: To assess the usefulness of the molar ratio of serum [E1]retinol-binding protein[/E1] (RBP) to transthyretin ([E2]TTR[/E2]) to determine vitamin A (VA) status during infection.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "retinol-binding protein", "entity_1_idx": [[64, 87]], "entity_1_idx_in_text_with_entity_marker": [68, 91], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s18_AIMed.d2.s18.p3", "text": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "text_with_entity_marker": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein ([E1]RBP[/E1]) to [E2]transthyretin[/E2] (TTR) to determine vitamin A (VA) status during infection.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[89, 92]], "entity_1_idx_in_text_with_entity_marker": [93, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "transthyretin", "entity_2_idx": [[97, 110]], "entity_2_idx_in_text_with_entity_marker": [110, 123], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s18_AIMed.d2.s18.p4", "text": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "text_with_entity_marker": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein ([E1]RBP[/E1]) to transthyretin ([E2]TTR[/E2]) to determine vitamin A (VA) status during infection.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[89, 92]], "entity_1_idx_in_text_with_entity_marker": [93, 96], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s18_AIMed.d2.s18.p5", "text": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to transthyretin (TTR) to determine vitamin A (VA) status during infection.", "text_with_entity_marker": "OBJECTIVE: To assess the usefulness of the molar ratio of serum retinol-binding protein (RBP) to [E1]transthyretin[/E1] ([E2]TTR[/E2]) to determine vitamin A (VA) status during infection.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "transthyretin", "entity_1_idx": [[97, 110]], "entity_1_idx_in_text_with_entity_marker": [101, 114], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s19_AIMed.d2.s19.p0", "text": "DESIGN: We took advantage of previously collected data during a randomised double-blind, placebo-controlled clinical trial to conduct a secondary analysis of the RBP/TTR ratio and its relationship to infection and VA status.", "text_with_entity_marker": "DESIGN: We took advantage of previously collected data during a randomised double-blind, placebo-controlled clinical trial to conduct a secondary analysis of the [E1]RBP[/E1]/[E2]TTR[/E2] ratio and its relationship to infection and VA status.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[162, 165]], "entity_1_idx_in_text_with_entity_marker": [166, 169], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[166, 169]], "entity_2_idx_in_text_with_entity_marker": [179, 182], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s23_AIMed.d2.s23.p0", "text": "MAIN OUTCOME MEASURES: RBP/TTR molar ratio after 7 days hospitalisation.", "text_with_entity_marker": "MAIN OUTCOME MEASURES: [E1]RBP[/E1]/[E2]TTR[/E2] molar ratio after 7 days hospitalisation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[23, 26]], "entity_1_idx_in_text_with_entity_marker": [27, 30], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[27, 30]], "entity_2_idx_in_text_with_entity_marker": [40, 43], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p0", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar [E1]RBP[/E1]:[E2]TTR[/E2] ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p1", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar [E1]RBP[/E1]:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in [E2]RBP[/E2]:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[407, 410]], "entity_2_idx_in_text_with_entity_marker": [420, 423], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p2", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar [E1]RBP[/E1]:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:[E2]TTR[/E2] ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[411, 414]], "entity_2_idx_in_text_with_entity_marker": [424, 427], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p3", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar [E1]RBP[/E1]:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar [E2]RBP[/E2]:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[604, 607]], "entity_2_idx_in_text_with_entity_marker": [617, 620], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p4", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar [E1]RBP[/E1]:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:[E2]TTR[/E2] ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[608, 611]], "entity_2_idx_in_text_with_entity_marker": [621, 624], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p5", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:[E1]TTR[/E1] ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in [E2]RBP[/E2]:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TTR", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[407, 410]], "entity_2_idx_in_text_with_entity_marker": [420, 423], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p6", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:[E1]TTR[/E1] ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:[E2]TTR[/E2] ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TTR", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[411, 414]], "entity_2_idx_in_text_with_entity_marker": [424, 427], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p7", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:[E1]TTR[/E1] ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar [E2]RBP[/E2]:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TTR", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[604, 607]], "entity_2_idx_in_text_with_entity_marker": [617, 620], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p8", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:[E1]TTR[/E1] ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:[E2]TTR[/E2] ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TTR", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[608, 611]], "entity_2_idx_in_text_with_entity_marker": [621, 624], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p9", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in [E1]RBP[/E1]:[E2]TTR[/E2] ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[407, 410]], "entity_1_idx_in_text_with_entity_marker": [411, 414], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[411, 414]], "entity_2_idx_in_text_with_entity_marker": [424, 427], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p10", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in [E1]RBP[/E1]:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar [E2]RBP[/E2]:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[407, 410]], "entity_1_idx_in_text_with_entity_marker": [411, 414], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[604, 607]], "entity_2_idx_in_text_with_entity_marker": [617, 620], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p11", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in [E1]RBP[/E1]:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:[E2]TTR[/E2] ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[407, 410]], "entity_1_idx_in_text_with_entity_marker": [411, 414], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[608, 611]], "entity_2_idx_in_text_with_entity_marker": [621, 624], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p12", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:[E1]TTR[/E1] ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar [E2]RBP[/E2]:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TTR", "entity_1_idx": [[411, 414]], "entity_1_idx_in_text_with_entity_marker": [415, 418], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "RBP", "entity_2_idx": [[604, 607]], "entity_2_idx_in_text_with_entity_marker": [617, 620], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p13", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:[E1]TTR[/E1] ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:[E2]TTR[/E2] ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TTR", "entity_1_idx": [[411, 414]], "entity_1_idx_in_text_with_entity_marker": [415, 418], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[608, 611]], "entity_2_idx_in_text_with_entity_marker": [621, 624], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d2.s24_AIMed.d2.s24.p14", "text": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar RBP:TTR ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "text_with_entity_marker": "RESULTS: After 7 days hospitalisation, molar RBP:TTR ratio (mean+/-s.d.) of infected children (C-reactive proteins>10 mg/l) was 0.67+/-0.31 in the high-dose group (n=81), 0.74+/-0.44 in the low dose group (n=71) and 0.73+/-0.39 in the placebo group (n=81). These values did not differ significantly (one-way ANOVA P=0.472). In patients with baseline serum retinol concentrations<0.70 micromol/l, changes in RBP:TTR ratio between admission and day 7 were not statistically different in the three groups (one-way ANOVA P=0.548). CONCLUSIONS: In this population of malnourished hospitalised children, molar [E1]RBP[/E1]:[E2]TTR[/E2] ratio does not appear to be useful to assess VA status during infection. SPONSORSHIP: Our research was partially supported by a grant from the Fonds de la Recherche Scientifique et Medicale (contract 3.4505.94) and the David and Alice Van Buuren Foundation.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RBP", "entity_1_idx": [[604, 607]], "entity_1_idx_in_text_with_entity_marker": [608, 611], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "TTR", "entity_2_idx": [[608, 611]], "entity_2_idx_in_text_with_entity_marker": [621, 624], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s88_AIMed.d11.s88.p0", "text": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.", "text_with_entity_marker": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members ([E1]ErbB-1[/E1], neu/[E2]ErbB-2[/E2], ErbB-3, and ErbB-4) and tumor recurrence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ErbB-1", "entity_1_idx": [[117, 123]], "entity_1_idx_in_text_with_entity_marker": [121, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-2", "entity_2_idx": [[129, 135]], "entity_2_idx_in_text_with_entity_marker": [142, 148], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s88_AIMed.d11.s88.p1", "text": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.", "text_with_entity_marker": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members ([E1]ErbB-1[/E1], neu/ErbB-2, [E2]ErbB-3[/E2], and ErbB-4) and tumor recurrence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ErbB-1", "entity_1_idx": [[117, 123]], "entity_1_idx_in_text_with_entity_marker": [121, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-3", "entity_2_idx": [[137, 143]], "entity_2_idx_in_text_with_entity_marker": [150, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s88_AIMed.d11.s88.p2", "text": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.", "text_with_entity_marker": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members ([E1]ErbB-1[/E1], neu/ErbB-2, ErbB-3, and [E2]ErbB-4[/E2]) and tumor recurrence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ErbB-1", "entity_1_idx": [[117, 123]], "entity_1_idx_in_text_with_entity_marker": [121, 127], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-4", "entity_2_idx": [[149, 155]], "entity_2_idx_in_text_with_entity_marker": [162, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s88_AIMed.d11.s88.p3", "text": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.", "text_with_entity_marker": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/[E1]ErbB-2[/E1], [E2]ErbB-3[/E2], and ErbB-4) and tumor recurrence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ErbB-2", "entity_1_idx": [[129, 135]], "entity_1_idx_in_text_with_entity_marker": [133, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-3", "entity_2_idx": [[137, 143]], "entity_2_idx_in_text_with_entity_marker": [150, 156], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s88_AIMed.d11.s88.p4", "text": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.", "text_with_entity_marker": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/[E1]ErbB-2[/E1], ErbB-3, and [E2]ErbB-4[/E2]) and tumor recurrence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ErbB-2", "entity_1_idx": [[129, 135]], "entity_1_idx_in_text_with_entity_marker": [133, 139], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-4", "entity_2_idx": [[149, 155]], "entity_2_idx_in_text_with_entity_marker": [162, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s88_AIMed.d11.s88.p5", "text": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.", "text_with_entity_marker": "BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, [E1]ErbB-3[/E1], and [E2]ErbB-4[/E2]) and tumor recurrence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ErbB-3", "entity_1_idx": [[137, 143]], "entity_1_idx_in_text_with_entity_marker": [141, 147], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-4", "entity_2_idx": [[149, 155]], "entity_2_idx_in_text_with_entity_marker": [162, 168], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d11.s90_AIMed.d11.s90.p0", "text": "RESULTS: Using Cox univariate analysis, we determined that angiolymphatic tumor emboli and non-well-differentiated tumor cells were two significant conventional pathologic predictors of tumor recurrence, and that ErbB-1 and ErbB-3 were also significant predictors.", "text_with_entity_marker": "RESULTS: Using Cox univariate analysis, we determined that angiolymphatic tumor emboli and non-well-differentiated tumor cells were two significant conventional pathologic predictors of tumor recurrence, and that [E1]ErbB-1[/E1] and [E2]ErbB-3[/E2] were also significant predictors.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "ErbB-1", "entity_1_idx": [[213, 219]], "entity_1_idx_in_text_with_entity_marker": [217, 223], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "ErbB-3", "entity_2_idx": [[224, 230]], "entity_2_idx_in_text_with_entity_marker": [237, 243], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d85.s718_AIMed.d85.s718.p0", "text": "In the second of a series of experiments designed to identify p47nck-Src homology 3 (SH3)-binding molecules, we report the cloning of SAKAP II (Src A box Nck-associated protein II) from an HL60 cDNA expression library.", "text_with_entity_marker": "In the second of a series of experiments designed to identify [E1]p47nck[/E1]-Src homology 3 (SH3)-binding molecules, we report the cloning of [E2]SAKAP II[/E2] (Src A box Nck-associated protein II) from an HL60 cDNA expression library.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p47nck", "entity_1_idx": [[62, 68]], "entity_1_idx_in_text_with_entity_marker": [66, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "SAKAP II", "entity_2_idx": [[134, 142]], "entity_2_idx_in_text_with_entity_marker": [147, 155], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d85.s718_AIMed.d85.s718.p1", "text": "In the second of a series of experiments designed to identify p47nck-Src homology 3 (SH3)-binding molecules, we report the cloning of SAKAP II (Src A box Nck-associated protein II) from an HL60 cDNA expression library.", "text_with_entity_marker": "In the second of a series of experiments designed to identify [E1]p47nck[/E1]-Src homology 3 (SH3)-binding molecules, we report the cloning of SAKAP II ([E2]Src A box Nck-associated protein II[/E2]) from an HL60 cDNA expression library.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "p47nck", "entity_1_idx": [[62, 68]], "entity_1_idx_in_text_with_entity_marker": [66, 72], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Src A box Nck-associated protein II", "entity_2_idx": [[144, 179]], "entity_2_idx_in_text_with_entity_marker": [157, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d85.s718_AIMed.d85.s718.p2", "text": "In the second of a series of experiments designed to identify p47nck-Src homology 3 (SH3)-binding molecules, we report the cloning of SAKAP II (Src A box Nck-associated protein II) from an HL60 cDNA expression library.", "text_with_entity_marker": "In the second of a series of experiments designed to identify p47nck-Src homology 3 (SH3)-binding molecules, we report the cloning of [E1]SAKAP II[/E1] ([E2]Src A box Nck-associated protein II[/E2]) from an HL60 cDNA expression library.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "SAKAP II", "entity_1_idx": [[134, 142]], "entity_1_idx_in_text_with_entity_marker": [138, 146], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "Src A box Nck-associated protein II", "entity_2_idx": [[144, 179]], "entity_2_idx_in_text_with_entity_marker": [157, 192], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "AIMed.d85.s722_AIMed.d85.s722.p0", "text": "In vitro translation studies identified the 66-kDa protein as the protein product of WASP, and subcellular fractionation experiments showed that p66WASP is mainly present in the cytosol fraction, although significant amounts are also present in membrane and nuclear fractions.", "text_with_entity_marker": "In vitro translation studies identified the 66-kDa protein as the protein product of [E1]WASP[/E1], and subcellular fractionation experiments showed that [E2]p66WASP[/E2] is mainly present in the cytosol fraction, although significant amounts are also present in membrane and nuclear fractions.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "WASP", "entity_1_idx": [[85, 89]], "entity_1_idx_in_text_with_entity_marker": [89, 93], "entity_1_type": "protein", "entity_1_type_id": 0, "entity_2": "p66WASP", "entity_2_idx": [[145, 152]], "entity_2_idx_in_text_with_entity_marker": [158, 165], "entity_2_type": "protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d322.s0_BioInfer.d322.s0.p0", "text": "In cell extracts, we found that complementary strand synthesis was inhibited by the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and rescued by the addition of proliferating cell nuclear antigen, arguing for the involvement of DNA polymerase (Pol) delta in the conversion reaction.", "text_with_entity_marker": "In cell extracts, we found that complementary strand synthesis was inhibited by the [E1]cyclin-dependent kinase inhibitor[/E1] p21([E2]WAF1[/E2]/CIP1) and rescued by the addition of proliferating cell nuclear antigen, arguing for the involvement of DNA polymerase (Pol) delta in the conversion reaction.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitor", "entity_1_idx": [[84, 117]], "entity_1_idx_in_text_with_entity_marker": [88, 121], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "WAF1", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d322.s0_BioInfer.d322.s0.p2", "text": "In cell extracts, we found that complementary strand synthesis was inhibited by the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and rescued by the addition of proliferating cell nuclear antigen, arguing for the involvement of DNA polymerase (Pol) delta in the conversion reaction.", "text_with_entity_marker": "In cell extracts, we found that complementary strand synthesis was inhibited by the [E1]cyclin-dependent kinase inhibitor[/E1] p21(WAF1/[E2]CIP1[/E2]) and rescued by the addition of proliferating cell nuclear antigen, arguing for the involvement of DNA polymerase (Pol) delta in the conversion reaction.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitor", "entity_1_idx": [[84, 117]], "entity_1_idx_in_text_with_entity_marker": [88, 121], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "CIP1", "entity_2_idx": [[127, 131]], "entity_2_idx_in_text_with_entity_marker": [140, 144], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d322.s0_BioInfer.d322.s0.p3", "text": "In cell extracts, we found that complementary strand synthesis was inhibited by the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and rescued by the addition of proliferating cell nuclear antigen, arguing for the involvement of DNA polymerase (Pol) delta in the conversion reaction.", "text_with_entity_marker": "In cell extracts, we found that complementary strand synthesis was inhibited by the [E1]cyclin-dependent kinase inhibitor[/E1] [E2]p21[/E2](WAF1/CIP1) and rescued by the addition of proliferating cell nuclear antigen, arguing for the involvement of DNA polymerase (Pol) delta in the conversion reaction.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitor", "entity_1_idx": [[84, 117]], "entity_1_idx_in_text_with_entity_marker": [88, 121], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "p21", "entity_2_idx": [[118, 121]], "entity_2_idx_in_text_with_entity_marker": [131, 134], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d633.s0_BioInfer.d633.s0.p1", "text": "The intracellular molecules calmodulin and profilin actively regulate actin-based motility and participate in the signaling pathways used to steer growth cones.", "text_with_entity_marker": "The intracellular molecules calmodulin and [E1]profilin[/E1] actively regulate [E2]actin[/E2]-based motility and participate in the signaling pathways used to steer growth cones.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[43, 51]], "entity_1_idx_in_text_with_entity_marker": [47, 55], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[70, 75]], "entity_2_idx_in_text_with_entity_marker": [83, 88], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d633.s0_BioInfer.d633.s0.p2", "text": "The intracellular molecules calmodulin and profilin actively regulate actin-based motility and participate in the signaling pathways used to steer growth cones.", "text_with_entity_marker": "The intracellular molecules [E1]calmodulin[/E1] and profilin actively regulate [E2]actin[/E2]-based motility and participate in the signaling pathways used to steer growth cones.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "calmodulin", "entity_1_idx": [[28, 38]], "entity_1_idx_in_text_with_entity_marker": [32, 42], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[70, 75]], "entity_2_idx_in_text_with_entity_marker": [83, 88], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d369.s0_BioInfer.d369.s0.p2", "text": "In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the Fas-associated protein FADD/MORT1 or the TNF receptor-associated protein TRADD [2-4].", "text_with_entity_marker": "In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the [E1]Fas[/E1]-associated protein FADD/[E2]MORT1[/E2] or the TNF receptor-associated protein TRADD [2-4].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Fas", "entity_1_idx": [[239, 242]], "entity_1_idx_in_text_with_entity_marker": [243, 246], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "MORT1", "entity_2_idx": [[267, 272]], "entity_2_idx_in_text_with_entity_marker": [280, 285], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d369.s0_BioInfer.d369.s0.p3", "text": "In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the Fas-associated protein FADD/MORT1 or the TNF receptor-associated protein TRADD [2-4].", "text_with_entity_marker": "In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the [E1]Fas[/E1]-associated protein [E2]FADD[/E2]/MORT1 or the TNF receptor-associated protein TRADD [2-4].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Fas", "entity_1_idx": [[239, 242]], "entity_1_idx_in_text_with_entity_marker": [243, 246], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "FADD", "entity_2_idx": [[262, 266]], "entity_2_idx_in_text_with_entity_marker": [275, 279], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d369.s0_BioInfer.d369.s0.p4", "text": "In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the Fas-associated protein FADD/MORT1 or the TNF receptor-associated protein TRADD [2-4].", "text_with_entity_marker": "In their cytoplasmic region, some of these receptors share a conserved sequence motif - the 'death domain' - which is required for transduction of the apoptotic signal by recruiting other death-domain-containing adaptor molecules like the Fas-associated protein FADD/MORT1 or the [E1]TNF receptor[/E1]-associated protein [E2]TRADD[/E2] [2-4].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TNF receptor", "entity_1_idx": [[280, 292]], "entity_1_idx_in_text_with_entity_marker": [284, 296], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TRADD", "entity_2_idx": [[312, 317]], "entity_2_idx_in_text_with_entity_marker": [325, 330], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d279.s0_BioInfer.d279.s0.p3", "text": "However, upon treatment with DMSO, cytoplasmic actin filaments were disrupted and intranuclear rod structures containing cofilin and actin were apparently larger and thicker in cells overexpressing cofilin than in normal cells.", "text_with_entity_marker": "However, upon treatment with DMSO, cytoplasmic actin filaments were disrupted and intranuclear rod structures containing [E1]cofilin[/E1] and [E2]actin[/E2] were apparently larger and thicker in cells overexpressing cofilin than in normal cells.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[121, 128]], "entity_1_idx_in_text_with_entity_marker": [125, 132], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d279.s1_BioInfer.d279.s1.p0", "text": "In cultured cells, cofilin, as well as ADF, translocates from the cytoplasm into the nucleus together with actin and forms rod-like structures in response to heat shock or dimethylsulfoxide (DMSO) treatment.", "text_with_entity_marker": "In cultured cells, cofilin, as well as [E1]ADF[/E1], translocates from the cytoplasm into the nucleus together with [E2]actin[/E2] and forms rod-like structures in response to heat shock or dimethylsulfoxide (DMSO) treatment.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "ADF", "entity_1_idx": [[39, 42]], "entity_1_idx_in_text_with_entity_marker": [43, 46], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[107, 112]], "entity_2_idx_in_text_with_entity_marker": [120, 125], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d279.s1_BioInfer.d279.s1.p2", "text": "In cultured cells, cofilin, as well as ADF, translocates from the cytoplasm into the nucleus together with actin and forms rod-like structures in response to heat shock or dimethylsulfoxide (DMSO) treatment.", "text_with_entity_marker": "In cultured cells, [E1]cofilin[/E1], as well as ADF, translocates from the cytoplasm into the nucleus together with [E2]actin[/E2] and forms rod-like structures in response to heat shock or dimethylsulfoxide (DMSO) treatment.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[19, 26]], "entity_1_idx_in_text_with_entity_marker": [23, 30], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[107, 112]], "entity_2_idx_in_text_with_entity_marker": [120, 125], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d279.s2_BioInfer.d279.s2.p0", "text": "Stimulus-dependent disorganization of actin filaments induced by overexpression of cofilin in C2 myoblasts.", "text_with_entity_marker": "Stimulus-dependent disorganization of [E1]actin[/E1] filaments induced by overexpression of [E2]cofilin[/E2] in C2 myoblasts.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[38, 43]], "entity_1_idx_in_text_with_entity_marker": [42, 47], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[83, 90]], "entity_2_idx_in_text_with_entity_marker": [96, 103], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d273.s0_BioInfer.d273.s0.p2", "text": "However, regulation of profilin function is generally unknown and controversy exists regarding profilin effects on actin polymerization.", "text_with_entity_marker": "However, regulation of profilin function is generally unknown and controversy exists regarding [E1]profilin[/E1] effects on [E2]actin[/E2] polymerization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[95, 103]], "entity_1_idx_in_text_with_entity_marker": [99, 107], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d88.s0_BioInfer.d88.s0.p1", "text": "At the light microscope level, brush cells can be identified by antibodies against the actin filament crosslinking proteins villin and fimbrin that not only stain the apical tuft of microvilli and their rootlets, but also label projections emanating from the basolateral surface of these cells.", "text_with_entity_marker": "At the light microscope level, brush cells can be identified by antibodies against the [E1]actin[/E1] filament crosslinking proteins [E2]villin[/E2] and fimbrin that not only stain the apical tuft of microvilli and their rootlets, but also label projections emanating from the basolateral surface of these cells.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "villin", "entity_2_idx": [[124, 130]], "entity_2_idx_in_text_with_entity_marker": [137, 143], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d88.s0_BioInfer.d88.s0.p2", "text": "At the light microscope level, brush cells can be identified by antibodies against the actin filament crosslinking proteins villin and fimbrin that not only stain the apical tuft of microvilli and their rootlets, but also label projections emanating from the basolateral surface of these cells.", "text_with_entity_marker": "At the light microscope level, brush cells can be identified by antibodies against the [E1]actin[/E1] filament crosslinking proteins villin and [E2]fimbrin[/E2] that not only stain the apical tuft of microvilli and their rootlets, but also label projections emanating from the basolateral surface of these cells.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[87, 92]], "entity_1_idx_in_text_with_entity_marker": [91, 96], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrin", "entity_2_idx": [[135, 142]], "entity_2_idx_in_text_with_entity_marker": [148, 155], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d154.s0_BioInfer.d154.s0.p0", "text": "Conversely, inhibition of LIMK's activity by expressing a dominant negative construct, LIMK1-, or expression of the constitutively active S3A cofilin mutant induces loss of actin filaments at the phagocytic cup and also inhibits phagocytosis.", "text_with_entity_marker": "Conversely, inhibition of [E1]LIMK[/E1]'s activity by expressing a dominant negative construct, LIMK1-, or expression of the constitutively active S3A cofilin mutant induces loss of [E2]actin[/E2] filaments at the phagocytic cup and also inhibits phagocytosis.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "LIMK", "entity_1_idx": [[26, 30]], "entity_1_idx_in_text_with_entity_marker": [30, 34], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d154.s0_BioInfer.d154.s0.p1", "text": "Conversely, inhibition of LIMK's activity by expressing a dominant negative construct, LIMK1-, or expression of the constitutively active S3A cofilin mutant induces loss of actin filaments at the phagocytic cup and also inhibits phagocytosis.", "text_with_entity_marker": "Conversely, inhibition of LIMK's activity by expressing a dominant negative construct, LIMK1-, or expression of the constitutively active S3A [E1]cofilin[/E1] mutant induces loss of [E2]actin[/E2] filaments at the phagocytic cup and also inhibits phagocytosis.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[142, 149]], "entity_1_idx_in_text_with_entity_marker": [146, 153], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d154.s0_BioInfer.d154.s0.p2", "text": "Conversely, inhibition of LIMK's activity by expressing a dominant negative construct, LIMK1-, or expression of the constitutively active S3A cofilin mutant induces loss of actin filaments at the phagocytic cup and also inhibits phagocytosis.", "text_with_entity_marker": "Conversely, inhibition of LIMK's activity by expressing a dominant negative construct, [E1]LIMK1-[/E1], or expression of the constitutively active S3A cofilin mutant induces loss of [E2]actin[/E2] filaments at the phagocytic cup and also inhibits phagocytosis.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "LIMK1-", "entity_1_idx": [[87, 93]], "entity_1_idx_in_text_with_entity_marker": [91, 97], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[173, 178]], "entity_2_idx_in_text_with_entity_marker": [186, 191], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d387.s0_BioInfer.d387.s0.p14", "text": "In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity.", "text_with_entity_marker": "In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of [E1]mitogen-activated protein kinase[/E1] (ERK) kinases ([E2]MEK[/E2]1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "mitogen-activated protein kinase", "entity_1_idx": [[150, 182], [189, 196]], "entity_1_idx_in_text_with_entity_marker": [154, 186], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "MEK", "entity_2_idx": [[198, 201], [203, 204]], "entity_2_idx_in_text_with_entity_marker": [211, 214], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d387.s0_BioInfer.d387.s0.p32", "text": "In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of mitogen-activated protein kinase (ERK) kinases (MEK1/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity.", "text_with_entity_marker": "In vitro studies indicated that suramin completely blocked PDGF receptor activation or phosphorylation stimulated by PDGF-AB, inhibited activation of [E1]mitogen-activated protein kinase[/E1] (ERK) kinases ([E2]MEK1[/E2]/2) and ERK1/2, and abrogated transcription factor AP-1 DNA-binding activity.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "mitogen-activated protein kinase", "entity_1_idx": [[150, 182], [189, 196]], "entity_1_idx_in_text_with_entity_marker": [154, 186], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "MEK1", "entity_2_idx": [[198, 202]], "entity_2_idx_in_text_with_entity_marker": [211, 215], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s0_BioInfer.d33.s0.p0", "text": "A highly significant correlation was observed between the loss of expression of E-cadherin, alpha-catenin and gamma-catenin, but not beta-catenin, with increased TNM stage (p <0.05).", "text_with_entity_marker": "A highly significant correlation was observed between the loss of expression of [E1]E-cadherin[/E1], [E2]alpha-catenin[/E2] and gamma-catenin, but not beta-catenin, with increased TNM stage (p <0.05).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "E-cadherin", "entity_1_idx": [[80, 90]], "entity_1_idx_in_text_with_entity_marker": [84, 94], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-catenin", "entity_2_idx": [[92, 105]], "entity_2_idx_in_text_with_entity_marker": [105, 118], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s0_BioInfer.d33.s0.p1", "text": "A highly significant correlation was observed between the loss of expression of E-cadherin, alpha-catenin and gamma-catenin, but not beta-catenin, with increased TNM stage (p <0.05).", "text_with_entity_marker": "A highly significant correlation was observed between the loss of expression of E-cadherin, [E1]alpha-catenin[/E1] and gamma-catenin, but not [E2]beta-catenin[/E2], with increased TNM stage (p <0.05).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[92, 105]], "entity_1_idx_in_text_with_entity_marker": [96, 109], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[133, 145]], "entity_2_idx_in_text_with_entity_marker": [146, 158], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s0_BioInfer.d33.s0.p2", "text": "A highly significant correlation was observed between the loss of expression of E-cadherin, alpha-catenin and gamma-catenin, but not beta-catenin, with increased TNM stage (p <0.05).", "text_with_entity_marker": "A highly significant correlation was observed between the loss of expression of E-cadherin, [E1]alpha-catenin[/E1] and [E2]gamma-catenin[/E2], but not beta-catenin, with increased TNM stage (p <0.05).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[92, 105]], "entity_1_idx_in_text_with_entity_marker": [96, 109], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "gamma-catenin", "entity_2_idx": [[110, 123]], "entity_2_idx_in_text_with_entity_marker": [123, 136], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s0_BioInfer.d33.s0.p3", "text": "A highly significant correlation was observed between the loss of expression of E-cadherin, alpha-catenin and gamma-catenin, but not beta-catenin, with increased TNM stage (p <0.05).", "text_with_entity_marker": "A highly significant correlation was observed between the loss of expression of [E1]E-cadherin[/E1], alpha-catenin and gamma-catenin, but not [E2]beta-catenin[/E2], with increased TNM stage (p <0.05).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "E-cadherin", "entity_1_idx": [[80, 90]], "entity_1_idx_in_text_with_entity_marker": [84, 94], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[133, 145]], "entity_2_idx_in_text_with_entity_marker": [146, 158], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s0_BioInfer.d33.s0.p4", "text": "A highly significant correlation was observed between the loss of expression of E-cadherin, alpha-catenin and gamma-catenin, but not beta-catenin, with increased TNM stage (p <0.05).", "text_with_entity_marker": "A highly significant correlation was observed between the loss of expression of [E1]E-cadherin[/E1], alpha-catenin and [E2]gamma-catenin[/E2], but not beta-catenin, with increased TNM stage (p <0.05).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "E-cadherin", "entity_1_idx": [[80, 90]], "entity_1_idx_in_text_with_entity_marker": [84, 94], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "gamma-catenin", "entity_2_idx": [[110, 123]], "entity_2_idx_in_text_with_entity_marker": [123, 136], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s0_BioInfer.d33.s0.p5", "text": "A highly significant correlation was observed between the loss of expression of E-cadherin, alpha-catenin and gamma-catenin, but not beta-catenin, with increased TNM stage (p <0.05).", "text_with_entity_marker": "A highly significant correlation was observed between the loss of expression of E-cadherin, alpha-catenin and [E1]gamma-catenin[/E1], but not [E2]beta-catenin[/E2], with increased TNM stage (p <0.05).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "gamma-catenin", "entity_1_idx": [[110, 123]], "entity_1_idx_in_text_with_entity_marker": [114, 127], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[133, 145]], "entity_2_idx_in_text_with_entity_marker": [146, 158], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d502.s1_BioInfer.d502.s1.p0", "text": "The presence of filamin in the cleavage furrows also suggests the possibility of an overlapping mechanism in addition to that of a talin mediated mechanism for the attachment of actin filaments to the cell surfaces in the cleavage furrow.", "text_with_entity_marker": "The presence of filamin in the cleavage furrows also suggests the possibility of an overlapping mechanism in addition to that of a [E1]talin[/E1] mediated mechanism for the attachment of [E2]actin[/E2] filaments to the cell surfaces in the cleavage furrow.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "talin", "entity_1_idx": [[131, 136]], "entity_1_idx_in_text_with_entity_marker": [135, 140], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[178, 183]], "entity_2_idx_in_text_with_entity_marker": [191, 196], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d588.s0_BioInfer.d588.s0.p0", "text": "The C374S mutation had the most pronounced effect; it reduced the polymerizability of the actin, abolished its binding to profilin, and filaments containing this mutation moved at reduced rates in the in vitro 'motility assay'.", "text_with_entity_marker": "The C374S mutation had the most pronounced effect; it reduced the polymerizability of the [E1]actin[/E1], abolished its binding to [E2]profilin[/E2], and filaments containing this mutation moved at reduced rates in the in vitro 'motility assay'.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[90, 95]], "entity_1_idx_in_text_with_entity_marker": [94, 99], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[122, 130]], "entity_2_idx_in_text_with_entity_marker": [135, 143], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d655.s0_BioInfer.d655.s0.p0", "text": "The ordered assembly of the talin homologue together with actin and a series of other proteins is considered to play a key role in chemotactic orientation.", "text_with_entity_marker": "The ordered assembly of the [E1]talin[/E1] homologue together with [E2]actin[/E2] and a series of other proteins is considered to play a key role in chemotactic orientation.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "talin", "entity_1_idx": [[28, 33]], "entity_1_idx_in_text_with_entity_marker": [32, 37], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[58, 63]], "entity_2_idx_in_text_with_entity_marker": [71, 76], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d637.s0_BioInfer.d637.s0.p0", "text": "The junctional multidomain protein AF-6 is a binding partner of the Rap1A GTPase and associates with the actin cytoskeletal regulator profilin.", "text_with_entity_marker": "The junctional multidomain protein [E1]AF-6[/E1] is a binding partner of the [E2]Rap1A[/E2] GTPase and associates with the actin cytoskeletal regulator profilin.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "AF-6", "entity_1_idx": [[35, 39]], "entity_1_idx_in_text_with_entity_marker": [39, 43], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "Rap1A", "entity_2_idx": [[68, 73]], "entity_2_idx_in_text_with_entity_marker": [81, 86], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d637.s0_BioInfer.d637.s0.p3", "text": "The junctional multidomain protein AF-6 is a binding partner of the Rap1A GTPase and associates with the actin cytoskeletal regulator profilin.", "text_with_entity_marker": "The junctional multidomain protein [E1]AF-6[/E1] is a binding partner of the Rap1A GTPase and associates with the actin cytoskeletal regulator [E2]profilin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "AF-6", "entity_1_idx": [[35, 39]], "entity_1_idx_in_text_with_entity_marker": [39, 43], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[134, 142]], "entity_2_idx_in_text_with_entity_marker": [147, 155], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d637.s0_BioInfer.d637.s0.p5", "text": "The junctional multidomain protein AF-6 is a binding partner of the Rap1A GTPase and associates with the actin cytoskeletal regulator profilin.", "text_with_entity_marker": "The junctional multidomain protein AF-6 is a binding partner of the [E1]Rap1A[/E1] [E2]GTPase[/E2] and associates with the actin cytoskeletal regulator profilin.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Rap1A", "entity_1_idx": [[68, 73]], "entity_1_idx_in_text_with_entity_marker": [72, 77], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "GTPase", "entity_2_idx": [[74, 80]], "entity_2_idx_in_text_with_entity_marker": [87, 93], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d637.s0_BioInfer.d637.s0.p8", "text": "The junctional multidomain protein AF-6 is a binding partner of the Rap1A GTPase and associates with the actin cytoskeletal regulator profilin.", "text_with_entity_marker": "The junctional multidomain protein AF-6 is a binding partner of the Rap1A GTPase and associates with the [E1]actin[/E1] cytoskeletal regulator [E2]profilin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[134, 142]], "entity_2_idx_in_text_with_entity_marker": [147, 155], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d637.s1_BioInfer.d637.s1.p0", "text": "To our knowledge, AF-6 is the only integral component in cell-cell junctions discovered thus far that interacts with profilin and thus could modulate actin modeling proximal to adhesion complexes.", "text_with_entity_marker": "To our knowledge, [E1]AF-6[/E1] is the only integral component in cell-cell junctions discovered thus far that interacts with [E2]profilin[/E2] and thus could modulate actin modeling proximal to adhesion complexes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "AF-6", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[117, 125]], "entity_2_idx_in_text_with_entity_marker": [130, 138], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d637.s1_BioInfer.d637.s1.p1", "text": "To our knowledge, AF-6 is the only integral component in cell-cell junctions discovered thus far that interacts with profilin and thus could modulate actin modeling proximal to adhesion complexes.", "text_with_entity_marker": "To our knowledge, [E1]AF-6[/E1] is the only integral component in cell-cell junctions discovered thus far that interacts with profilin and thus could modulate [E2]actin[/E2] modeling proximal to adhesion complexes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "AF-6", "entity_1_idx": [[18, 22]], "entity_1_idx_in_text_with_entity_marker": [22, 26], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[150, 155]], "entity_2_idx_in_text_with_entity_marker": [163, 168], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d314.s0_BioInfer.d314.s0.p0", "text": "In addition, we demonstrate that cofilin and its actin binding peptide compete with gelsolin segments 2-3 for binding to actin filaments.", "text_with_entity_marker": "In addition, we demonstrate that [E1]cofilin[/E1] and its [E2]actin[/E2] binding peptide compete with gelsolin segments 2-3 for binding to actin filaments.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[33, 40]], "entity_1_idx_in_text_with_entity_marker": [37, 44], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[49, 54]], "entity_2_idx_in_text_with_entity_marker": [62, 67], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d314.s0_BioInfer.d314.s0.p3", "text": "In addition, we demonstrate that cofilin and its actin binding peptide compete with gelsolin segments 2-3 for binding to actin filaments.", "text_with_entity_marker": "In addition, we demonstrate that [E1]cofilin[/E1] and its actin binding peptide compete with gelsolin segments 2-3 for binding to [E2]actin[/E2] filaments.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[33, 40]], "entity_1_idx_in_text_with_entity_marker": [37, 44], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d314.s0_BioInfer.d314.s0.p5", "text": "In addition, we demonstrate that cofilin and its actin binding peptide compete with gelsolin segments 2-3 for binding to actin filaments.", "text_with_entity_marker": "In addition, we demonstrate that cofilin and its actin binding peptide compete with [E1]gelsolin[/E1] segments 2-3 for binding to [E2]actin[/E2] filaments.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "gelsolin", "entity_1_idx": [[84, 92]], "entity_1_idx_in_text_with_entity_marker": [88, 96], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d185.s0_BioInfer.d185.s0.p2", "text": "Effects of macrophage profilin on actin in the presence and absence of acumentin and gelsolin.", "text_with_entity_marker": "Effects of [E1]macrophage profilin[/E1] on [E2]actin[/E2] in the presence and absence of acumentin and gelsolin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "macrophage profilin", "entity_1_idx": [[11, 30]], "entity_1_idx_in_text_with_entity_marker": [15, 34], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[34, 39]], "entity_2_idx_in_text_with_entity_marker": [47, 52], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d635.s0_BioInfer.d635.s0.p0", "text": "Their abilities to store lipids and express desmin intermediate filaments, alpha-smooth muscle actin, and smooth muscle myosin heavy chain in contractile filaments in vitro illustrate similarities among the pulmonary LF, the hepatic lipocyte, and the contractile interstitial cell, which contribute to the repair reaction in the lung after pulmonary injury.", "text_with_entity_marker": "Their abilities to store lipids and express [E1]desmin[/E1] intermediate filaments, alpha-smooth muscle actin, and [E2]smooth muscle myosin heavy chain[/E2] in contractile filaments in vitro illustrate similarities among the pulmonary LF, the hepatic lipocyte, and the contractile interstitial cell, which contribute to the repair reaction in the lung after pulmonary injury.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "desmin", "entity_1_idx": [[44, 50]], "entity_1_idx_in_text_with_entity_marker": [48, 54], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "smooth muscle myosin heavy chain", "entity_2_idx": [[106, 138]], "entity_2_idx_in_text_with_entity_marker": [119, 151], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d635.s0_BioInfer.d635.s0.p1", "text": "Their abilities to store lipids and express desmin intermediate filaments, alpha-smooth muscle actin, and smooth muscle myosin heavy chain in contractile filaments in vitro illustrate similarities among the pulmonary LF, the hepatic lipocyte, and the contractile interstitial cell, which contribute to the repair reaction in the lung after pulmonary injury.", "text_with_entity_marker": "Their abilities to store lipids and express desmin intermediate filaments, [E1]alpha-smooth muscle actin[/E1], and [E2]smooth muscle myosin heavy chain[/E2] in contractile filaments in vitro illustrate similarities among the pulmonary LF, the hepatic lipocyte, and the contractile interstitial cell, which contribute to the repair reaction in the lung after pulmonary injury.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-smooth muscle actin", "entity_1_idx": [[75, 100]], "entity_1_idx_in_text_with_entity_marker": [79, 104], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "smooth muscle myosin heavy chain", "entity_2_idx": [[106, 138]], "entity_2_idx_in_text_with_entity_marker": [119, 151], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d635.s0_BioInfer.d635.s0.p2", "text": "Their abilities to store lipids and express desmin intermediate filaments, alpha-smooth muscle actin, and smooth muscle myosin heavy chain in contractile filaments in vitro illustrate similarities among the pulmonary LF, the hepatic lipocyte, and the contractile interstitial cell, which contribute to the repair reaction in the lung after pulmonary injury.", "text_with_entity_marker": "Their abilities to store lipids and express [E1]desmin[/E1] intermediate filaments, [E2]alpha-smooth muscle actin[/E2], and smooth muscle myosin heavy chain in contractile filaments in vitro illustrate similarities among the pulmonary LF, the hepatic lipocyte, and the contractile interstitial cell, which contribute to the repair reaction in the lung after pulmonary injury.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "desmin", "entity_1_idx": [[44, 50]], "entity_1_idx_in_text_with_entity_marker": [48, 54], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-smooth muscle actin", "entity_2_idx": [[75, 100]], "entity_2_idx_in_text_with_entity_marker": [88, 113], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d479.s0_BioInfer.d479.s0.p0", "text": "p21 (p21WAF1/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen (PCNA).", "text_with_entity_marker": "[E1]p21[/E1] (p21WAF1/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen ([E2]PCNA[/E2]).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p21", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "PCNA", "entity_2_idx": [[147, 151]], "entity_2_idx_in_text_with_entity_marker": [160, 164], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d479.s0_BioInfer.d479.s0.p3", "text": "p21 (p21WAF1/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen (PCNA).", "text_with_entity_marker": "[E1]p21[/E1] (p21WAF1/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the [E2]proliferating cell nuclear antigen[/E2] (PCNA).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p21", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "proliferating cell nuclear antigen", "entity_2_idx": [[111, 145]], "entity_2_idx_in_text_with_entity_marker": [124, 158], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d479.s0_BioInfer.d479.s0.p4", "text": "p21 (p21WAF1/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen (PCNA).", "text_with_entity_marker": "[E1]p21[/E1] (p21WAF1/Cip1), a [E2]cyclin-dependent kinase inhibitor[/E2], induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen (PCNA).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p21", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin-dependent kinase inhibitor", "entity_2_idx": [[22, 55]], "entity_2_idx_in_text_with_entity_marker": [35, 68], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d479.s0_BioInfer.d479.s0.p5", "text": "p21 (p21WAF1/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen (PCNA).", "text_with_entity_marker": "p21 (p21WAF1/[E1]Cip1[/E1]), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen ([E2]PCNA[/E2]).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Cip1", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "PCNA", "entity_2_idx": [[147, 151]], "entity_2_idx_in_text_with_entity_marker": [160, 164], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d479.s0_BioInfer.d479.s0.p6", "text": "p21 (p21WAF1/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen (PCNA).", "text_with_entity_marker": "p21 ([E1]p21WAF1[/E1]/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen ([E2]PCNA[/E2]).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p21WAF1", "entity_1_idx": [[5, 12]], "entity_1_idx_in_text_with_entity_marker": [9, 16], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "PCNA", "entity_2_idx": [[147, 151]], "entity_2_idx_in_text_with_entity_marker": [160, 164], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d479.s0_BioInfer.d479.s0.p10", "text": "p21 (p21WAF1/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen (PCNA).", "text_with_entity_marker": "p21 (p21WAF1/[E1]Cip1[/E1]), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the [E2]proliferating cell nuclear antigen[/E2] (PCNA).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Cip1", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "proliferating cell nuclear antigen", "entity_2_idx": [[111, 145]], "entity_2_idx_in_text_with_entity_marker": [124, 158], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d479.s0_BioInfer.d479.s0.p11", "text": "p21 (p21WAF1/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen (PCNA).", "text_with_entity_marker": "p21 (p21WAF1/[E1]Cip1[/E1]), a [E2]cyclin-dependent kinase inhibitor[/E2], induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen (PCNA).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Cip1", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin-dependent kinase inhibitor", "entity_2_idx": [[22, 55]], "entity_2_idx_in_text_with_entity_marker": [35, 68], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d479.s0_BioInfer.d479.s0.p12", "text": "p21 (p21WAF1/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen (PCNA).", "text_with_entity_marker": "p21 ([E1]p21WAF1[/E1]/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the [E2]proliferating cell nuclear antigen[/E2] (PCNA).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p21WAF1", "entity_1_idx": [[5, 12]], "entity_1_idx_in_text_with_entity_marker": [9, 16], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "proliferating cell nuclear antigen", "entity_2_idx": [[111, 145]], "entity_2_idx_in_text_with_entity_marker": [124, 158], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d479.s0_BioInfer.d479.s0.p13", "text": "p21 (p21WAF1/Cip1), a cyclin-dependent kinase inhibitor, induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen (PCNA).", "text_with_entity_marker": "p21 ([E1]p21WAF1[/E1]/Cip1), a [E2]cyclin-dependent kinase inhibitor[/E2], induces G1 arrest and can inhibit the activity of the proliferating cell nuclear antigen (PCNA).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p21WAF1", "entity_1_idx": [[5, 12]], "entity_1_idx_in_text_with_entity_marker": [9, 16], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin-dependent kinase inhibitor", "entity_2_idx": [[22, 55]], "entity_2_idx_in_text_with_entity_marker": [35, 68], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d663.s0_BioInfer.d663.s0.p0", "text": "The potentiating effect of insulin appears to involve increases in the expression of cyclin E and decreases in the expression of the cyclin-dependent kinase inhibitor p27(Kip1).", "text_with_entity_marker": "The potentiating effect of insulin appears to involve increases in the expression of cyclin E and decreases in the expression of the [E1]cyclin-dependent kinase inhibitor[/E1] p27([E2]Kip1[/E2]).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitor", "entity_1_idx": [[133, 166]], "entity_1_idx_in_text_with_entity_marker": [137, 170], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "Kip1", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d663.s0_BioInfer.d663.s0.p3", "text": "The potentiating effect of insulin appears to involve increases in the expression of cyclin E and decreases in the expression of the cyclin-dependent kinase inhibitor p27(Kip1).", "text_with_entity_marker": "The potentiating effect of insulin appears to involve increases in the expression of cyclin E and decreases in the expression of the [E1]cyclin-dependent kinase inhibitor[/E1] [E2]p27[/E2](Kip1).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitor", "entity_1_idx": [[133, 166]], "entity_1_idx_in_text_with_entity_marker": [137, 170], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "p27", "entity_2_idx": [[167, 170]], "entity_2_idx_in_text_with_entity_marker": [180, 183], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d663.s0_BioInfer.d663.s0.p5", "text": "The potentiating effect of insulin appears to involve increases in the expression of cyclin E and decreases in the expression of the cyclin-dependent kinase inhibitor p27(Kip1).", "text_with_entity_marker": "The potentiating effect of [E1]insulin[/E1] appears to involve increases in the expression of cyclin E and decreases in the expression of the cyclin-dependent kinase inhibitor p27([E2]Kip1[/E2]).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[27, 34]], "entity_1_idx_in_text_with_entity_marker": [31, 38], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "Kip1", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d663.s0_BioInfer.d663.s0.p7", "text": "The potentiating effect of insulin appears to involve increases in the expression of cyclin E and decreases in the expression of the cyclin-dependent kinase inhibitor p27(Kip1).", "text_with_entity_marker": "The potentiating effect of [E1]insulin[/E1] appears to involve increases in the expression of [E2]cyclin E[/E2] and decreases in the expression of the cyclin-dependent kinase inhibitor p27(Kip1).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[27, 34]], "entity_1_idx_in_text_with_entity_marker": [31, 38], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cyclin E", "entity_2_idx": [[85, 93]], "entity_2_idx_in_text_with_entity_marker": [98, 106], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d663.s0_BioInfer.d663.s0.p9", "text": "The potentiating effect of insulin appears to involve increases in the expression of cyclin E and decreases in the expression of the cyclin-dependent kinase inhibitor p27(Kip1).", "text_with_entity_marker": "The potentiating effect of [E1]insulin[/E1] appears to involve increases in the expression of cyclin E and decreases in the expression of the cyclin-dependent kinase inhibitor [E2]p27[/E2](Kip1).", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "insulin", "entity_1_idx": [[27, 34]], "entity_1_idx_in_text_with_entity_marker": [31, 38], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "p27", "entity_2_idx": [[167, 170]], "entity_2_idx_in_text_with_entity_marker": [180, 183], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d168.s0_BioInfer.d168.s0.p0", "text": "Demembranated stereociliary cores consisted primarily of protein bands corresponding to actin and fimbrin and several proteins ranging from 43 to 63 kDa.", "text_with_entity_marker": "Demembranated stereociliary cores consisted primarily of protein bands corresponding to [E1]actin[/E1] and [E2]fimbrin[/E2] and several proteins ranging from 43 to 63 kDa.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[88, 93]], "entity_1_idx_in_text_with_entity_marker": [92, 97], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrin", "entity_2_idx": [[98, 105]], "entity_2_idx_in_text_with_entity_marker": [111, 118], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d74.s0_BioInfer.d74.s0.p4", "text": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal histone (H3+H4)2tetramers.", "text_with_entity_marker": "Archaeal histones are most similar to the globular histone fold region of eukaryal [E1]histone[/E1] [E2]H4[/E2], and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal histone (H3+H4)2tetramers.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "histone", "entity_1_idx": [[83, 90]], "entity_1_idx_in_text_with_entity_marker": [87, 94], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "H4", "entity_2_idx": [[91, 93]], "entity_2_idx_in_text_with_entity_marker": [104, 106], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d74.s0_BioInfer.d74.s0.p7", "text": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal histone (H3+H4)2tetramers.", "text_with_entity_marker": "Archaeal [E1]histones[/E1] are most similar to the globular [E2]histone[/E2] fold region of eukaryal histone H4, and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal histone (H3+H4)2tetramers.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "histones", "entity_1_idx": [[9, 17]], "entity_1_idx_in_text_with_entity_marker": [13, 21], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "histone", "entity_2_idx": [[51, 58]], "entity_2_idx_in_text_with_entity_marker": [64, 71], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d74.s0_BioInfer.d74.s0.p15", "text": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal histone (H3+H4)2tetramers.", "text_with_entity_marker": "Archaeal histones are most similar to the globular [E1]histone[/E1] fold region of eukaryal histone [E2]H4[/E2], and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal histone (H3+H4)2tetramers.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "histone", "entity_1_idx": [[51, 58]], "entity_1_idx_in_text_with_entity_marker": [55, 62], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "H4", "entity_2_idx": [[91, 93]], "entity_2_idx_in_text_with_entity_marker": [104, 106], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d74.s0_BioInfer.d74.s0.p18", "text": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal histone (H3+H4)2tetramers.", "text_with_entity_marker": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal [E1]nucleosomes[/E1] resembling the structure formed by eukaryal histone (H3+[E2]H4[/E2])2tetramers.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "nucleosomes", "entity_1_idx": [[149, 160]], "entity_1_idx_in_text_with_entity_marker": [153, 164], "entity_1_type": "Protein_complex", "entity_1_type_id": 5, "entity_2": "H4", "entity_2_idx": [[217, 219]], "entity_2_idx_in_text_with_entity_marker": [230, 232], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d74.s0_BioInfer.d74.s0.p20", "text": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal histone (H3+H4)2tetramers.", "text_with_entity_marker": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal [E1]nucleosomes[/E1] resembling the structure formed by eukaryal histone ([E2]H3[/E2]+H4)2tetramers.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "nucleosomes", "entity_1_idx": [[149, 160]], "entity_1_idx_in_text_with_entity_marker": [153, 164], "entity_1_type": "Protein_complex", "entity_1_type_id": 5, "entity_2": "H3", "entity_2_idx": [[214, 216]], "entity_2_idx_in_text_with_entity_marker": [227, 229], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d74.s0_BioInfer.d74.s0.p23", "text": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal histone (H3+H4)2tetramers.", "text_with_entity_marker": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal histone ([E1]H3[/E1]+[E2]H4[/E2])2tetramers.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "H3", "entity_1_idx": [[214, 216]], "entity_1_idx_in_text_with_entity_marker": [218, 220], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "H4", "entity_2_idx": [[217, 219]], "entity_2_idx_in_text_with_entity_marker": [230, 232], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d74.s0_BioInfer.d74.s0.p24", "text": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal histone (H3+H4)2tetramers.", "text_with_entity_marker": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal [E1]histone[/E1] (H3+[E2]H4[/E2])2tetramers.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "histone", "entity_1_idx": [[205, 212]], "entity_1_idx_in_text_with_entity_marker": [209, 216], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "H4", "entity_2_idx": [[217, 219]], "entity_2_idx_in_text_with_entity_marker": [230, 232], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d74.s0_BioInfer.d74.s0.p27", "text": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal histone (H3+H4)2tetramers.", "text_with_entity_marker": "Archaeal histones are most similar to the globular histone fold region of eukaryal histone H4, and the results reported are consistent with archaeal nucleosomes resembling the structure formed by eukaryal [E1]histone[/E1] ([E2]H3[/E2]+H4)2tetramers.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "histone", "entity_1_idx": [[205, 212]], "entity_1_idx_in_text_with_entity_marker": [209, 216], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "H3", "entity_2_idx": [[214, 216]], "entity_2_idx_in_text_with_entity_marker": [227, 229], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d164.s0_BioInfer.d164.s0.p1", "text": "Death receptors belong to the TNF receptor family and are characterised by an intracellular death domain that serves to recruit adapter proteins such as TRADD and FADD and cysteine proteases such as Caspase-8.", "text_with_entity_marker": "[E1]Death receptors[/E1] belong to the TNF receptor family and are characterised by an intracellular death domain that serves to recruit adapter proteins such as [E2]TRADD[/E2] and FADD and cysteine proteases such as Caspase-8.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Death receptors", "entity_1_idx": [[0, 15]], "entity_1_idx_in_text_with_entity_marker": [4, 19], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TRADD", "entity_2_idx": [[153, 158]], "entity_2_idx_in_text_with_entity_marker": [166, 171], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d164.s0_BioInfer.d164.s0.p2", "text": "Death receptors belong to the TNF receptor family and are characterised by an intracellular death domain that serves to recruit adapter proteins such as TRADD and FADD and cysteine proteases such as Caspase-8.", "text_with_entity_marker": "[E1]Death receptors[/E1] belong to the TNF receptor family and are characterised by an intracellular death domain that serves to recruit adapter proteins such as TRADD and [E2]FADD[/E2] and cysteine proteases such as Caspase-8.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Death receptors", "entity_1_idx": [[0, 15]], "entity_1_idx_in_text_with_entity_marker": [4, 19], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "FADD", "entity_2_idx": [[163, 167]], "entity_2_idx_in_text_with_entity_marker": [176, 180], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d164.s0_BioInfer.d164.s0.p3", "text": "Death receptors belong to the TNF receptor family and are characterised by an intracellular death domain that serves to recruit adapter proteins such as TRADD and FADD and cysteine proteases such as Caspase-8.", "text_with_entity_marker": "[E1]Death receptors[/E1] belong to the TNF receptor family and are characterised by an intracellular death domain that serves to recruit adapter proteins such as TRADD and FADD and [E2]cysteine proteases[/E2] such as Caspase-8.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Death receptors", "entity_1_idx": [[0, 15]], "entity_1_idx_in_text_with_entity_marker": [4, 19], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cysteine proteases", "entity_2_idx": [[172, 190]], "entity_2_idx_in_text_with_entity_marker": [185, 203], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d164.s0_BioInfer.d164.s0.p4", "text": "Death receptors belong to the TNF receptor family and are characterised by an intracellular death domain that serves to recruit adapter proteins such as TRADD and FADD and cysteine proteases such as Caspase-8.", "text_with_entity_marker": "[E1]Death receptors[/E1] belong to the [E2]TNF receptor[/E2] family and are characterised by an intracellular death domain that serves to recruit adapter proteins such as TRADD and FADD and cysteine proteases such as Caspase-8.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Death receptors", "entity_1_idx": [[0, 15]], "entity_1_idx_in_text_with_entity_marker": [4, 19], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TNF receptor", "entity_2_idx": [[30, 42]], "entity_2_idx_in_text_with_entity_marker": [43, 55], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d164.s0_BioInfer.d164.s0.p7", "text": "Death receptors belong to the TNF receptor family and are characterised by an intracellular death domain that serves to recruit adapter proteins such as TRADD and FADD and cysteine proteases such as Caspase-8.", "text_with_entity_marker": "Death receptors belong to the TNF receptor family and are characterised by an intracellular death domain that serves to recruit adapter proteins such as TRADD and FADD and [E1]cysteine proteases[/E1] such as [E2]Caspase-8[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cysteine proteases", "entity_1_idx": [[172, 190]], "entity_1_idx_in_text_with_entity_marker": [176, 194], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "Caspase-8", "entity_2_idx": [[199, 208]], "entity_2_idx_in_text_with_entity_marker": [212, 221], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d592.s0_BioInfer.d592.s0.p0", "text": "The cellular transcription co-activators p300 and the CREB-binding protein CBP are cellular targets for transformation by the E1A proteins of non-oncogenic adenovirus 5 (Ad5).", "text_with_entity_marker": "The cellular transcription co-activators p300 and the [E1]CREB-binding protein[/E1] [E2]CBP[/E2] are cellular targets for transformation by the E1A proteins of non-oncogenic adenovirus 5 (Ad5).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CREB-binding protein", "entity_1_idx": [[54, 74]], "entity_1_idx_in_text_with_entity_marker": [58, 78], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "CBP", "entity_2_idx": [[75, 78]], "entity_2_idx_in_text_with_entity_marker": [88, 91], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d592.s0_BioInfer.d592.s0.p4", "text": "The cellular transcription co-activators p300 and the CREB-binding protein CBP are cellular targets for transformation by the E1A proteins of non-oncogenic adenovirus 5 (Ad5).", "text_with_entity_marker": "The cellular transcription co-activators p300 and the CREB-binding protein [E1]CBP[/E1] are cellular targets for transformation by the [E2]E1A[/E2] proteins of non-oncogenic adenovirus 5 (Ad5).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CBP", "entity_1_idx": [[75, 78]], "entity_1_idx_in_text_with_entity_marker": [79, 82], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "E1A", "entity_2_idx": [[126, 129]], "entity_2_idx_in_text_with_entity_marker": [139, 142], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d592.s0_BioInfer.d592.s0.p5", "text": "The cellular transcription co-activators p300 and the CREB-binding protein CBP are cellular targets for transformation by the E1A proteins of non-oncogenic adenovirus 5 (Ad5).", "text_with_entity_marker": "The cellular transcription co-activators [E1]p300[/E1] and the CREB-binding protein CBP are cellular targets for transformation by the [E2]E1A[/E2] proteins of non-oncogenic adenovirus 5 (Ad5).", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "p300", "entity_1_idx": [[41, 45]], "entity_1_idx_in_text_with_entity_marker": [45, 49], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "E1A", "entity_2_idx": [[126, 129]], "entity_2_idx_in_text_with_entity_marker": [139, 142], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d741.s0_BioInfer.d741.s0.p1", "text": "This is the first report describing the coexistence of profilin with actin filaments in the division furrow, implying the possible involvement of profilin in assembly and disassembly of contractile ring microfilaments in the process of cytokinesis.", "text_with_entity_marker": "This is the first report describing the coexistence of [E1]profilin[/E1] with [E2]actin[/E2] filaments in the division furrow, implying the possible involvement of profilin in assembly and disassembly of contractile ring microfilaments in the process of cytokinesis.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[55, 63]], "entity_1_idx_in_text_with_entity_marker": [59, 67], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[69, 74]], "entity_2_idx_in_text_with_entity_marker": [82, 87], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d620.s0_BioInfer.d620.s0.p1", "text": "The herpes simplex virus type-1 DNA helicase-primase is a heterotrimer encoded by the UL5, UL8, and UL52 genes.", "text_with_entity_marker": "The herpes simplex virus type-1 [E1]DNA helicase-primase[/E1] is a heterotrimer encoded by the UL5, [E2]UL8[/E2], and UL52 genes.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "DNA helicase-primase", "entity_1_idx": [[32, 52]], "entity_1_idx_in_text_with_entity_marker": [36, 56], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "UL8", "entity_2_idx": [[91, 94]], "entity_2_idx_in_text_with_entity_marker": [104, 107], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d620.s0_BioInfer.d620.s0.p3", "text": "The herpes simplex virus type-1 DNA helicase-primase is a heterotrimer encoded by the UL5, UL8, and UL52 genes.", "text_with_entity_marker": "The herpes simplex virus type-1 [E1]DNA helicase-primase[/E1] is a heterotrimer encoded by the UL5, UL8, and [E2]UL52[/E2] genes.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "DNA helicase-primase", "entity_1_idx": [[32, 52]], "entity_1_idx_in_text_with_entity_marker": [36, 56], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "UL52", "entity_2_idx": [[100, 104]], "entity_2_idx_in_text_with_entity_marker": [113, 117], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d620.s0_BioInfer.d620.s0.p5", "text": "The herpes simplex virus type-1 DNA helicase-primase is a heterotrimer encoded by the UL5, UL8, and UL52 genes.", "text_with_entity_marker": "The herpes simplex virus type-1 [E1]DNA helicase-primase[/E1] is a heterotrimer encoded by the [E2]UL5[/E2], UL8, and UL52 genes.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "DNA helicase-primase", "entity_1_idx": [[32, 52]], "entity_1_idx_in_text_with_entity_marker": [36, 56], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "UL5", "entity_2_idx": [[86, 89]], "entity_2_idx_in_text_with_entity_marker": [99, 102], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d43.s0_BioInfer.d43.s0.p0", "text": "Although co-localization of glucokinase with actin filaments was not clearly demonstrated in the pancreatic beta-cell line MIN6, islet glucokinase was found to be present in both the nucleus and the cytoplasm, though predominantly in the nucleus.", "text_with_entity_marker": "Although co-localization of [E1]glucokinase[/E1] with [E2]actin[/E2] filaments was not clearly demonstrated in the pancreatic beta-cell line MIN6, islet glucokinase was found to be present in both the nucleus and the cytoplasm, though predominantly in the nucleus.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "glucokinase", "entity_1_idx": [[28, 39]], "entity_1_idx_in_text_with_entity_marker": [32, 43], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[45, 50]], "entity_2_idx_in_text_with_entity_marker": [58, 63], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d43.s1_BioInfer.d43.s1.p0", "text": "A portion of glucokinase appeared to be co-localized with actin filaments in the cytoplasm of cultured rat hepatocytes incubated with 25 mM glucose.", "text_with_entity_marker": "A portion of [E1]glucokinase[/E1] appeared to be co-localized with [E2]actin[/E2] filaments in the cytoplasm of cultured rat hepatocytes incubated with 25 mM glucose.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "glucokinase", "entity_1_idx": [[13, 24]], "entity_1_idx_in_text_with_entity_marker": [17, 28], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[58, 63]], "entity_2_idx_in_text_with_entity_marker": [71, 76], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d43.s2_BioInfer.d43.s2.p0", "text": "Co-localization of glucokinase with actin filaments.", "text_with_entity_marker": "Co-localization of [E1]glucokinase[/E1] with [E2]actin[/E2] filaments.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "glucokinase", "entity_1_idx": [[19, 30]], "entity_1_idx_in_text_with_entity_marker": [23, 34], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[36, 41]], "entity_2_idx_in_text_with_entity_marker": [49, 54], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d43.s3_BioInfer.d43.s3.p4", "text": "When liver- or islet-type glucokinase was transiently expressed in COS-7 cells, the expressed glucokinase was also co-localized with actin filaments in the cytoplasm of these transfected cells.", "text_with_entity_marker": "When liver- or islet-type glucokinase was transiently expressed in COS-7 cells, the expressed [E1]glucokinase[/E1] was also co-localized with [E2]actin[/E2] filaments in the cytoplasm of these transfected cells.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "glucokinase", "entity_1_idx": [[94, 105]], "entity_1_idx_in_text_with_entity_marker": [98, 109], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d367.s0_BioInfer.d367.s0.p0", "text": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "text_with_entity_marker": "In the cytoplasm, HBx was shown to stimulate the [E1]Ras[/E1]-Raf-mitogen-activated protein kinase ([E2]MAP kinase[/E2]) cascade, which is essential for activation of transcription factor AP-1.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Ras", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "MAP kinase", "entity_2_idx": [[91, 101]], "entity_2_idx_in_text_with_entity_marker": [104, 114], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d367.s0_BioInfer.d367.s0.p2", "text": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "text_with_entity_marker": "In the cytoplasm, HBx was shown to stimulate the [E1]Ras[/E1]-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor [E2]AP-1[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Ras", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "AP-1", "entity_2_idx": [[170, 174]], "entity_2_idx_in_text_with_entity_marker": [183, 187], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d367.s0_BioInfer.d367.s0.p3", "text": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "text_with_entity_marker": "In the cytoplasm, HBx was shown to stimulate the [E1]Ras[/E1]-Raf-[E2]mitogen-activated protein kinase[/E2] (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Ras", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "mitogen-activated protein kinase", "entity_2_idx": [[57, 89]], "entity_2_idx_in_text_with_entity_marker": [70, 102], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d367.s0_BioInfer.d367.s0.p4", "text": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "text_with_entity_marker": "In the cytoplasm, HBx was shown to stimulate the [E1]Ras[/E1]-[E2]Raf[/E2]-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Ras", "entity_1_idx": [[49, 52]], "entity_1_idx_in_text_with_entity_marker": [53, 56], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "Raf", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d367.s0_BioInfer.d367.s0.p6", "text": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "text_with_entity_marker": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase ([E1]MAP kinase[/E1]) cascade, which is essential for activation of transcription factor [E2]AP-1[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "MAP kinase", "entity_1_idx": [[91, 101]], "entity_1_idx_in_text_with_entity_marker": [95, 105], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "AP-1", "entity_2_idx": [[170, 174]], "entity_2_idx_in_text_with_entity_marker": [183, 187], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d367.s0_BioInfer.d367.s0.p7", "text": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "text_with_entity_marker": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-[E1]mitogen-activated protein kinase[/E1] ([E2]MAP kinase[/E2]) cascade, which is essential for activation of transcription factor AP-1.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "mitogen-activated protein kinase", "entity_1_idx": [[57, 89]], "entity_1_idx_in_text_with_entity_marker": [61, 93], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "MAP kinase", "entity_2_idx": [[91, 101]], "entity_2_idx_in_text_with_entity_marker": [104, 114], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d367.s0_BioInfer.d367.s0.p8", "text": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "text_with_entity_marker": "In the cytoplasm, HBx was shown to stimulate the Ras-[E1]Raf[/E1]-mitogen-activated protein kinase ([E2]MAP kinase[/E2]) cascade, which is essential for activation of transcription factor AP-1.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Raf", "entity_1_idx": [[53, 56]], "entity_1_idx_in_text_with_entity_marker": [57, 60], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "MAP kinase", "entity_2_idx": [[91, 101]], "entity_2_idx_in_text_with_entity_marker": [104, 114], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d367.s0_BioInfer.d367.s0.p12", "text": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "text_with_entity_marker": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-[E1]mitogen-activated protein kinase[/E1] (MAP kinase) cascade, which is essential for activation of transcription factor [E2]AP-1[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "mitogen-activated protein kinase", "entity_1_idx": [[57, 89]], "entity_1_idx_in_text_with_entity_marker": [61, 93], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "AP-1", "entity_2_idx": [[170, 174]], "entity_2_idx_in_text_with_entity_marker": [183, 187], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d367.s0_BioInfer.d367.s0.p13", "text": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "text_with_entity_marker": "In the cytoplasm, HBx was shown to stimulate the Ras-[E1]Raf[/E1]-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor [E2]AP-1[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Raf", "entity_1_idx": [[53, 56]], "entity_1_idx_in_text_with_entity_marker": [57, 60], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "AP-1", "entity_2_idx": [[170, 174]], "entity_2_idx_in_text_with_entity_marker": [183, 187], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d367.s0_BioInfer.d367.s0.p14", "text": "In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "text_with_entity_marker": "In the cytoplasm, HBx was shown to stimulate the Ras-[E1]Raf[/E1]-[E2]mitogen-activated protein kinase[/E2] (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Raf", "entity_1_idx": [[53, 56]], "entity_1_idx_in_text_with_entity_marker": [57, 60], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "mitogen-activated protein kinase", "entity_2_idx": [[57, 89]], "entity_2_idx_in_text_with_entity_marker": [70, 102], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d580.s0_BioInfer.d580.s0.p1", "text": "The UL8 component of the herpes simplex virus helicase-primase complex stimulates primer synthesis by a subassembly of the UL5 and UL52 components.", "text_with_entity_marker": "The [E1]UL8[/E1] component of the herpes simplex virus helicase-primase complex stimulates primer synthesis by a subassembly of the UL5 and [E2]UL52[/E2] components.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UL8", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "UL52", "entity_2_idx": [[131, 135]], "entity_2_idx_in_text_with_entity_marker": [144, 148], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d580.s0_BioInfer.d580.s0.p2", "text": "The UL8 component of the herpes simplex virus helicase-primase complex stimulates primer synthesis by a subassembly of the UL5 and UL52 components.", "text_with_entity_marker": "The UL8 component of the herpes simplex virus helicase-primase complex stimulates primer synthesis by a subassembly of the [E1]UL5[/E1] and [E2]UL52[/E2] components.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UL5", "entity_1_idx": [[123, 126]], "entity_1_idx_in_text_with_entity_marker": [127, 130], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "UL52", "entity_2_idx": [[131, 135]], "entity_2_idx_in_text_with_entity_marker": [144, 148], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d580.s0_BioInfer.d580.s0.p3", "text": "The UL8 component of the herpes simplex virus helicase-primase complex stimulates primer synthesis by a subassembly of the UL5 and UL52 components.", "text_with_entity_marker": "The [E1]UL8[/E1] component of the herpes simplex virus [E2]helicase-primase[/E2] complex stimulates primer synthesis by a subassembly of the UL5 and UL52 components.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UL8", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "helicase-primase", "entity_2_idx": [[46, 62]], "entity_2_idx_in_text_with_entity_marker": [59, 75], "entity_2_type": "Protein_complex", "entity_2_type_id": 5}], "directed": false, "reverse": false}
{"id": "BioInfer.d580.s0_BioInfer.d580.s0.p5", "text": "The UL8 component of the herpes simplex virus helicase-primase complex stimulates primer synthesis by a subassembly of the UL5 and UL52 components.", "text_with_entity_marker": "The [E1]UL8[/E1] component of the herpes simplex virus helicase-primase complex stimulates primer synthesis by a subassembly of the [E2]UL5[/E2] and UL52 components.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UL8", "entity_1_idx": [[4, 7]], "entity_1_idx_in_text_with_entity_marker": [8, 11], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "UL5", "entity_2_idx": [[123, 126]], "entity_2_idx_in_text_with_entity_marker": [136, 139], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d580.s1_BioInfer.d580.s1.p0", "text": "The herpes simplex virus type 1 (HSV) UL5, UL8, and UL52 proteins form a helicase-primase complex in infected cells.", "text_with_entity_marker": "The herpes simplex virus type 1 (HSV) UL5, [E1]UL8[/E1], and [E2]UL52[/E2] proteins form a helicase-primase complex in infected cells.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UL8", "entity_1_idx": [[43, 46]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "UL52", "entity_2_idx": [[52, 56]], "entity_2_idx_in_text_with_entity_marker": [65, 69], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d580.s1_BioInfer.d580.s1.p1", "text": "The herpes simplex virus type 1 (HSV) UL5, UL8, and UL52 proteins form a helicase-primase complex in infected cells.", "text_with_entity_marker": "The herpes simplex virus type 1 (HSV) [E1]UL5[/E1], UL8, and [E2]UL52[/E2] proteins form a helicase-primase complex in infected cells.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UL5", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "UL52", "entity_2_idx": [[52, 56]], "entity_2_idx_in_text_with_entity_marker": [65, 69], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d580.s1_BioInfer.d580.s1.p2", "text": "The herpes simplex virus type 1 (HSV) UL5, UL8, and UL52 proteins form a helicase-primase complex in infected cells.", "text_with_entity_marker": "The herpes simplex virus type 1 (HSV) [E1]UL5[/E1], [E2]UL8[/E2], and UL52 proteins form a helicase-primase complex in infected cells.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "UL5", "entity_1_idx": [[38, 41]], "entity_1_idx_in_text_with_entity_marker": [42, 45], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "UL8", "entity_2_idx": [[43, 46]], "entity_2_idx_in_text_with_entity_marker": [56, 59], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d681.s1_BioInfer.d681.s1.p43", "text": "These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.", "text_with_entity_marker": "These histone [E1]H3[/E1] and H2a genes encode approximately 40% of the total [E2]H3[/E2] and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "H3", "entity_1_idx": [[14, 16]], "entity_1_idx_in_text_with_entity_marker": [18, 20], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "H3", "entity_2_idx": [[69, 71]], "entity_2_idx_in_text_with_entity_marker": [82, 84], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d681.s1_BioInfer.d681.s1.p46", "text": "These histone H3 and H2a genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.", "text_with_entity_marker": "These [E1]histone[/E1] H3 and [E2]H2a[/E2] genes encode approximately 40% of the total H3 and H2a mRNA, whereas the histone H4 and histone H2b genes encode < 10% of the total H4 and H2b mRNA.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "histone", "entity_1_idx": [[6, 13]], "entity_1_idx_in_text_with_entity_marker": [10, 17], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "H2a", "entity_2_idx": [[21, 24]], "entity_2_idx_in_text_with_entity_marker": [34, 37], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d718.s0_BioInfer.d718.s0.p2", "text": "These two proteins were identified as the phosphorylated and non-phosphorylated forms of the pH-sensitive actin-depolymerizing protein, cofilin, by sequencing of peptide fragments and immunoblotting with a monoclonal antibody specific for cofilin.", "text_with_entity_marker": "These two proteins were identified as the phosphorylated and non-phosphorylated forms of the pH-sensitive [E1]actin[/E1]-depolymerizing protein, [E2]cofilin[/E2], by sequencing of peptide fragments and immunoblotting with a monoclonal antibody specific for cofilin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[106, 111]], "entity_1_idx_in_text_with_entity_marker": [110, 115], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[136, 143]], "entity_2_idx_in_text_with_entity_marker": [149, 156], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d26.s0_BioInfer.d26.s0.p0", "text": "A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1.", "text_with_entity_marker": "A distinct modulating domain in [E1]glucocorticoid receptor[/E1] monomers in the repression of activity of the transcription factor [E2]AP-1[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "glucocorticoid receptor", "entity_1_idx": [[32, 55]], "entity_1_idx_in_text_with_entity_marker": [36, 59], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "AP-1", "entity_2_idx": [[123, 127]], "entity_2_idx_in_text_with_entity_marker": [136, 140], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d416.s0_BioInfer.d416.s0.p2", "text": "Mechanism of inhibition of proliferating cell nuclear antigen-dependent DNA synthesis by the cyclin-dependent kinase inhibitor p21.", "text_with_entity_marker": "Mechanism of inhibition of proliferating cell nuclear antigen-dependent DNA synthesis by the [E1]cyclin-dependent kinase inhibitor[/E1] [E2]p21[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitor", "entity_1_idx": [[93, 126]], "entity_1_idx_in_text_with_entity_marker": [97, 130], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "p21", "entity_2_idx": [[127, 130]], "entity_2_idx_in_text_with_entity_marker": [140, 143], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d494.s0_BioInfer.d494.s0.p0", "text": "Production of PIP and PIP2 may be important downstream signals since these polyphosphoinositides are able to regulate the interaction of gelsolin and profilin with actin.", "text_with_entity_marker": "Production of PIP and PIP2 may be important downstream signals since these polyphosphoinositides are able to regulate the interaction of [E1]gelsolin[/E1] and profilin with [E2]actin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "gelsolin", "entity_1_idx": [[137, 145]], "entity_1_idx_in_text_with_entity_marker": [141, 149], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[164, 169]], "entity_2_idx_in_text_with_entity_marker": [177, 182], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d494.s0_BioInfer.d494.s0.p1", "text": "Production of PIP and PIP2 may be important downstream signals since these polyphosphoinositides are able to regulate the interaction of gelsolin and profilin with actin.", "text_with_entity_marker": "Production of PIP and PIP2 may be important downstream signals since these polyphosphoinositides are able to regulate the interaction of gelsolin and [E1]profilin[/E1] with [E2]actin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[150, 158]], "entity_1_idx_in_text_with_entity_marker": [154, 162], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[164, 169]], "entity_2_idx_in_text_with_entity_marker": [177, 182], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d399.s0_BioInfer.d399.s0.p0", "text": "Kinetic studies on the effect of yeast cofilin on yeast actin polymerization.", "text_with_entity_marker": "Kinetic studies on the effect of yeast [E1]cofilin[/E1] on yeast [E2]actin[/E2] polymerization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[39, 46]], "entity_1_idx_in_text_with_entity_marker": [43, 50], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[56, 61]], "entity_2_idx_in_text_with_entity_marker": [69, 74], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d399.s1_BioInfer.d399.s1.p0", "text": "The results suggest some cooperativity with respect to cofilin binding to filamentous actin which may be pH dependent.", "text_with_entity_marker": "The results suggest some cooperativity with respect to [E1]cofilin[/E1] binding to filamentous [E2]actin[/E2] which may be pH dependent.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[55, 62]], "entity_1_idx_in_text_with_entity_marker": [59, 66], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[86, 91]], "entity_2_idx_in_text_with_entity_marker": [99, 104], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d276.s0_BioInfer.d276.s0.p2", "text": "However, some proteins (e.g., profilin) and other agents (e.g., cytochalasin D) that bind to actin are affected by the presence of fluorescent labels, making actin intrinsic fluorescence potentially useful in investigating the interaction of these agents with actin, and in validating data obtained using labeled actin.", "text_with_entity_marker": "However, some proteins (e.g., [E1]profilin[/E1]) and other agents (e.g., cytochalasin D) that bind to actin are affected by the presence of fluorescent labels, making actin intrinsic fluorescence potentially useful in investigating the interaction of these agents with [E2]actin[/E2], and in validating data obtained using labeled actin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[30, 38]], "entity_1_idx_in_text_with_entity_marker": [34, 42], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[260, 265]], "entity_2_idx_in_text_with_entity_marker": [273, 278], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d276.s0_BioInfer.d276.s0.p3", "text": "However, some proteins (e.g., profilin) and other agents (e.g., cytochalasin D) that bind to actin are affected by the presence of fluorescent labels, making actin intrinsic fluorescence potentially useful in investigating the interaction of these agents with actin, and in validating data obtained using labeled actin.", "text_with_entity_marker": "However, some proteins (e.g., [E1]profilin[/E1]) and other agents (e.g., cytochalasin D) that bind to [E2]actin[/E2] are affected by the presence of fluorescent labels, making actin intrinsic fluorescence potentially useful in investigating the interaction of these agents with actin, and in validating data obtained using labeled actin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[30, 38]], "entity_1_idx_in_text_with_entity_marker": [34, 42], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[93, 98]], "entity_2_idx_in_text_with_entity_marker": [106, 111], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d184.s0_BioInfer.d184.s0.p0", "text": "Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "text_with_entity_marker": "Effects of [E1]profilin[/E1]-annexin I association on some properties of both [E2]profilin[/E2] and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[11, 19]], "entity_1_idx_in_text_with_entity_marker": [15, 23], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[69, 77]], "entity_2_idx_in_text_with_entity_marker": [82, 90], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d184.s0_BioInfer.d184.s0.p1", "text": "Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "text_with_entity_marker": "Effects of profilin-[E1]annexin I[/E1] association on some properties of both [E2]profilin[/E2] and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "annexin I", "entity_1_idx": [[20, 29]], "entity_1_idx_in_text_with_entity_marker": [24, 33], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[69, 77]], "entity_2_idx_in_text_with_entity_marker": [82, 90], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d184.s0_BioInfer.d184.s0.p6", "text": "Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "text_with_entity_marker": "Effects of [E1]profilin[/E1]-[E2]annexin I[/E2] association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[11, 19]], "entity_1_idx_in_text_with_entity_marker": [15, 23], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "annexin I", "entity_2_idx": [[20, 29]], "entity_2_idx_in_text_with_entity_marker": [33, 42], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d184.s0_BioInfer.d184.s0.p7", "text": "Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "text_with_entity_marker": "Effects of [E1]profilin[/E1]-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of [E2]profilin[/E2] on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[11, 19]], "entity_1_idx_in_text_with_entity_marker": [15, 23], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[136, 144]], "entity_2_idx_in_text_with_entity_marker": [149, 157], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d184.s0_BioInfer.d184.s0.p8", "text": "Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "text_with_entity_marker": "Effects of [E1]profilin[/E1]-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of [E2]annexin I[/E2] and its interactions with liposomes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[11, 19]], "entity_1_idx_in_text_with_entity_marker": [15, 23], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "annexin I", "entity_2_idx": [[211, 220]], "entity_2_idx_in_text_with_entity_marker": [224, 233], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d184.s0_BioInfer.d184.s0.p9", "text": "Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "text_with_entity_marker": "Effects of [E1]profilin[/E1]-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on [E2]actin[/E2] polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[11, 19]], "entity_1_idx_in_text_with_entity_marker": [15, 23], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d184.s0_BioInfer.d184.s0.p10", "text": "Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "text_with_entity_marker": "Effects of [E1]profilin[/E1]-annexin I association on some properties of both profilin and [E2]annexin I[/E2]: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[11, 19]], "entity_1_idx_in_text_with_entity_marker": [15, 23], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "annexin I", "entity_2_idx": [[82, 91]], "entity_2_idx_in_text_with_entity_marker": [95, 104], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d184.s0_BioInfer.d184.s0.p12", "text": "Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "text_with_entity_marker": "Effects of profilin-[E1]annexin I[/E1] association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of [E2]annexin I[/E2] and its interactions with liposomes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "annexin I", "entity_1_idx": [[20, 29]], "entity_1_idx_in_text_with_entity_marker": [24, 33], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "annexin I", "entity_2_idx": [[211, 220]], "entity_2_idx_in_text_with_entity_marker": [224, 233], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d184.s0_BioInfer.d184.s0.p13", "text": "Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "text_with_entity_marker": "Effects of profilin-[E1]annexin I[/E1] association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on [E2]actin[/E2] polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "annexin I", "entity_1_idx": [[20, 29]], "entity_1_idx_in_text_with_entity_marker": [24, 33], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[148, 153]], "entity_2_idx_in_text_with_entity_marker": [161, 166], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d184.s0_BioInfer.d184.s0.p14", "text": "Effects of profilin-annexin I association on some properties of both profilin and annexin I: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "text_with_entity_marker": "Effects of profilin-[E1]annexin I[/E1] association on some properties of both profilin and [E2]annexin I[/E2]: modification of the inhibitory activity of profilin on actin polymerization and inhibition of the self-association of annexin I and its interactions with liposomes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "annexin I", "entity_1_idx": [[20, 29]], "entity_1_idx_in_text_with_entity_marker": [24, 33], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "annexin I", "entity_2_idx": [[82, 91]], "entity_2_idx_in_text_with_entity_marker": [95, 104], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d123.s0_BioInfer.d123.s0.p52", "text": "By using a chromatin immunoprecipitation (ChIP) assay, we observed that histone H4, and not histone H3, was acetylated from the endogenous p21/waf1 promoter in vivo, implying that CBP/p300, and not the SAGA complex, was critical in complexing with E2A in up-regulation of p21/waf1 in HTLV-1-infected cells.", "text_with_entity_marker": "By using a chromatin immunoprecipitation (ChIP) assay, we observed that histone H4, and not histone H3, was acetylated from the endogenous p21/[E1]waf1[/E1] promoter in vivo, implying that CBP/p300, and not the SAGA complex, was critical in complexing with E2A in up-regulation of [E2]p21[/E2]/waf1 in HTLV-1-infected cells.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "waf1", "entity_1_idx": [[143, 147]], "entity_1_idx_in_text_with_entity_marker": [147, 151], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "p21", "entity_2_idx": [[272, 275]], "entity_2_idx_in_text_with_entity_marker": [285, 288], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d123.s0_BioInfer.d123.s0.p54", "text": "By using a chromatin immunoprecipitation (ChIP) assay, we observed that histone H4, and not histone H3, was acetylated from the endogenous p21/waf1 promoter in vivo, implying that CBP/p300, and not the SAGA complex, was critical in complexing with E2A in up-regulation of p21/waf1 in HTLV-1-infected cells.", "text_with_entity_marker": "By using a chromatin immunoprecipitation (ChIP) assay, we observed that histone H4, and not histone H3, was acetylated from the endogenous p21/[E1]waf1[/E1] promoter in vivo, implying that CBP/p300, and not the SAGA complex, was critical in complexing with [E2]E2A[/E2] in up-regulation of p21/waf1 in HTLV-1-infected cells.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "waf1", "entity_1_idx": [[143, 147]], "entity_1_idx_in_text_with_entity_marker": [147, 151], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "E2A", "entity_2_idx": [[248, 251]], "entity_2_idx_in_text_with_entity_marker": [261, 264], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d123.s0_BioInfer.d123.s0.p58", "text": "By using a chromatin immunoprecipitation (ChIP) assay, we observed that histone H4, and not histone H3, was acetylated from the endogenous p21/waf1 promoter in vivo, implying that CBP/p300, and not the SAGA complex, was critical in complexing with E2A in up-regulation of p21/waf1 in HTLV-1-infected cells.", "text_with_entity_marker": "By using a chromatin immunoprecipitation (ChIP) assay, we observed that histone H4, and not histone H3, was acetylated from the endogenous p21/waf1 promoter in vivo, implying that CBP/p300, and not the SAGA complex, was critical in complexing with [E1]E2A[/E1] in up-regulation of p21/[E2]waf1[/E2] in HTLV-1-infected cells.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "E2A", "entity_1_idx": [[248, 251]], "entity_1_idx_in_text_with_entity_marker": [252, 255], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "waf1", "entity_2_idx": [[276, 280]], "entity_2_idx_in_text_with_entity_marker": [289, 293], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d123.s0_BioInfer.d123.s0.p61", "text": "By using a chromatin immunoprecipitation (ChIP) assay, we observed that histone H4, and not histone H3, was acetylated from the endogenous p21/waf1 promoter in vivo, implying that CBP/p300, and not the SAGA complex, was critical in complexing with E2A in up-regulation of p21/waf1 in HTLV-1-infected cells.", "text_with_entity_marker": "By using a chromatin immunoprecipitation (ChIP) assay, we observed that histone H4, and not histone H3, was acetylated from the endogenous p21/waf1 promoter in vivo, implying that CBP/p300, and not the SAGA complex, was critical in complexing with [E1]E2A[/E1] in up-regulation of [E2]p21[/E2]/waf1 in HTLV-1-infected cells.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "E2A", "entity_1_idx": [[248, 251]], "entity_1_idx_in_text_with_entity_marker": [252, 255], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "p21", "entity_2_idx": [[272, 275]], "entity_2_idx_in_text_with_entity_marker": [285, 288], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d177.s0_BioInfer.d177.s0.p2", "text": "Disruption of the RVS167 gene, which is homologous to END6/RVS161 and which is also required for correct actin localization, also blocks endocytosis.", "text_with_entity_marker": "Disruption of the [E1]RVS167[/E1] gene, which is homologous to END6/RVS161 and which is also required for correct [E2]actin[/E2] localization, also blocks endocytosis.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "RVS167", "entity_1_idx": [[18, 24]], "entity_1_idx_in_text_with_entity_marker": [22, 28], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "actin", "entity_2_idx": [[105, 110]], "entity_2_idx_in_text_with_entity_marker": [118, 123], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d126.s0_BioInfer.d126.s0.p0", "text": "Calorimetric data show ternary complex formation between talin, vinculin, and actin.", "text_with_entity_marker": "Calorimetric data show ternary complex formation between talin, [E1]vinculin[/E1], and [E2]actin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "vinculin", "entity_1_idx": [[64, 72]], "entity_1_idx_in_text_with_entity_marker": [68, 76], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d126.s0_BioInfer.d126.s0.p1", "text": "Calorimetric data show ternary complex formation between talin, vinculin, and actin.", "text_with_entity_marker": "Calorimetric data show ternary complex formation between [E1]talin[/E1], vinculin, and [E2]actin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "talin", "entity_1_idx": [[57, 62]], "entity_1_idx_in_text_with_entity_marker": [61, 66], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[78, 83]], "entity_2_idx_in_text_with_entity_marker": [91, 96], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d126.s0_BioInfer.d126.s0.p2", "text": "Calorimetric data show ternary complex formation between talin, vinculin, and actin.", "text_with_entity_marker": "Calorimetric data show ternary complex formation between [E1]talin[/E1], [E2]vinculin[/E2], and actin.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "talin", "entity_1_idx": [[57, 62]], "entity_1_idx_in_text_with_entity_marker": [61, 66], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "vinculin", "entity_2_idx": [[64, 72]], "entity_2_idx_in_text_with_entity_marker": [77, 85], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d542.s0_BioInfer.d542.s0.p0", "text": "Since RAD54 is a recombinational protein associated with RAD51, this is the first genetic evidence that cancer arises from a defect in repair processes involving homologous recombination.", "text_with_entity_marker": "Since [E1]RAD54[/E1] is a recombinational protein associated with [E2]RAD51[/E2], this is the first genetic evidence that cancer arises from a defect in repair processes involving homologous recombination.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "RAD54", "entity_1_idx": [[6, 11]], "entity_1_idx_in_text_with_entity_marker": [10, 15], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "RAD51", "entity_2_idx": [[57, 62]], "entity_2_idx_in_text_with_entity_marker": [70, 75], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d664.s0_BioInfer.d664.s0.p4", "text": "The predicted sequence of AtFim1 shares ca. 40% identity with nonplant fimbrins and contains two tandem repeats, each possessing a 27 amino acid region identified as a putative actin-binding domain in fimbrins and in a larger family of actin cross-linking proteins.", "text_with_entity_marker": "The predicted sequence of AtFim1 shares ca. 40% identity with nonplant fimbrins and contains two tandem repeats, each possessing a 27 amino acid region identified as a putative [E1]actin[/E1]-binding domain in [E2]fimbrins[/E2] and in a larger family of actin cross-linking proteins.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[177, 182]], "entity_1_idx_in_text_with_entity_marker": [181, 186], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrins", "entity_2_idx": [[201, 209]], "entity_2_idx_in_text_with_entity_marker": [214, 222], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d664.s0_BioInfer.d664.s0.p6", "text": "The predicted sequence of AtFim1 shares ca. 40% identity with nonplant fimbrins and contains two tandem repeats, each possessing a 27 amino acid region identified as a putative actin-binding domain in fimbrins and in a larger family of actin cross-linking proteins.", "text_with_entity_marker": "The predicted sequence of [E1]AtFim1[/E1] shares ca. 40% identity with nonplant fimbrins and contains two tandem repeats, each possessing a 27 amino acid region identified as a putative [E2]actin[/E2]-binding domain in fimbrins and in a larger family of actin cross-linking proteins.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "AtFim1", "entity_1_idx": [[26, 32]], "entity_1_idx_in_text_with_entity_marker": [30, 36], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[177, 182]], "entity_2_idx_in_text_with_entity_marker": [190, 195], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d664.s0_BioInfer.d664.s0.p9", "text": "The predicted sequence of AtFim1 shares ca. 40% identity with nonplant fimbrins and contains two tandem repeats, each possessing a 27 amino acid region identified as a putative actin-binding domain in fimbrins and in a larger family of actin cross-linking proteins.", "text_with_entity_marker": "The predicted sequence of [E1]AtFim1[/E1] shares ca. 40% identity with nonplant [E2]fimbrins[/E2] and contains two tandem repeats, each possessing a 27 amino acid region identified as a putative actin-binding domain in fimbrins and in a larger family of actin cross-linking proteins.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "AtFim1", "entity_1_idx": [[26, 32]], "entity_1_idx_in_text_with_entity_marker": [30, 36], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrins", "entity_2_idx": [[71, 79]], "entity_2_idx_in_text_with_entity_marker": [84, 92], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d714.s0_BioInfer.d714.s0.p2", "text": "These results suggest that the heptapeptide sequence is specific for the interaction with actin and, therefore, may constitute part of the actin-binding domain of cofilin.", "text_with_entity_marker": "These results suggest that the heptapeptide sequence is specific for the interaction with actin and, therefore, may constitute part of the [E1]actin[/E1]-binding domain of [E2]cofilin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[139, 144]], "entity_1_idx_in_text_with_entity_marker": [143, 148], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[163, 170]], "entity_2_idx_in_text_with_entity_marker": [176, 183], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d800.s0_BioInfer.d800.s0.p7", "text": "We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of \"pancadherin\" with alpha-catenin, beta-catenin, p120, and vinculin, and the association of these complexes with the actin microfilaments.", "text_with_entity_marker": "We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of \"[E1]pancadherin[/E1]\" with alpha-catenin, beta-catenin, [E2]p120[/E2], and vinculin, and the association of these complexes with the actin microfilaments.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "pancadherin", "entity_1_idx": [[137, 148]], "entity_1_idx_in_text_with_entity_marker": [141, 152], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "p120", "entity_2_idx": [[184, 188]], "entity_2_idx_in_text_with_entity_marker": [197, 201], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d800.s0_BioInfer.d800.s0.p8", "text": "We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of \"pancadherin\" with alpha-catenin, beta-catenin, p120, and vinculin, and the association of these complexes with the actin microfilaments.", "text_with_entity_marker": "We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of \"[E1]pancadherin[/E1]\" with [E2]alpha-catenin[/E2], beta-catenin, p120, and vinculin, and the association of these complexes with the actin microfilaments.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "pancadherin", "entity_1_idx": [[137, 148]], "entity_1_idx_in_text_with_entity_marker": [141, 152], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-catenin", "entity_2_idx": [[155, 168]], "entity_2_idx_in_text_with_entity_marker": [168, 181], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d800.s0_BioInfer.d800.s0.p9", "text": "We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of \"pancadherin\" with alpha-catenin, beta-catenin, p120, and vinculin, and the association of these complexes with the actin microfilaments.", "text_with_entity_marker": "We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of \"[E1]pancadherin[/E1]\" with alpha-catenin, beta-catenin, p120, and [E2]vinculin[/E2], and the association of these complexes with the actin microfilaments.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "pancadherin", "entity_1_idx": [[137, 148]], "entity_1_idx_in_text_with_entity_marker": [141, 152], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "vinculin", "entity_2_idx": [[194, 202]], "entity_2_idx_in_text_with_entity_marker": [207, 215], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d800.s0_BioInfer.d800.s0.p11", "text": "We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of \"pancadherin\" with alpha-catenin, beta-catenin, p120, and vinculin, and the association of these complexes with the actin microfilaments.", "text_with_entity_marker": "We describe the localization of cadherin-11 and N-cadherin along the cell margins of mouse osteoblast-like cells, the colocalization of \"[E1]pancadherin[/E1]\" with alpha-catenin, [E2]beta-catenin[/E2], p120, and vinculin, and the association of these complexes with the actin microfilaments.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "pancadherin", "entity_1_idx": [[137, 148]], "entity_1_idx_in_text_with_entity_marker": [141, 152], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[170, 182]], "entity_2_idx_in_text_with_entity_marker": [183, 195], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d264.s0_BioInfer.d264.s0.p3", "text": "Histone H3 showed at least seven sites of acetylation, histone H2B.1 had six sites and histone H4 had five sites.", "text_with_entity_marker": "Histone H3 showed at least seven sites of acetylation, histone H2B.1 had six sites and [E1]histone[/E1] [E2]H4[/E2] had five sites.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "histone", "entity_1_idx": [[87, 94]], "entity_1_idx_in_text_with_entity_marker": [91, 98], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "H4", "entity_2_idx": [[95, 97]], "entity_2_idx_in_text_with_entity_marker": [108, 110], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d264.s0_BioInfer.d264.s0.p8", "text": "Histone H3 showed at least seven sites of acetylation, histone H2B.1 had six sites and histone H4 had five sites.", "text_with_entity_marker": "[E1]Histone[/E1] [E2]H3[/E2] showed at least seven sites of acetylation, histone H2B.1 had six sites and histone H4 had five sites.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Histone", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "H3", "entity_2_idx": [[8, 10]], "entity_2_idx_in_text_with_entity_marker": [21, 23], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d264.s0_BioInfer.d264.s0.p9", "text": "Histone H3 showed at least seven sites of acetylation, histone H2B.1 had six sites and histone H4 had five sites.", "text_with_entity_marker": "Histone H3 showed at least seven sites of acetylation, [E1]histone[/E1] [E2]H2B.1[/E2] had six sites and histone H4 had five sites.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "histone", "entity_1_idx": [[55, 62]], "entity_1_idx_in_text_with_entity_marker": [59, 66], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "H2B.1", "entity_2_idx": [[63, 68]], "entity_2_idx_in_text_with_entity_marker": [76, 81], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d722.s0_BioInfer.d722.s0.p0", "text": "The Src homology domain 3 (SH3) of a yeast type I myosin, Myo5p, binds to verprolin and is required for targeting to sites of actin polarization.", "text_with_entity_marker": "The Src homology domain 3 (SH3) of a yeast type I myosin, [E1]Myo5p[/E1], binds to [E2]verprolin[/E2] and is required for targeting to sites of actin polarization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Myo5p", "entity_1_idx": [[58, 63]], "entity_1_idx_in_text_with_entity_marker": [62, 67], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "verprolin", "entity_2_idx": [[74, 83]], "entity_2_idx_in_text_with_entity_marker": [87, 96], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d722.s0_BioInfer.d722.s0.p4", "text": "The Src homology domain 3 (SH3) of a yeast type I myosin, Myo5p, binds to verprolin and is required for targeting to sites of actin polarization.", "text_with_entity_marker": "The Src homology domain 3 (SH3) of a yeast [E1]type I myosin[/E1], [E2]Myo5p[/E2], binds to verprolin and is required for targeting to sites of actin polarization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "type I myosin", "entity_1_idx": [[43, 56]], "entity_1_idx_in_text_with_entity_marker": [47, 60], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "Myo5p", "entity_2_idx": [[58, 63]], "entity_2_idx_in_text_with_entity_marker": [71, 76], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d244.s0_BioInfer.d244.s0.p5", "text": "Here, we have detected a polypeptide in rat rod outer segments that is recognized by myosin heavy chain antibodies and was found to possess other characteristics of conventional non-muscle myosin heavy chain: it comigrates in SDS-PAGE with non-muscle myosin heavy chain; it associates with the cytoskeleton of rod outer segments in an ATP-sensitive manner; and it binds to purified actin filaments in the absence of ATP.", "text_with_entity_marker": "Here, we have detected a polypeptide in rat rod outer segments that is recognized by myosin heavy chain antibodies and was found to possess other characteristics of conventional [E1]non-muscle myosin heavy chain[/E1]: it comigrates in SDS-PAGE with non-muscle myosin heavy chain; it associates with the cytoskeleton of rod outer segments in an ATP-sensitive manner; and it binds to purified [E2]actin[/E2] filaments in the absence of ATP.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "non-muscle myosin heavy chain", "entity_1_idx": [[178, 207]], "entity_1_idx_in_text_with_entity_marker": [182, 211], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[382, 387]], "entity_2_idx_in_text_with_entity_marker": [395, 400], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d78.s0_BioInfer.d78.s0.p2", "text": "As a nuclear transport signal sequence exists in cofilin and ADF but not in actin, ADF and/or cofilin may be responsible for the nuclear import of actin in myogenic cells under certain conditions.", "text_with_entity_marker": "As a nuclear transport signal sequence exists in cofilin and ADF but not in actin, ADF and/or [E1]cofilin[/E1] may be responsible for the nuclear import of [E2]actin[/E2] in myogenic cells under certain conditions.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[94, 101]], "entity_1_idx_in_text_with_entity_marker": [98, 105], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[147, 152]], "entity_2_idx_in_text_with_entity_marker": [160, 165], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d78.s0_BioInfer.d78.s0.p12", "text": "As a nuclear transport signal sequence exists in cofilin and ADF but not in actin, ADF and/or cofilin may be responsible for the nuclear import of actin in myogenic cells under certain conditions.", "text_with_entity_marker": "As a nuclear transport signal sequence exists in cofilin and ADF but not in actin, [E1]ADF[/E1] and/or cofilin may be responsible for the nuclear import of [E2]actin[/E2] in myogenic cells under certain conditions.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "ADF", "entity_1_idx": [[83, 86]], "entity_1_idx_in_text_with_entity_marker": [87, 90], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[147, 152]], "entity_2_idx_in_text_with_entity_marker": [160, 165], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d78.s1_BioInfer.d78.s1.p1", "text": "Immunofluorescence microscopy revealed that two actin-binding proteins of low molecular weight with different functional activity, ADF and cofilin, are transported into nuclei of cultured myogenic cells to form rod structures there together with actin, when the cells were incubated in medium containing dimethylsulfoxide.", "text_with_entity_marker": "Immunofluorescence microscopy revealed that two actin-binding proteins of low molecular weight with different functional activity, ADF and [E1]cofilin[/E1], are transported into nuclei of cultured myogenic cells to form rod structures there together with [E2]actin[/E2], when the cells were incubated in medium containing dimethylsulfoxide.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[139, 146]], "entity_1_idx_in_text_with_entity_marker": [143, 150], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[246, 251]], "entity_2_idx_in_text_with_entity_marker": [259, 264], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d78.s1_BioInfer.d78.s1.p2", "text": "Immunofluorescence microscopy revealed that two actin-binding proteins of low molecular weight with different functional activity, ADF and cofilin, are transported into nuclei of cultured myogenic cells to form rod structures there together with actin, when the cells were incubated in medium containing dimethylsulfoxide.", "text_with_entity_marker": "Immunofluorescence microscopy revealed that two [E1]actin-binding proteins[/E1] of low molecular weight with different functional activity, ADF and [E2]cofilin[/E2], are transported into nuclei of cultured myogenic cells to form rod structures there together with actin, when the cells were incubated in medium containing dimethylsulfoxide.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin-binding proteins", "entity_1_idx": [[48, 70]], "entity_1_idx_in_text_with_entity_marker": [52, 74], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "cofilin", "entity_2_idx": [[139, 146]], "entity_2_idx_in_text_with_entity_marker": [152, 159], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d78.s1_BioInfer.d78.s1.p3", "text": "Immunofluorescence microscopy revealed that two actin-binding proteins of low molecular weight with different functional activity, ADF and cofilin, are transported into nuclei of cultured myogenic cells to form rod structures there together with actin, when the cells were incubated in medium containing dimethylsulfoxide.", "text_with_entity_marker": "Immunofluorescence microscopy revealed that two actin-binding proteins of low molecular weight with different functional activity, [E1]ADF[/E1] and cofilin, are transported into nuclei of cultured myogenic cells to form rod structures there together with [E2]actin[/E2], when the cells were incubated in medium containing dimethylsulfoxide.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "ADF", "entity_1_idx": [[131, 134]], "entity_1_idx_in_text_with_entity_marker": [135, 138], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[246, 251]], "entity_2_idx_in_text_with_entity_marker": [259, 264], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d78.s2_BioInfer.d78.s2.p5", "text": "In most cases, ADF and cofilin colocalized in the same nuclear actin rods, but ADF appeared to predominate in mononucleated cells, while cofilin was present in multinucleated myotubes.", "text_with_entity_marker": "In most cases, [E1]ADF[/E1] and cofilin colocalized in the same nuclear [E2]actin[/E2] rods, but ADF appeared to predominate in mononucleated cells, while cofilin was present in multinucleated myotubes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "ADF", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[63, 68]], "entity_2_idx_in_text_with_entity_marker": [76, 81], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d78.s2_BioInfer.d78.s2.p6", "text": "In most cases, ADF and cofilin colocalized in the same nuclear actin rods, but ADF appeared to predominate in mononucleated cells, while cofilin was present in multinucleated myotubes.", "text_with_entity_marker": "In most cases, [E1]ADF[/E1] and [E2]cofilin[/E2] colocalized in the same nuclear actin rods, but ADF appeared to predominate in mononucleated cells, while cofilin was present in multinucleated myotubes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "ADF", "entity_1_idx": [[15, 18]], "entity_1_idx_in_text_with_entity_marker": [19, 22], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[23, 30]], "entity_2_idx_in_text_with_entity_marker": [36, 43], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d78.s2_BioInfer.d78.s2.p9", "text": "In most cases, ADF and cofilin colocalized in the same nuclear actin rods, but ADF appeared to predominate in mononucleated cells, while cofilin was present in multinucleated myotubes.", "text_with_entity_marker": "In most cases, ADF and [E1]cofilin[/E1] colocalized in the same nuclear [E2]actin[/E2] rods, but ADF appeared to predominate in mononucleated cells, while cofilin was present in multinucleated myotubes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[23, 30]], "entity_1_idx_in_text_with_entity_marker": [27, 34], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[63, 68]], "entity_2_idx_in_text_with_entity_marker": [76, 81], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d143.s0_BioInfer.d143.s0.p0", "text": "Class II profilins had higher affinity for poly-l-proline and sequestered more monomeric actin than did class I profilins.", "text_with_entity_marker": "Class II profilins had higher affinity for poly-l-proline and sequestered more monomeric [E1]actin[/E1] than did [E2]class I profilins[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[89, 94]], "entity_1_idx_in_text_with_entity_marker": [93, 98], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "class I profilins", "entity_2_idx": [[104, 121]], "entity_2_idx_in_text_with_entity_marker": [117, 134], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d143.s0_BioInfer.d143.s0.p2", "text": "Class II profilins had higher affinity for poly-l-proline and sequestered more monomeric actin than did class I profilins.", "text_with_entity_marker": "[E1]Class II profilins[/E1] had higher affinity for poly-l-proline and sequestered more monomeric [E2]actin[/E2] than did class I profilins.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Class II profilins", "entity_1_idx": [[0, 18]], "entity_1_idx_in_text_with_entity_marker": [4, 22], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[89, 94]], "entity_2_idx_in_text_with_entity_marker": [102, 107], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d143.s1_BioInfer.d143.s1.p0", "text": "The actin-sequestering activity of both maize profilin classes was found to be dependent on the concentration of free calcium.", "text_with_entity_marker": "The [E1]actin[/E1]-sequestering activity of both maize [E2]profilin[/E2] classes was found to be dependent on the concentration of free calcium.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[4, 9]], "entity_1_idx_in_text_with_entity_marker": [8, 13], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "profilin", "entity_2_idx": [[46, 54]], "entity_2_idx_in_text_with_entity_marker": [59, 67], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d143.s2_BioInfer.d143.s2.p0", "text": "We propose a model in which profilin alters cellular concentrations of actin polymers in response to fluctuations in cytosolic calcium concentration.", "text_with_entity_marker": "We propose a model in which [E1]profilin[/E1] alters cellular concentrations of [E2]actin[/E2] polymers in response to fluctuations in cytosolic calcium concentration.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[28, 36]], "entity_1_idx_in_text_with_entity_marker": [32, 40], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[71, 76]], "entity_2_idx_in_text_with_entity_marker": [84, 89], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d405.s0_BioInfer.d405.s0.p2", "text": "LIM-kinase 1 (LIMK1) phosphorylates cofilin, an actin-depolymerizing factor, and regulates actin cytoskeletal reorganization.", "text_with_entity_marker": "LIM-kinase 1 ([E1]LIMK1[/E1]) phosphorylates cofilin, an actin-depolymerizing factor, and regulates [E2]actin[/E2] cytoskeletal reorganization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "LIMK1", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[91, 96]], "entity_2_idx_in_text_with_entity_marker": [104, 109], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d405.s0_BioInfer.d405.s0.p3", "text": "LIM-kinase 1 (LIMK1) phosphorylates cofilin, an actin-depolymerizing factor, and regulates actin cytoskeletal reorganization.", "text_with_entity_marker": "[E1]LIM-kinase 1[/E1] (LIMK1) phosphorylates cofilin, an actin-depolymerizing factor, and regulates [E2]actin[/E2] cytoskeletal reorganization.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LIM-kinase 1", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[91, 96]], "entity_2_idx_in_text_with_entity_marker": [104, 109], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d405.s0_BioInfer.d405.s0.p4", "text": "LIM-kinase 1 (LIMK1) phosphorylates cofilin, an actin-depolymerizing factor, and regulates actin cytoskeletal reorganization.", "text_with_entity_marker": "LIM-kinase 1 (LIMK1) phosphorylates [E1]cofilin[/E1], an [E2]actin-depolymerizing factor[/E2], and regulates actin cytoskeletal reorganization.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cofilin", "entity_1_idx": [[36, 43]], "entity_1_idx_in_text_with_entity_marker": [40, 47], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin-depolymerizing factor", "entity_2_idx": [[48, 75]], "entity_2_idx_in_text_with_entity_marker": [61, 88], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d405.s0_BioInfer.d405.s0.p7", "text": "LIM-kinase 1 (LIMK1) phosphorylates cofilin, an actin-depolymerizing factor, and regulates actin cytoskeletal reorganization.", "text_with_entity_marker": "LIM-kinase 1 ([E1]LIMK1[/E1]) phosphorylates [E2]cofilin[/E2], an actin-depolymerizing factor, and regulates actin cytoskeletal reorganization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "LIMK1", "entity_1_idx": [[14, 19]], "entity_1_idx_in_text_with_entity_marker": [18, 23], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[36, 43]], "entity_2_idx_in_text_with_entity_marker": [49, 56], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d405.s0_BioInfer.d405.s0.p8", "text": "LIM-kinase 1 (LIMK1) phosphorylates cofilin, an actin-depolymerizing factor, and regulates actin cytoskeletal reorganization.", "text_with_entity_marker": "[E1]LIM-kinase 1[/E1] (LIMK1) phosphorylates [E2]cofilin[/E2], an actin-depolymerizing factor, and regulates actin cytoskeletal reorganization.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LIM-kinase 1", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[36, 43]], "entity_2_idx_in_text_with_entity_marker": [49, 56], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d151.s0_BioInfer.d151.s0.p0", "text": "CONCLUSIONS: These results suggest the cooperative modulation of the actin cytoskeleton by cofilin and Aip1.", "text_with_entity_marker": "CONCLUSIONS: These results suggest the cooperative modulation of the actin cytoskeleton by [E1]cofilin[/E1] and [E2]Aip1[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "cofilin", "entity_1_idx": [[91, 98]], "entity_1_idx_in_text_with_entity_marker": [95, 102], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "Aip1", "entity_2_idx": [[103, 107]], "entity_2_idx_in_text_with_entity_marker": [116, 120], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d151.s0_BioInfer.d151.s0.p1", "text": "CONCLUSIONS: These results suggest the cooperative modulation of the actin cytoskeleton by cofilin and Aip1.", "text_with_entity_marker": "CONCLUSIONS: These results suggest the cooperative modulation of the [E1]actin[/E1] cytoskeleton by cofilin and [E2]Aip1[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "Aip1", "entity_2_idx": [[103, 107]], "entity_2_idx_in_text_with_entity_marker": [116, 120], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d151.s0_BioInfer.d151.s0.p2", "text": "CONCLUSIONS: These results suggest the cooperative modulation of the actin cytoskeleton by cofilin and Aip1.", "text_with_entity_marker": "CONCLUSIONS: These results suggest the cooperative modulation of the [E1]actin[/E1] cytoskeleton by [E2]cofilin[/E2] and Aip1.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[69, 74]], "entity_1_idx_in_text_with_entity_marker": [73, 78], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[91, 98]], "entity_2_idx_in_text_with_entity_marker": [104, 111], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d151.s1_BioInfer.d151.s1.p0", "text": "Immunofluorescence staining of a wild-type strain using anti-Aip1 antibodies revealed that Aip1 was distributed in cortical actin patches where cofilin was also co-localized.", "text_with_entity_marker": "Immunofluorescence staining of a wild-type strain using anti-Aip1 antibodies revealed that Aip1 was distributed in cortical [E1]actin[/E1] patches where [E2]cofilin[/E2] was also co-localized.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[124, 129]], "entity_1_idx_in_text_with_entity_marker": [128, 133], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[144, 151]], "entity_2_idx_in_text_with_entity_marker": [157, 164], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d151.s1_BioInfer.d151.s1.p1", "text": "Immunofluorescence staining of a wild-type strain using anti-Aip1 antibodies revealed that Aip1 was distributed in cortical actin patches where cofilin was also co-localized.", "text_with_entity_marker": "Immunofluorescence staining of a wild-type strain using anti-Aip1 antibodies revealed that [E1]Aip1[/E1] was distributed in cortical [E2]actin[/E2] patches where cofilin was also co-localized.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Aip1", "entity_1_idx": [[91, 95]], "entity_1_idx_in_text_with_entity_marker": [95, 99], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[124, 129]], "entity_2_idx_in_text_with_entity_marker": [137, 142], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d765.s0_BioInfer.d765.s0.p0", "text": "To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors (CKIs) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.", "text_with_entity_marker": "To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors ([E1]CKIs[/E1]) [E2]p27[/E2] and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CKIs", "entity_1_idx": [[186, 190]], "entity_1_idx_in_text_with_entity_marker": [190, 194], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "p27", "entity_2_idx": [[192, 195]], "entity_2_idx_in_text_with_entity_marker": [205, 208], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d765.s0_BioInfer.d765.s0.p1", "text": "To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors (CKIs) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.", "text_with_entity_marker": "To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the [E1]cyclin-dependent kinase inhibitors[/E1] (CKIs) [E2]p27[/E2] and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitors", "entity_1_idx": [[150, 184]], "entity_1_idx_in_text_with_entity_marker": [154, 188], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "p27", "entity_2_idx": [[192, 195]], "entity_2_idx_in_text_with_entity_marker": [205, 208], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d765.s0_BioInfer.d765.s0.p10", "text": "To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors (CKIs) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.", "text_with_entity_marker": "To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors ([E1]CKIs[/E1]) p27 and [E2]p57[/E2], and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CKIs", "entity_1_idx": [[186, 190]], "entity_1_idx_in_text_with_entity_marker": [190, 194], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "p57", "entity_2_idx": [[200, 203]], "entity_2_idx_in_text_with_entity_marker": [213, 216], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d765.s0_BioInfer.d765.s0.p14", "text": "To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the cyclin-dependent kinase inhibitors (CKIs) p27 and p57, and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.", "text_with_entity_marker": "To determine the relationship between cell cycle regulation and differentiation, the spatiotemporal expression of cyclin A, cyclin B1, cyclin D1, the [E1]cyclin-dependent kinase inhibitors[/E1] (CKIs) p27 and [E2]p57[/E2], and markers of differentiating podocytes in developing human kidneys was investigated by immunohistochemistry.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cyclin-dependent kinase inhibitors", "entity_1_idx": [[150, 184]], "entity_1_idx_in_text_with_entity_marker": [154, 188], "entity_1_type": "Protein_family_or_group", "entity_1_type_id": 1, "entity_2": "p57", "entity_2_idx": [[200, 203]], "entity_2_idx_in_text_with_entity_marker": [213, 216], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d509.s0_BioInfer.d509.s0.p0", "text": "Recombinant human beta-catenin can simultaneously bind to the alpha-catenin/actin complex but does not bind actin directly.", "text_with_entity_marker": "Recombinant human [E1]beta-catenin[/E1] can simultaneously bind to the alpha-catenin/actin complex but does not bind [E2]actin[/E2] directly.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "beta-catenin", "entity_1_idx": [[18, 30]], "entity_1_idx_in_text_with_entity_marker": [22, 34], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[108, 113]], "entity_2_idx_in_text_with_entity_marker": [121, 126], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d509.s0_BioInfer.d509.s0.p1", "text": "Recombinant human beta-catenin can simultaneously bind to the alpha-catenin/actin complex but does not bind actin directly.", "text_with_entity_marker": "Recombinant human [E1]beta-catenin[/E1] can simultaneously bind to the alpha-catenin/[E2]actin[/E2] complex but does not bind actin directly.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "beta-catenin", "entity_1_idx": [[18, 30]], "entity_1_idx_in_text_with_entity_marker": [22, 34], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[76, 81]], "entity_2_idx_in_text_with_entity_marker": [89, 94], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d509.s0_BioInfer.d509.s0.p2", "text": "Recombinant human beta-catenin can simultaneously bind to the alpha-catenin/actin complex but does not bind actin directly.", "text_with_entity_marker": "Recombinant human [E1]beta-catenin[/E1] can simultaneously bind to the [E2]alpha-catenin[/E2]/actin complex but does not bind actin directly.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "beta-catenin", "entity_1_idx": [[18, 30]], "entity_1_idx_in_text_with_entity_marker": [22, 34], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-catenin", "entity_2_idx": [[62, 75]], "entity_2_idx_in_text_with_entity_marker": [75, 88], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d509.s0_BioInfer.d509.s0.p5", "text": "Recombinant human beta-catenin can simultaneously bind to the alpha-catenin/actin complex but does not bind actin directly.", "text_with_entity_marker": "Recombinant human beta-catenin can simultaneously bind to the [E1]alpha-catenin[/E1]/[E2]actin[/E2] complex but does not bind actin directly.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[62, 75]], "entity_1_idx_in_text_with_entity_marker": [66, 79], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[76, 81]], "entity_2_idx_in_text_with_entity_marker": [89, 94], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d332.s0_BioInfer.d332.s0.p0", "text": "Increasing the ionic strength within a relatively narrow range significantly decreased ability of talin to bind to actin, regardless of pH.", "text_with_entity_marker": "Increasing the ionic strength within a relatively narrow range significantly decreased ability of [E1]talin[/E1] to bind to [E2]actin[/E2], regardless of pH.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "talin", "entity_1_idx": [[98, 103]], "entity_1_idx_in_text_with_entity_marker": [102, 107], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[115, 120]], "entity_2_idx_in_text_with_entity_marker": [128, 133], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d332.s1_BioInfer.d332.s1.p0", "text": "Interaction of talin with actin: sensitive modulation of filament crosslinking activity.", "text_with_entity_marker": "Interaction of [E1]talin[/E1] with [E2]actin[/E2]: sensitive modulation of filament crosslinking activity.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "talin", "entity_1_idx": [[15, 20]], "entity_1_idx_in_text_with_entity_marker": [19, 24], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[26, 31]], "entity_2_idx_in_text_with_entity_marker": [39, 44], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d146.s0_BioInfer.d146.s0.p0", "text": "Cofilin and profilin may also be involved in the redistribution of actin during myofibrillogenesis and in the process of actin disassembly in degenerating muscles.", "text_with_entity_marker": "Cofilin and [E1]profilin[/E1] may also be involved in the redistribution of [E2]actin[/E2] during myofibrillogenesis and in the process of actin disassembly in degenerating muscles.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[12, 20]], "entity_1_idx_in_text_with_entity_marker": [16, 24], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[67, 72]], "entity_2_idx_in_text_with_entity_marker": [80, 85], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d146.s0_BioInfer.d146.s0.p1", "text": "Cofilin and profilin may also be involved in the redistribution of actin during myofibrillogenesis and in the process of actin disassembly in degenerating muscles.", "text_with_entity_marker": "Cofilin and [E1]profilin[/E1] may also be involved in the redistribution of actin during myofibrillogenesis and in the process of [E2]actin[/E2] disassembly in degenerating muscles.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "profilin", "entity_1_idx": [[12, 20]], "entity_1_idx_in_text_with_entity_marker": [16, 24], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d146.s0_BioInfer.d146.s0.p4", "text": "Cofilin and profilin may also be involved in the redistribution of actin during myofibrillogenesis and in the process of actin disassembly in degenerating muscles.", "text_with_entity_marker": "[E1]Cofilin[/E1] and profilin may also be involved in the redistribution of [E2]actin[/E2] during myofibrillogenesis and in the process of actin disassembly in degenerating muscles.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Cofilin", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[67, 72]], "entity_2_idx_in_text_with_entity_marker": [80, 85], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d146.s0_BioInfer.d146.s0.p5", "text": "Cofilin and profilin may also be involved in the redistribution of actin during myofibrillogenesis and in the process of actin disassembly in degenerating muscles.", "text_with_entity_marker": "[E1]Cofilin[/E1] and profilin may also be involved in the redistribution of actin during myofibrillogenesis and in the process of [E2]actin[/E2] disassembly in degenerating muscles.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "Cofilin", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d559.s0_BioInfer.d559.s0.p0", "text": "Testicular protein kinase 1 (TESK1) is a serine/threonine kinase highly expressed in testicular germ cells and has the potential to phosphorylate cofilin and induce actin cytoskeletal reorganization.", "text_with_entity_marker": "Testicular protein kinase 1 ([E1]TESK1[/E1]) is a serine/threonine kinase highly expressed in testicular germ cells and has the potential to phosphorylate cofilin and induce [E2]actin[/E2] cytoskeletal reorganization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "TESK1", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[165, 170]], "entity_2_idx_in_text_with_entity_marker": [178, 183], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d559.s0_BioInfer.d559.s0.p1", "text": "Testicular protein kinase 1 (TESK1) is a serine/threonine kinase highly expressed in testicular germ cells and has the potential to phosphorylate cofilin and induce actin cytoskeletal reorganization.", "text_with_entity_marker": "[E1]Testicular protein kinase 1[/E1] (TESK1) is a serine/threonine kinase highly expressed in testicular germ cells and has the potential to phosphorylate cofilin and induce [E2]actin[/E2] cytoskeletal reorganization.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Testicular protein kinase 1", "entity_1_idx": [[0, 27]], "entity_1_idx_in_text_with_entity_marker": [4, 31], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[165, 170]], "entity_2_idx_in_text_with_entity_marker": [178, 183], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d559.s0_BioInfer.d559.s0.p5", "text": "Testicular protein kinase 1 (TESK1) is a serine/threonine kinase highly expressed in testicular germ cells and has the potential to phosphorylate cofilin and induce actin cytoskeletal reorganization.", "text_with_entity_marker": "Testicular protein kinase 1 ([E1]TESK1[/E1]) is a [E2]serine/threonine kinase[/E2] highly expressed in testicular germ cells and has the potential to phosphorylate cofilin and induce actin cytoskeletal reorganization.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "TESK1", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "serine/threonine kinase", "entity_2_idx": [[41, 64]], "entity_2_idx_in_text_with_entity_marker": [54, 77], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d559.s0_BioInfer.d559.s0.p6", "text": "Testicular protein kinase 1 (TESK1) is a serine/threonine kinase highly expressed in testicular germ cells and has the potential to phosphorylate cofilin and induce actin cytoskeletal reorganization.", "text_with_entity_marker": "Testicular protein kinase 1 ([E1]TESK1[/E1]) is a serine/threonine kinase highly expressed in testicular germ cells and has the potential to phosphorylate [E2]cofilin[/E2] and induce actin cytoskeletal reorganization.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "TESK1", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[146, 153]], "entity_2_idx_in_text_with_entity_marker": [159, 166], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d559.s0_BioInfer.d559.s0.p7", "text": "Testicular protein kinase 1 (TESK1) is a serine/threonine kinase highly expressed in testicular germ cells and has the potential to phosphorylate cofilin and induce actin cytoskeletal reorganization.", "text_with_entity_marker": "[E1]Testicular protein kinase 1[/E1] (TESK1) is a [E2]serine/threonine kinase[/E2] highly expressed in testicular germ cells and has the potential to phosphorylate cofilin and induce actin cytoskeletal reorganization.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Testicular protein kinase 1", "entity_1_idx": [[0, 27]], "entity_1_idx_in_text_with_entity_marker": [4, 31], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "serine/threonine kinase", "entity_2_idx": [[41, 64]], "entity_2_idx_in_text_with_entity_marker": [54, 77], "entity_2_type": "Protein_family_or_group", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "BioInfer.d559.s0_BioInfer.d559.s0.p8", "text": "Testicular protein kinase 1 (TESK1) is a serine/threonine kinase highly expressed in testicular germ cells and has the potential to phosphorylate cofilin and induce actin cytoskeletal reorganization.", "text_with_entity_marker": "[E1]Testicular protein kinase 1[/E1] (TESK1) is a serine/threonine kinase highly expressed in testicular germ cells and has the potential to phosphorylate [E2]cofilin[/E2] and induce actin cytoskeletal reorganization.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Testicular protein kinase 1", "entity_1_idx": [[0, 27]], "entity_1_idx_in_text_with_entity_marker": [4, 31], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cofilin", "entity_2_idx": [[146, 153]], "entity_2_idx_in_text_with_entity_marker": [159, 166], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d524.s0_BioInfer.d524.s0.p7", "text": "Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.", "text_with_entity_marker": "Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although [E1]alpha-catenin[/E1] expression did prevent accumulation of [E2]beta-catenin[/E2] in the nucleus.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[179, 192]], "entity_1_idx_in_text_with_entity_marker": [183, 196], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[232, 244]], "entity_2_idx_in_text_with_entity_marker": [245, 257], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d524.s0_BioInfer.d524.s0.p27", "text": "Rod formation was prevented by coexpression of N-cadherin, APC, and Tcf-4, which bind to the armadillo repeats of beta-catenin, but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.", "text_with_entity_marker": "Rod formation was prevented by coexpression of [E1]N-cadherin[/E1], APC, and Tcf-4, which bind to the armadillo repeats of [E2]beta-catenin[/E2], but not by coexpression of alpha-catenin, although alpha-catenin expression did prevent accumulation of beta-catenin in the nucleus.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "N-cadherin", "entity_1_idx": [[47, 57]], "entity_1_idx_in_text_with_entity_marker": [51, 61], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[114, 126]], "entity_2_idx_in_text_with_entity_marker": [127, 139], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d29.s0_BioInfer.d29.s0.p0", "text": "After digestion of the 60 kDa fragment with cyanogen bromide, the N-terminal 21-amino acid sequence of one of the resulting peptides was found to show sequence similarity to a region near the actin-binding site (amino acid residues 260-281) of yeast fimbrin.", "text_with_entity_marker": "After digestion of the 60 kDa fragment with cyanogen bromide, the N-terminal 21-amino acid sequence of one of the resulting peptides was found to show sequence similarity to a region near the [E1]actin[/E1]-binding site (amino acid residues 260-281) of yeast [E2]fimbrin[/E2].", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[192, 197]], "entity_1_idx_in_text_with_entity_marker": [196, 201], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "fimbrin", "entity_2_idx": [[250, 257]], "entity_2_idx_in_text_with_entity_marker": [263, 270], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d236.s0_BioInfer.d236.s0.p0", "text": "Hence, we conclude that in its dimeric form, which is used in actin and lipid binding, talin is a dumbbell-shaped molecule built of two antiparallel subunits.", "text_with_entity_marker": "Hence, we conclude that in its dimeric form, which is used in [E1]actin[/E1] and lipid binding, [E2]talin[/E2] is a dumbbell-shaped molecule built of two antiparallel subunits.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "actin", "entity_1_idx": [[62, 67]], "entity_1_idx_in_text_with_entity_marker": [66, 71], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "talin", "entity_2_idx": [[87, 92]], "entity_2_idx_in_text_with_entity_marker": [100, 105], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d236.s1_BioInfer.d236.s1.p0", "text": "The talin dimer, which is crucial for actin and lipid binding, is built of a backbone containing the 200 kDa rod portions, at both ends of which a 47 kDa globular domain is attached.", "text_with_entity_marker": "The [E1]talin[/E1] dimer, which is crucial for [E2]actin[/E2] and lipid binding, is built of a backbone containing the 200 kDa rod portions, at both ends of which a 47 kDa globular domain is attached.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "talin", "entity_1_idx": [[4, 9]], "entity_1_idx_in_text_with_entity_marker": [8, 13], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[38, 43]], "entity_2_idx_in_text_with_entity_marker": [51, 56], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d106.s0_BioInfer.d106.s0.p0", "text": "Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.", "text_with_entity_marker": "[E1]Neuropilin-1[/E1] is expressed by endothelial and tumor cells as an isoform-specific receptor for [E2]vascular endothelial growth factor[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Neuropilin-1", "entity_1_idx": [[0, 12]], "entity_1_idx_in_text_with_entity_marker": [4, 16], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "vascular endothelial growth factor", "entity_2_idx": [[93, 127]], "entity_2_idx_in_text_with_entity_marker": [106, 140], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d575.s2_BioInfer.d575.s2.p0", "text": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the cadherin-catenin complexes.", "text_with_entity_marker": "Thus, APC forms distinct heteromeric complexes containing combinations of [E1]alpha-catenin[/E1], [E2]beta-catenin[/E2], and plakoglobin which are independent from the cadherin-catenin complexes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[74, 87]], "entity_1_idx_in_text_with_entity_marker": [78, 91], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "beta-catenin", "entity_2_idx": [[89, 101]], "entity_2_idx_in_text_with_entity_marker": [102, 114], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d575.s2_BioInfer.d575.s2.p1", "text": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the cadherin-catenin complexes.", "text_with_entity_marker": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, [E1]beta-catenin[/E1], and [E2]plakoglobin[/E2] which are independent from the cadherin-catenin complexes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "beta-catenin", "entity_1_idx": [[89, 101]], "entity_1_idx_in_text_with_entity_marker": [93, 105], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "plakoglobin", "entity_2_idx": [[107, 118]], "entity_2_idx_in_text_with_entity_marker": [120, 131], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d575.s2_BioInfer.d575.s2.p2", "text": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the cadherin-catenin complexes.", "text_with_entity_marker": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, [E1]beta-catenin[/E1], and plakoglobin which are independent from the [E2]cadherin[/E2]-catenin complexes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "beta-catenin", "entity_1_idx": [[89, 101]], "entity_1_idx_in_text_with_entity_marker": [93, 105], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cadherin", "entity_2_idx": [[150, 158]], "entity_2_idx_in_text_with_entity_marker": [163, 171], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d575.s2_BioInfer.d575.s2.p4", "text": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the cadherin-catenin complexes.", "text_with_entity_marker": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, [E1]beta-catenin[/E1], and plakoglobin which are independent from the cadherin-[E2]catenin[/E2] complexes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "beta-catenin", "entity_1_idx": [[89, 101]], "entity_1_idx_in_text_with_entity_marker": [93, 105], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "catenin", "entity_2_idx": [[159, 166]], "entity_2_idx_in_text_with_entity_marker": [172, 179], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d575.s2_BioInfer.d575.s2.p5", "text": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the cadherin-catenin complexes.", "text_with_entity_marker": "Thus, APC forms distinct heteromeric complexes containing combinations of [E1]alpha-catenin[/E1], beta-catenin, and [E2]plakoglobin[/E2] which are independent from the cadherin-catenin complexes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[74, 87]], "entity_1_idx_in_text_with_entity_marker": [78, 91], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "plakoglobin", "entity_2_idx": [[107, 118]], "entity_2_idx_in_text_with_entity_marker": [120, 131], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d575.s2_BioInfer.d575.s2.p6", "text": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the cadherin-catenin complexes.", "text_with_entity_marker": "Thus, APC forms distinct heteromeric complexes containing combinations of [E1]alpha-catenin[/E1], beta-catenin, and plakoglobin which are independent from the [E2]cadherin[/E2]-catenin complexes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[74, 87]], "entity_1_idx_in_text_with_entity_marker": [78, 91], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cadherin", "entity_2_idx": [[150, 158]], "entity_2_idx_in_text_with_entity_marker": [163, 171], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d575.s2_BioInfer.d575.s2.p7", "text": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the cadherin-catenin complexes.", "text_with_entity_marker": "Thus, [E1]APC[/E1] forms distinct heteromeric complexes containing combinations of [E2]alpha-catenin[/E2], beta-catenin, and plakoglobin which are independent from the cadherin-catenin complexes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "APC", "entity_1_idx": [[6, 9]], "entity_1_idx_in_text_with_entity_marker": [10, 13], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-catenin", "entity_2_idx": [[74, 87]], "entity_2_idx_in_text_with_entity_marker": [87, 100], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d575.s2_BioInfer.d575.s2.p8", "text": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the cadherin-catenin complexes.", "text_with_entity_marker": "Thus, APC forms distinct heteromeric complexes containing combinations of [E1]alpha-catenin[/E1], beta-catenin, and plakoglobin which are independent from the cadherin-[E2]catenin[/E2] complexes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "alpha-catenin", "entity_1_idx": [[74, 87]], "entity_1_idx_in_text_with_entity_marker": [78, 91], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "catenin", "entity_2_idx": [[159, 166]], "entity_2_idx_in_text_with_entity_marker": [172, 179], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d575.s2_BioInfer.d575.s2.p9", "text": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the cadherin-catenin complexes.", "text_with_entity_marker": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and [E1]plakoglobin[/E1] which are independent from the [E2]cadherin[/E2]-catenin complexes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "plakoglobin", "entity_1_idx": [[107, 118]], "entity_1_idx_in_text_with_entity_marker": [111, 122], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "cadherin", "entity_2_idx": [[150, 158]], "entity_2_idx_in_text_with_entity_marker": [163, 171], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d575.s2_BioInfer.d575.s2.p10", "text": "Thus, APC forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and plakoglobin which are independent from the cadherin-catenin complexes.", "text_with_entity_marker": "Thus, [E1]APC[/E1] forms distinct heteromeric complexes containing combinations of alpha-catenin, beta-catenin, and [E2]plakoglobin[/E2] which are independent from the cadherin-catenin complexes.", "relation": [{"relation_type": "structural", "relation_id": 1, "entity_1": "APC", "entity_1_idx": [[6, 9]], "entity_1_idx_in_text_with_entity_marker": [10, 13], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "plakoglobin", "entity_2_idx": [[107, 118]], "entity_2_idx_in_text_with_entity_marker": [120, 131], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d574.s0_BioInfer.d574.s0.p0", "text": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, nucleocapsid (N) and matrix (M) proteins.", "text_with_entity_marker": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion ([E1]F[/E1]), phosphoprotein (P), H, nucleocapsid (N) and matrix ([E2]M[/E2]) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F", "entity_1_idx": [[128, 129]], "entity_1_idx_in_text_with_entity_marker": [132, 133], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[184, 185]], "entity_2_idx_in_text_with_entity_marker": [197, 198], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d574.s0_BioInfer.d574.s0.p1", "text": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, nucleocapsid (N) and matrix (M) proteins.", "text_with_entity_marker": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, [E1]nucleocapsid[/E1] (N) and matrix ([E2]M[/E2]) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nucleocapsid", "entity_1_idx": [[155, 167], [187, 195]], "entity_1_idx_in_text_with_entity_marker": [159, 171], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[184, 185]], "entity_2_idx_in_text_with_entity_marker": [197, 198], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d574.s0_BioInfer.d574.s0.p2", "text": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, nucleocapsid (N) and matrix (M) proteins.", "text_with_entity_marker": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein ([E1]P[/E1]), H, nucleocapsid (N) and matrix ([E2]M[/E2]) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[148, 149]], "entity_1_idx_in_text_with_entity_marker": [152, 153], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[184, 185]], "entity_2_idx_in_text_with_entity_marker": [197, 198], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d574.s0_BioInfer.d574.s0.p3", "text": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, nucleocapsid (N) and matrix (M) proteins.", "text_with_entity_marker": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, nucleocapsid ([E1]N[/E1]) and matrix ([E2]M[/E2]) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[169, 170]], "entity_1_idx_in_text_with_entity_marker": [173, 174], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[184, 185]], "entity_2_idx_in_text_with_entity_marker": [197, 198], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d574.s0_BioInfer.d574.s0.p4", "text": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, nucleocapsid (N) and matrix (M) proteins.", "text_with_entity_marker": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), [E1]H[/E1], nucleocapsid (N) and matrix ([E2]M[/E2]) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "H", "entity_1_idx": [[152, 153], [187, 195]], "entity_1_idx_in_text_with_entity_marker": [156, 157], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "M", "entity_2_idx": [[184, 185]], "entity_2_idx_in_text_with_entity_marker": [197, 198], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d574.s0_BioInfer.d574.s0.p5", "text": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, nucleocapsid (N) and matrix (M) proteins.", "text_with_entity_marker": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the [E1]fusion[/E1] (F), phosphoprotein (P), H, nucleocapsid (N) and matrix ([E2]M[/E2]) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fusion", "entity_1_idx": [[120, 126], [187, 195]], "entity_1_idx_in_text_with_entity_marker": [124, 130], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[184, 185]], "entity_2_idx_in_text_with_entity_marker": [197, 198], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d574.s0_BioInfer.d574.s0.p6", "text": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, nucleocapsid (N) and matrix (M) proteins.", "text_with_entity_marker": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, nucleocapsid (N) and [E1]matrix[/E1] ([E2]M[/E2]) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "matrix", "entity_1_idx": [[176, 182], [187, 195]], "entity_1_idx_in_text_with_entity_marker": [180, 186], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[184, 185]], "entity_2_idx_in_text_with_entity_marker": [197, 198], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d574.s0_BioInfer.d574.s0.p7", "text": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, nucleocapsid (N) and matrix (M) proteins.", "text_with_entity_marker": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), [E1]phosphoprotein[/E1] (P), H, nucleocapsid (N) and matrix ([E2]M[/E2]) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[132, 146], [187, 195]], "entity_1_idx_in_text_with_entity_marker": [136, 150], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[184, 185]], "entity_2_idx_in_text_with_entity_marker": [197, 198], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d574.s0_BioInfer.d574.s0.p8", "text": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, nucleocapsid (N) and matrix (M) proteins.", "text_with_entity_marker": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion ([E1]F[/E1]), phosphoprotein (P), H, [E2]nucleocapsid[/E2] (N) and matrix (M) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F", "entity_1_idx": [[128, 129]], "entity_1_idx_in_text_with_entity_marker": [132, 133], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "nucleocapsid", "entity_2_idx": [[155, 167], [187, 195]], "entity_2_idx_in_text_with_entity_marker": [168, 180], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d574.s0_BioInfer.d574.s0.p9", "text": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion (F), phosphoprotein (P), H, nucleocapsid (N) and matrix (M) proteins.", "text_with_entity_marker": "The analysis of the viral proteins by electrophoresis indicates molecular weight differences between CDV and PDV in the fusion ([E1]F[/E1]), phosphoprotein ([E2]P[/E2]), H, nucleocapsid (N) and matrix (M) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F", "entity_1_idx": [[128, 129]], "entity_1_idx_in_text_with_entity_marker": [132, 133], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P", "entity_2_idx": [[148, 149]], "entity_2_idx_in_text_with_entity_marker": [161, 162], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d762.s0_BioInfer.d762.s0.p0", "text": "To check its applicability, well characterized, commercially available antibodies (against E-cadherin, alpha-catenin, and beta-catenin) were used on sections of human small intestine.", "text_with_entity_marker": "To check its applicability, well characterized, commercially available antibodies (against E-cadherin, [E1]alpha-catenin[/E1], and [E2]beta-catenin[/E2]) were used on sections of human small intestine.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-catenin", "entity_1_idx": [[103, 116]], "entity_1_idx_in_text_with_entity_marker": [107, 120], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[122, 134]], "entity_2_idx_in_text_with_entity_marker": [135, 147], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d762.s0_BioInfer.d762.s0.p1", "text": "To check its applicability, well characterized, commercially available antibodies (against E-cadherin, alpha-catenin, and beta-catenin) were used on sections of human small intestine.", "text_with_entity_marker": "To check its applicability, well characterized, commercially available antibodies (against [E1]E-cadherin[/E1], [E2]alpha-catenin[/E2], and beta-catenin) were used on sections of human small intestine.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[91, 101]], "entity_1_idx_in_text_with_entity_marker": [95, 105], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-catenin", "entity_2_idx": [[103, 116]], "entity_2_idx_in_text_with_entity_marker": [116, 129], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d762.s0_BioInfer.d762.s0.p2", "text": "To check its applicability, well characterized, commercially available antibodies (against E-cadherin, alpha-catenin, and beta-catenin) were used on sections of human small intestine.", "text_with_entity_marker": "To check its applicability, well characterized, commercially available antibodies (against [E1]E-cadherin[/E1], alpha-catenin, and [E2]beta-catenin[/E2]) were used on sections of human small intestine.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[91, 101]], "entity_1_idx_in_text_with_entity_marker": [95, 105], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[122, 134]], "entity_2_idx_in_text_with_entity_marker": [135, 147], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p0", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for [E1]5S[/E1], [E2]5.8S[/E2] and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "5S", "entity_1_idx": [[35, 37], [52, 56]], "entity_1_idx_in_text_with_entity_marker": [39, 41], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "5.8S", "entity_2_idx": [[39, 43], [52, 56]], "entity_2_idx_in_text_with_entity_marker": [52, 56], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p1", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, [E1]5.8S[/E1] and [E2]18S rRNA[/E2], actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "5.8S", "entity_1_idx": [[39, 43], [52, 56]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "18S rRNA", "entity_2_idx": [[48, 56]], "entity_2_idx_in_text_with_entity_marker": [61, 69], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p2", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, [E1]5.8S[/E1] and 18S rRNA, actin I, [E2]profilins Ia[/E2]/b and II, myosins IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "5.8S", "entity_1_idx": [[39, 43], [52, 56]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "profilins Ia", "entity_2_idx": [[67, 79]], "entity_2_idx_in_text_with_entity_marker": [80, 92], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p3", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, [E1]5.8S[/E1] and 18S rRNA, actin I, profilins Ia/b and II, [E2]myosins[/E2] IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "5.8S", "entity_1_idx": [[39, 43], [52, 56]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosins", "entity_2_idx": [[90, 97], [102, 104]], "entity_2_idx_in_text_with_entity_marker": [103, 110], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p4", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, [E1]5.8S[/E1] and 18S rRNA, [E2]actin I[/E2], profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "5.8S", "entity_1_idx": [[39, 43], [52, 56]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin I", "entity_2_idx": [[58, 65]], "entity_2_idx_in_text_with_entity_marker": [71, 78], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p5", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, [E1]5.8S[/E1] and 18S rRNA, actin I, [E2]profilins[/E2] Ia/b and II, myosins IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "5.8S", "entity_1_idx": [[39, 43], [52, 56]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "profilins", "entity_2_idx": [[67, 76], [86, 88]], "entity_2_idx_in_text_with_entity_marker": [80, 89], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p6", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, [E1]5.8S[/E1] and 18S rRNA, actin I, profilins Ia/b and II, [E2]myosins[/E2] IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "5.8S", "entity_1_idx": [[39, 43], [52, 56]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosins", "entity_2_idx": [[90, 97], [109, 111]], "entity_2_idx_in_text_with_entity_marker": [103, 110], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p7", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, [E1]5.8S[/E1] and 18S rRNA, actin I, [E2]profilins I[/E2]a/b and II, myosins IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "5.8S", "entity_1_idx": [[39, 43], [52, 56]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "profilins I", "entity_2_idx": [[67, 78], [80, 81]], "entity_2_idx_in_text_with_entity_marker": [80, 91], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p8", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, [E1]5.8S[/E1] and 18S rRNA, actin I, profilins Ia/b and II, [E2]myosins IB[/E2], IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "5.8S", "entity_1_idx": [[39, 43], [52, 56]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosins IB", "entity_2_idx": [[90, 100]], "entity_2_idx_in_text_with_entity_marker": [103, 113], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p9", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, [E1]5.8S[/E1] and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and [E2]calmodulin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "5.8S", "entity_1_idx": [[39, 43], [52, 56]], "entity_1_idx_in_text_with_entity_marker": [43, 47], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "calmodulin", "entity_2_idx": [[117, 127]], "entity_2_idx_in_text_with_entity_marker": [130, 140], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p20", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, 5.8S and [E1]18S rRNA[/E1], actin I, profilins Ia/b and II, [E2]myosins[/E2] IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "18S rRNA", "entity_1_idx": [[48, 56]], "entity_1_idx_in_text_with_entity_marker": [52, 60], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosins", "entity_2_idx": [[90, 97], [102, 104]], "entity_2_idx_in_text_with_entity_marker": [103, 110], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p21", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, 5.8S and [E1]18S rRNA[/E1], [E2]actin I[/E2], profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "18S rRNA", "entity_1_idx": [[48, 56]], "entity_1_idx_in_text_with_entity_marker": [52, 60], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin I", "entity_2_idx": [[58, 65]], "entity_2_idx_in_text_with_entity_marker": [71, 78], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p22", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, 5.8S and [E1]18S rRNA[/E1], actin I, [E2]profilins[/E2] Ia/b and II, myosins IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "18S rRNA", "entity_1_idx": [[48, 56]], "entity_1_idx_in_text_with_entity_marker": [52, 60], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "profilins", "entity_2_idx": [[67, 76], [86, 88]], "entity_2_idx_in_text_with_entity_marker": [80, 89], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p23", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, 5.8S and [E1]18S rRNA[/E1], actin I, profilins Ia/b and II, [E2]myosins[/E2] IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "18S rRNA", "entity_1_idx": [[48, 56]], "entity_1_idx_in_text_with_entity_marker": [52, 60], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosins", "entity_2_idx": [[90, 97], [109, 111]], "entity_2_idx_in_text_with_entity_marker": [103, 110], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p24", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, 5.8S and [E1]18S rRNA[/E1], actin I, [E2]profilins I[/E2]a/b and II, myosins IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "18S rRNA", "entity_1_idx": [[48, 56]], "entity_1_idx_in_text_with_entity_marker": [52, 60], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "profilins I", "entity_2_idx": [[67, 78], [80, 81]], "entity_2_idx_in_text_with_entity_marker": [80, 91], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p25", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, 5.8S and [E1]18S rRNA[/E1], actin I, profilins Ia/b and II, [E2]myosins IB[/E2], IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "18S rRNA", "entity_1_idx": [[48, 56]], "entity_1_idx_in_text_with_entity_marker": [52, 60], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosins IB", "entity_2_idx": [[90, 100]], "entity_2_idx_in_text_with_entity_marker": [103, 113], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p26", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, 5.8S and [E1]18S rRNA[/E1], actin I, profilins Ia/b and II, myosins IB, IC and II, and [E2]calmodulin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "18S rRNA", "entity_1_idx": [[48, 56]], "entity_1_idx_in_text_with_entity_marker": [52, 60], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "calmodulin", "entity_2_idx": [[117, 127]], "entity_2_idx_in_text_with_entity_marker": [130, 140], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p27", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, [E1]profilins Ia[/E1]/b and II, [E2]myosins[/E2] IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "profilins Ia", "entity_1_idx": [[67, 79]], "entity_1_idx_in_text_with_entity_marker": [71, 83], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosins", "entity_2_idx": [[90, 97], [102, 104]], "entity_2_idx_in_text_with_entity_marker": [103, 110], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p28", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, 5.8S and 18S rRNA, [E1]actin I[/E1], [E2]profilins Ia[/E2]/b and II, myosins IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin I", "entity_1_idx": [[58, 65]], "entity_1_idx_in_text_with_entity_marker": [62, 69], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "profilins Ia", "entity_2_idx": [[67, 79]], "entity_2_idx_in_text_with_entity_marker": [80, 92], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d616.s0_BioInfer.d616.s0.p29", "text": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, profilins Ia/b and II, myosins IB, IC and II, and calmodulin.", "text_with_entity_marker": "The genes considered are those for 5S, 5.8S and 18S rRNA, actin I, [E1-E2]profilins[/E1] Ia[/E2]/b and II, myosins IB, IC and II, and calmodulin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "profilins", "entity_1_idx": [[67, 76], [86, 88]], "entity_1_idx_in_text_with_entity_marker": [74, 83], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "profilins[/E1] Ia", "entity_2_idx": [[67, 79]], "entity_2_idx_in_text_with_entity_marker": [74, 91], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d220.s0_BioInfer.d220.s0.p0", "text": "Frozen tissue sections, isolated cardiomyocytes, cultured neonatal cardiomyocytes and fibroblasts were hybridized with DNA probes for type-specific collagens, actin, and myosin heavy chain.", "text_with_entity_marker": "Frozen tissue sections, isolated cardiomyocytes, cultured neonatal cardiomyocytes and fibroblasts were hybridized with DNA probes for type-specific [E1]collagens[/E1], actin, and [E2]myosin heavy chain[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "collagens", "entity_1_idx": [[148, 157]], "entity_1_idx_in_text_with_entity_marker": [152, 161], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosin heavy chain", "entity_2_idx": [[170, 188]], "entity_2_idx_in_text_with_entity_marker": [183, 201], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d220.s0_BioInfer.d220.s0.p1", "text": "Frozen tissue sections, isolated cardiomyocytes, cultured neonatal cardiomyocytes and fibroblasts were hybridized with DNA probes for type-specific collagens, actin, and myosin heavy chain.", "text_with_entity_marker": "Frozen tissue sections, isolated cardiomyocytes, cultured neonatal cardiomyocytes and fibroblasts were hybridized with DNA probes for type-specific [E1]collagens[/E1], [E2]actin[/E2], and myosin heavy chain.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "collagens", "entity_1_idx": [[148, 157]], "entity_1_idx_in_text_with_entity_marker": [152, 161], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d220.s0_BioInfer.d220.s0.p2", "text": "Frozen tissue sections, isolated cardiomyocytes, cultured neonatal cardiomyocytes and fibroblasts were hybridized with DNA probes for type-specific collagens, actin, and myosin heavy chain.", "text_with_entity_marker": "Frozen tissue sections, isolated cardiomyocytes, cultured neonatal cardiomyocytes and fibroblasts were hybridized with DNA probes for type-specific collagens, [E1]actin[/E1], and [E2]myosin heavy chain[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosin heavy chain", "entity_2_idx": [[170, 188]], "entity_2_idx_in_text_with_entity_marker": [183, 201], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d323.s0_BioInfer.d323.s0.p0", "text": "In cells lacking the myosin-II heavy chain, the bundles, which were induced by an over-expression of cofilin, shortened and became straight following hyperosmotic stress, forming a polygonal structure.", "text_with_entity_marker": "In cells lacking the [E1]myosin-II heavy chain[/E1], the bundles, which were induced by an over-expression of [E2]cofilin[/E2], shortened and became straight following hyperosmotic stress, forming a polygonal structure.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin-II heavy chain", "entity_1_idx": [[21, 42]], "entity_1_idx_in_text_with_entity_marker": [25, 46], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "cofilin", "entity_2_idx": [[101, 108]], "entity_2_idx_in_text_with_entity_marker": [114, 121], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p30", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins ([E1]TRAF-1[/E1], TRAF-2, [E2]TRAF-3[/E2]) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRAF-1", "entity_1_idx": [[123, 129]], "entity_1_idx_in_text_with_entity_marker": [127, 133], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-3", "entity_2_idx": [[139, 145]], "entity_2_idx_in_text_with_entity_marker": [152, 158], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p31", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain ([E1]TNF-RI[/E1], Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins ([E2]TRAF-1[/E2], TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNF-RI", "entity_1_idx": [[48, 54]], "entity_1_idx_in_text_with_entity_marker": [52, 58], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-1", "entity_2_idx": [[123, 129]], "entity_2_idx_in_text_with_entity_marker": [136, 142], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p32", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, [E1]TRADD[/E1], FADD/MORT-1, RIP) and TRAF domain-containing proteins ([E2]TRAF-1[/E2], TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRADD", "entity_1_idx": [[61, 66]], "entity_1_idx_in_text_with_entity_marker": [65, 70], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-1", "entity_2_idx": [[123, 129]], "entity_2_idx_in_text_with_entity_marker": [136, 142], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p33", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, [E1]Fas[/E1], TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins ([E2]TRAF-1[/E2], TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas", "entity_1_idx": [[56, 59]], "entity_1_idx_in_text_with_entity_marker": [60, 63], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-1", "entity_2_idx": [[123, 129]], "entity_2_idx_in_text_with_entity_marker": [136, 142], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p34", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, [E1]RIP[/E1]) and TRAF domain-containing proteins ([E2]TRAF-1[/E2], TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RIP", "entity_1_idx": [[81, 84]], "entity_1_idx_in_text_with_entity_marker": [85, 88], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-1", "entity_2_idx": [[123, 129]], "entity_2_idx_in_text_with_entity_marker": [136, 142], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p35", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain ([E1]TNF-RI[/E1], Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, [E2]TRAF-3[/E2]) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNF-RI", "entity_1_idx": [[48, 54]], "entity_1_idx_in_text_with_entity_marker": [52, 58], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-3", "entity_2_idx": [[139, 145]], "entity_2_idx_in_text_with_entity_marker": [152, 158], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p36", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, [E1]TRADD[/E1], FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, [E2]TRAF-3[/E2]) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRADD", "entity_1_idx": [[61, 66]], "entity_1_idx_in_text_with_entity_marker": [65, 70], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-3", "entity_2_idx": [[139, 145]], "entity_2_idx_in_text_with_entity_marker": [152, 158], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p37", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, [E1]Fas[/E1], TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, [E2]TRAF-3[/E2]) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas", "entity_1_idx": [[56, 59]], "entity_1_idx_in_text_with_entity_marker": [60, 63], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-3", "entity_2_idx": [[139, 145]], "entity_2_idx_in_text_with_entity_marker": [152, 158], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p38", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, [E1]RIP[/E1]) and TRAF domain-containing proteins (TRAF-1, TRAF-2, [E2]TRAF-3[/E2]) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RIP", "entity_1_idx": [[81, 84]], "entity_1_idx_in_text_with_entity_marker": [85, 88], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRAF-3", "entity_2_idx": [[139, 145]], "entity_2_idx_in_text_with_entity_marker": [152, 158], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d390.s0_BioInfer.d390.s0.p39", "text": "Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "text_with_entity_marker": "Isolation and characterization of death domain ([E1]TNF-RI[/E1], Fas, [E2]TRADD[/E2], FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1, TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNF-RI", "entity_1_idx": [[48, 54]], "entity_1_idx_in_text_with_entity_marker": [52, 58], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "TRADD", "entity_2_idx": [[61, 66]], "entity_2_idx_in_text_with_entity_marker": [74, 79], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d761.s0_BioInfer.d761.s0.p0", "text": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and alpha-smooth muscle actin (alpha-SM actin) in IgA nephropathy.", "text_with_entity_marker": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and [E1]alpha-smooth muscle actin[/E1] (alpha-SM actin) in [E2]IgA[/E2] nephropathy.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-smooth muscle actin", "entity_1_idx": [[170, 195]], "entity_1_idx_in_text_with_entity_marker": [174, 199], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "IgA", "entity_2_idx": [[216, 219]], "entity_2_idx_in_text_with_entity_marker": [229, 232], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d761.s0_BioInfer.d761.s0.p1", "text": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and alpha-smooth muscle actin (alpha-SM actin) in IgA nephropathy.", "text_with_entity_marker": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of [E1]nonmuscle-type myosin heavy chain[/E1], SMemb, and alpha-smooth muscle actin (alpha-SM actin) in [E2]IgA[/E2] nephropathy.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nonmuscle-type myosin heavy chain", "entity_1_idx": [[124, 157]], "entity_1_idx_in_text_with_entity_marker": [128, 161], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "IgA", "entity_2_idx": [[216, 219]], "entity_2_idx_in_text_with_entity_marker": [229, 232], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d761.s0_BioInfer.d761.s0.p2", "text": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and alpha-smooth muscle actin (alpha-SM actin) in IgA nephropathy.", "text_with_entity_marker": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and alpha-smooth muscle actin ([E1]alpha-SM actin[/E1]) in [E2]IgA[/E2] nephropathy.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-SM actin", "entity_1_idx": [[197, 211]], "entity_1_idx_in_text_with_entity_marker": [201, 215], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "IgA", "entity_2_idx": [[216, 219]], "entity_2_idx_in_text_with_entity_marker": [229, 232], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d761.s0_BioInfer.d761.s0.p3", "text": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and alpha-smooth muscle actin (alpha-SM actin) in IgA nephropathy.", "text_with_entity_marker": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, [E1]SMemb[/E1], and alpha-smooth muscle actin (alpha-SM actin) in [E2]IgA[/E2] nephropathy.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "SMemb", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "IgA", "entity_2_idx": [[216, 219]], "entity_2_idx_in_text_with_entity_marker": [229, 232], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d761.s0_BioInfer.d761.s0.p4", "text": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and alpha-smooth muscle actin (alpha-SM actin) in IgA nephropathy.", "text_with_entity_marker": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of [E1]nonmuscle-type myosin heavy chain[/E1], SMemb, and [E2]alpha-smooth muscle actin[/E2] (alpha-SM actin) in IgA nephropathy.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nonmuscle-type myosin heavy chain", "entity_1_idx": [[124, 157]], "entity_1_idx_in_text_with_entity_marker": [128, 161], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-smooth muscle actin", "entity_2_idx": [[170, 195]], "entity_2_idx_in_text_with_entity_marker": [183, 208], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d761.s0_BioInfer.d761.s0.p5", "text": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and alpha-smooth muscle actin (alpha-SM actin) in IgA nephropathy.", "text_with_entity_marker": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and [E1]alpha-smooth muscle actin[/E1] ([E2]alpha-SM actin[/E2]) in IgA nephropathy.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-smooth muscle actin", "entity_1_idx": [[170, 195]], "entity_1_idx_in_text_with_entity_marker": [174, 199], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-SM actin", "entity_2_idx": [[197, 211]], "entity_2_idx_in_text_with_entity_marker": [210, 224], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d761.s0_BioInfer.d761.s0.p6", "text": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and alpha-smooth muscle actin (alpha-SM actin) in IgA nephropathy.", "text_with_entity_marker": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, [E1]SMemb[/E1], and [E2]alpha-smooth muscle actin[/E2] (alpha-SM actin) in IgA nephropathy.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "SMemb", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-smooth muscle actin", "entity_2_idx": [[170, 195]], "entity_2_idx_in_text_with_entity_marker": [183, 208], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d761.s0_BioInfer.d761.s0.p7", "text": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and alpha-smooth muscle actin (alpha-SM actin) in IgA nephropathy.", "text_with_entity_marker": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of [E1]nonmuscle-type myosin heavy chain[/E1], SMemb, and alpha-smooth muscle actin ([E2]alpha-SM actin[/E2]) in IgA nephropathy.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nonmuscle-type myosin heavy chain", "entity_1_idx": [[124, 157]], "entity_1_idx_in_text_with_entity_marker": [128, 161], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-SM actin", "entity_2_idx": [[197, 211]], "entity_2_idx_in_text_with_entity_marker": [210, 224], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d761.s0_BioInfer.d761.s0.p8", "text": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and alpha-smooth muscle actin (alpha-SM actin) in IgA nephropathy.", "text_with_entity_marker": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of [E1]nonmuscle-type myosin heavy chain[/E1], [E2]SMemb[/E2], and alpha-smooth muscle actin (alpha-SM actin) in IgA nephropathy.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nonmuscle-type myosin heavy chain", "entity_1_idx": [[124, 157]], "entity_1_idx_in_text_with_entity_marker": [128, 161], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "SMemb", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d761.s0_BioInfer.d761.s0.p9", "text": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, SMemb, and alpha-smooth muscle actin (alpha-SM actin) in IgA nephropathy.", "text_with_entity_marker": "To characterize the phenotypic alteration in mesangial cells in human glomerulonephritis, we investigated the expression of nonmuscle-type myosin heavy chain, [E1]SMemb[/E1], and alpha-smooth muscle actin ([E2]alpha-SM actin[/E2]) in IgA nephropathy.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "SMemb", "entity_1_idx": [[159, 164]], "entity_1_idx_in_text_with_entity_marker": [163, 168], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-SM actin", "entity_2_idx": [[197, 211]], "entity_2_idx_in_text_with_entity_marker": [210, 224], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d438.s0_BioInfer.d438.s0.p0", "text": "Moreover, the virus-encoded profilin homolog was not required for actin-associated events, including intracellular virus movement to the periphery of the cell, formation of specialized microvilli, or release of mature virions, as shown by electron microscopy and yields of infectious intra- and extracellular virus.", "text_with_entity_marker": "Moreover, the virus-encoded [E1]profilin[/E1] homolog was not required for [E2]actin[/E2]-associated events, including intracellular virus movement to the periphery of the cell, formation of specialized microvilli, or release of mature virions, as shown by electron microscopy and yields of infectious intra- and extracellular virus.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "profilin", "entity_1_idx": [[28, 36]], "entity_1_idx_in_text_with_entity_marker": [32, 40], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "actin", "entity_2_idx": [[66, 71]], "entity_2_idx_in_text_with_entity_marker": [79, 84], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p10", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large ([E1]L[/E1]; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural ([E2]V[/E2]; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "L", "entity_1_idx": [[170, 171]], "entity_1_idx_in_text_with_entity_marker": [174, 175], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "V", "entity_2_idx": [[340, 341]], "entity_2_idx_in_text_with_entity_marker": [353, 354], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p11", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large ([E1]L[/E1]; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid ([E2]N[/E2]; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "L", "entity_1_idx": [[170, 171]], "entity_1_idx_in_text_with_entity_marker": [174, 175], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "N", "entity_2_idx": [[240, 241]], "entity_2_idx_in_text_with_entity_marker": [253, 254], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p12", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large ([E1]L[/E1]; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix ([E2]M[/E2]; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "L", "entity_1_idx": [[170, 171]], "entity_1_idx_in_text_with_entity_marker": [174, 175], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[309, 310]], "entity_2_idx_in_text_with_entity_marker": [322, 323], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p13", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), [E1]fusion[/E1] ([E2]F0[/E2]; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fusion", "entity_1_idx": [[252, 258], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [256, 262], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F0", "entity_2_idx": [[260, 262]], "entity_2_idx_in_text_with_entity_marker": [273, 275], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p14", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion ([E1]F0[/E1]; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and [E2]non-structural[/E2] (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F0", "entity_1_idx": [[260, 262]], "entity_1_idx_in_text_with_entity_marker": [264, 266], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "non-structural", "entity_2_idx": [[324, 338], [351, 359]], "entity_2_idx_in_text_with_entity_marker": [337, 351], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p15", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion ([E1]F0[/E1]; 63 kDa), phosphoprotein (P; 49 kDa), [E2]matrix[/E2] (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F0", "entity_1_idx": [[260, 262]], "entity_1_idx_in_text_with_entity_marker": [264, 266], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "matrix", "entity_2_idx": [[301, 307], [351, 359]], "entity_2_idx_in_text_with_entity_marker": [314, 320], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p16", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase ([E1]HN[/E1]; 74 kDa), nucleocapsid (N; 66 kDa), fusion ([E2]F0[/E2]; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "HN", "entity_1_idx": [[213, 215]], "entity_1_idx_in_text_with_entity_marker": [217, 219], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F0", "entity_2_idx": [[260, 262]], "entity_2_idx_in_text_with_entity_marker": [273, 275], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p17", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the [E1]large[/E1] (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion ([E2]F0[/E2]; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "large", "entity_1_idx": [[163, 168], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [167, 172], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F0", "entity_2_idx": [[260, 262]], "entity_2_idx_in_text_with_entity_marker": [273, 275], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p18", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), [E1]nucleocapsid[/E1] (N; 66 kDa), fusion ([E2]F0[/E2]; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nucleocapsid", "entity_1_idx": [[226, 238], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [230, 242], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F0", "entity_2_idx": [[260, 262]], "entity_2_idx_in_text_with_entity_marker": [273, 275], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p19", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), [E1]haemagglutinin neuraminidase[/E1] (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion ([E2]F0[/E2]; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "haemagglutinin neuraminidase", "entity_1_idx": [[183, 211], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [187, 215], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F0", "entity_2_idx": [[260, 262]], "entity_2_idx_in_text_with_entity_marker": [273, 275], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p80", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), [E1]haemagglutinin neuraminidase[/E1] (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix ([E2]M[/E2]; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "haemagglutinin neuraminidase", "entity_1_idx": [[183, 211], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [187, 215], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[309, 310]], "entity_2_idx_in_text_with_entity_marker": [322, 323], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p81", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), [E1]phosphoprotein[/E1] ([E2]P[/E2]; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[273, 287], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [277, 291], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P", "entity_2_idx": [[289, 290]], "entity_2_idx_in_text_with_entity_marker": [302, 303], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p82", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), [E1]phosphoprotein[/E1] (P; 49 kDa), matrix (M; 43 kDa) and non-structural ([E2]V[/E2]; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[273, 287], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [277, 291], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "V", "entity_2_idx": [[340, 341]], "entity_2_idx_in_text_with_entity_marker": [353, 354], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p83", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid ([E1]N[/E1]; 66 kDa), fusion (F0; 63 kDa), [E2]phosphoprotein[/E2] (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[240, 241]], "entity_1_idx_in_text_with_entity_marker": [244, 245], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "phosphoprotein", "entity_2_idx": [[273, 287], [351, 359]], "entity_2_idx_in_text_with_entity_marker": [286, 300], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p84", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), [E1]phosphoprotein[/E1] (P; 49 kDa), matrix ([E2]M[/E2]; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[273, 287], [351, 359]], "entity_1_idx_in_text_with_entity_marker": [277, 291], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[309, 310]], "entity_2_idx_in_text_with_entity_marker": [322, 323], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p85", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein ([E1]P[/E1]; 49 kDa), matrix (M; 43 kDa) and non-structural ([E2]V[/E2]; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[289, 290]], "entity_1_idx_in_text_with_entity_marker": [293, 294], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "V", "entity_2_idx": [[340, 341]], "entity_2_idx_in_text_with_entity_marker": [353, 354], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p86", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid ([E1]N[/E1]; 66 kDa), fusion (F0; 63 kDa), phosphoprotein ([E2]P[/E2]; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[240, 241]], "entity_1_idx_in_text_with_entity_marker": [244, 245], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P", "entity_2_idx": [[289, 290]], "entity_2_idx_in_text_with_entity_marker": [302, 303], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p87", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein ([E1]P[/E1]; 49 kDa), matrix ([E2]M[/E2]; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[289, 290]], "entity_1_idx_in_text_with_entity_marker": [293, 294], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[309, 310]], "entity_2_idx_in_text_with_entity_marker": [322, 323], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p88", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid ([E1]N[/E1]; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural ([E2]V[/E2]; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[240, 241]], "entity_1_idx_in_text_with_entity_marker": [244, 245], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "V", "entity_2_idx": [[340, 341]], "entity_2_idx_in_text_with_entity_marker": [353, 354], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p89", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix ([E1]M[/E1]; 43 kDa) and non-structural ([E2]V[/E2]; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[309, 310]], "entity_1_idx_in_text_with_entity_marker": [313, 314], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "V", "entity_2_idx": [[340, 341]], "entity_2_idx_in_text_with_entity_marker": [353, 354], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d721.s0_BioInfer.d721.s0.p90", "text": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid (N; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix (M; 43 kDa) and non-structural (V; 35 kDa) proteins.", "text_with_entity_marker": "The sizes and characteristics of each of the proteins determined from various radiolabelling experiments allowed preliminary identification of the proteins as the large (L; 190 kDa), haemagglutinin neuraminidase (HN; 74 kDa), nucleocapsid ([E1]N[/E1]; 66 kDa), fusion (F0; 63 kDa), phosphoprotein (P; 49 kDa), matrix ([E2]M[/E2]; 43 kDa) and non-structural (V; 35 kDa) proteins.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[240, 241]], "entity_1_idx_in_text_with_entity_marker": [244, 245], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "M", "entity_2_idx": [[309, 310]], "entity_2_idx_in_text_with_entity_marker": [322, 323], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d517.s0_BioInfer.d517.s0.p0", "text": "Removal of one nonhomologous DNA end during gene conversion by a RAD1- and MSH2-independent pathway.", "text_with_entity_marker": "Removal of one nonhomologous DNA end during gene conversion by a [E1]RAD1[/E1]- and [E2]MSH2[/E2]-independent pathway.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD1", "entity_1_idx": [[65, 69]], "entity_1_idx_in_text_with_entity_marker": [69, 73], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MSH2", "entity_2_idx": [[75, 79]], "entity_2_idx_in_text_with_entity_marker": [88, 92], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d767.s0_BioInfer.d767.s0.p0", "text": "To determine whether alpha 1-adrenergic stimulation produced similar effects on the turnover of myofibrillar proteins, rates of synthesis and degradation were estimated for a myofibrillar-enriched protein fraction and for myosin heavy chain and actin.", "text_with_entity_marker": "To determine whether alpha 1-adrenergic stimulation produced similar effects on the turnover of myofibrillar proteins, rates of synthesis and degradation were estimated for a myofibrillar-enriched protein fraction and for [E1]myosin heavy chain[/E1] and [E2]actin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin heavy chain", "entity_1_idx": [[222, 240]], "entity_1_idx_in_text_with_entity_marker": [226, 244], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[245, 250]], "entity_2_idx_in_text_with_entity_marker": [258, 263], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s3_BioInfer.d33.s3.p4", "text": "RESULTS: E-cadherin, alpha-catenin, beta-catenin and gamma-catenin were expressed in a normal membranous pattern in all normal bladder epithelium specimens.", "text_with_entity_marker": "RESULTS: E-cadherin, alpha-catenin, [E1]beta-catenin[/E1] and [E2]gamma-catenin[/E2] were expressed in a normal membranous pattern in all normal bladder epithelium specimens.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta-catenin", "entity_1_idx": [[36, 48]], "entity_1_idx_in_text_with_entity_marker": [40, 52], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "gamma-catenin", "entity_2_idx": [[53, 66]], "entity_2_idx_in_text_with_entity_marker": [66, 79], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d33.s3_BioInfer.d33.s3.p5", "text": "RESULTS: E-cadherin, alpha-catenin, beta-catenin and gamma-catenin were expressed in a normal membranous pattern in all normal bladder epithelium specimens.", "text_with_entity_marker": "RESULTS: [E1]E-cadherin[/E1], alpha-catenin, [E2]beta-catenin[/E2] and gamma-catenin were expressed in a normal membranous pattern in all normal bladder epithelium specimens.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "E-cadherin", "entity_1_idx": [[9, 19]], "entity_1_idx_in_text_with_entity_marker": [13, 23], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "beta-catenin", "entity_2_idx": [[36, 48]], "entity_2_idx_in_text_with_entity_marker": [49, 61], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p0", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain ([E1]MLC[/E1]), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin ([E2]alpha-SMA[/E2]), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MLC", "entity_1_idx": [[122, 125]], "entity_1_idx_in_text_with_entity_marker": [126, 129], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-SMA", "entity_2_idx": [[213, 222]], "entity_2_idx_in_text_with_entity_marker": [226, 235], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p1", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain ([E1]MLC[/E1]), troponin I (TnI) isoforms, connexin 43 ([E2]Cx43[/E2]), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MLC", "entity_1_idx": [[122, 125]], "entity_1_idx_in_text_with_entity_marker": [126, 129], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "Cx43", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p2", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain ([E1]MLC[/E1]), troponin I (TnI) isoforms, [E2]connexin 43[/E2] (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MLC", "entity_1_idx": [[122, 125]], "entity_1_idx_in_text_with_entity_marker": [126, 129], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "connexin 43", "entity_2_idx": [[155, 166]], "entity_2_idx_in_text_with_entity_marker": [168, 179], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p3", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain ([E1]MHC[/E1]), myosin light chain ([E2]MLC[/E2]), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MHC", "entity_1_idx": [[96, 99]], "entity_1_idx_in_text_with_entity_marker": [100, 103], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "MLC", "entity_2_idx": [[122, 125]], "entity_2_idx_in_text_with_entity_marker": [135, 138], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p4", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain ([E1]MLC[/E1]), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and [E2]alpha-smooth muscle actin[/E2] (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MLC", "entity_1_idx": [[122, 125]], "entity_1_idx_in_text_with_entity_marker": [126, 129], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-smooth muscle actin", "entity_2_idx": [[186, 211]], "entity_2_idx_in_text_with_entity_marker": [199, 224], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p5", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain ([E1]MLC[/E1]), troponin I ([E2]TnI[/E2]) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MLC", "entity_1_idx": [[122, 125]], "entity_1_idx_in_text_with_entity_marker": [126, 129], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "TnI", "entity_2_idx": [[140, 143]], "entity_2_idx_in_text_with_entity_marker": [153, 156], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p6", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of [E1]myosin heavy chain[/E1] (MHC), myosin light chain ([E2]MLC[/E2]), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin heavy chain", "entity_1_idx": [[76, 94]], "entity_1_idx_in_text_with_entity_marker": [80, 98], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "MLC", "entity_2_idx": [[122, 125]], "entity_2_idx_in_text_with_entity_marker": [135, 138], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p7", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain ([E1]MLC[/E1]), [E2]troponin I[/E2] (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MLC", "entity_1_idx": [[122, 125]], "entity_1_idx_in_text_with_entity_marker": [126, 129], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "troponin I", "entity_2_idx": [[128, 138]], "entity_2_idx_in_text_with_entity_marker": [141, 151], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p8", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), [E1]myosin light chain[/E1] ([E2]MLC[/E2]), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin light chain", "entity_1_idx": [[102, 120]], "entity_1_idx_in_text_with_entity_marker": [106, 124], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "MLC", "entity_2_idx": [[122, 125]], "entity_2_idx_in_text_with_entity_marker": [135, 138], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p9", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain ([E1]MLC[/E1]), troponin I (TnI) isoforms, connexin 43 (Cx43), [E2]desmin[/E2] and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MLC", "entity_1_idx": [[122, 125]], "entity_1_idx_in_text_with_entity_marker": [126, 129], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "desmin", "entity_2_idx": [[175, 181]], "entity_2_idx_in_text_with_entity_marker": [188, 194], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p10", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 ([E1]Cx43[/E1]), desmin and alpha-smooth muscle actin ([E2]alpha-SMA[/E2]), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Cx43", "entity_1_idx": [[168, 172]], "entity_1_idx_in_text_with_entity_marker": [172, 176], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-SMA", "entity_2_idx": [[213, 222]], "entity_2_idx_in_text_with_entity_marker": [226, 235], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p11", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, [E1]connexin 43[/E1] (Cx43), desmin and alpha-smooth muscle actin ([E2]alpha-SMA[/E2]), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "connexin 43", "entity_1_idx": [[155, 166]], "entity_1_idx_in_text_with_entity_marker": [159, 170], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-SMA", "entity_2_idx": [[213, 222]], "entity_2_idx_in_text_with_entity_marker": [226, 235], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p12", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain ([E1]MHC[/E1]), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin ([E2]alpha-SMA[/E2]), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MHC", "entity_1_idx": [[96, 99]], "entity_1_idx_in_text_with_entity_marker": [100, 103], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-SMA", "entity_2_idx": [[213, 222]], "entity_2_idx_in_text_with_entity_marker": [226, 235], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p13", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and [E1]alpha-smooth muscle actin[/E1] ([E2]alpha-SMA[/E2]), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "alpha-smooth muscle actin", "entity_1_idx": [[186, 211]], "entity_1_idx_in_text_with_entity_marker": [190, 215], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-SMA", "entity_2_idx": [[213, 222]], "entity_2_idx_in_text_with_entity_marker": [226, 235], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p14", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I ([E1]TnI[/E1]) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin ([E2]alpha-SMA[/E2]), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TnI", "entity_1_idx": [[140, 143]], "entity_1_idx_in_text_with_entity_marker": [144, 147], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-SMA", "entity_2_idx": [[213, 222]], "entity_2_idx_in_text_with_entity_marker": [226, 235], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p15", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of [E1]myosin heavy chain[/E1] (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin ([E2]alpha-SMA[/E2]), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin heavy chain", "entity_1_idx": [[76, 94]], "entity_1_idx_in_text_with_entity_marker": [80, 98], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-SMA", "entity_2_idx": [[213, 222]], "entity_2_idx_in_text_with_entity_marker": [226, 235], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p16", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), [E1]troponin I[/E1] (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin ([E2]alpha-SMA[/E2]), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "troponin I", "entity_1_idx": [[128, 138]], "entity_1_idx_in_text_with_entity_marker": [132, 142], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-SMA", "entity_2_idx": [[213, 222]], "entity_2_idx_in_text_with_entity_marker": [226, 235], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p17", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), [E1]myosin light chain[/E1] (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin ([E2]alpha-SMA[/E2]), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin light chain", "entity_1_idx": [[102, 120]], "entity_1_idx_in_text_with_entity_marker": [106, 124], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "alpha-SMA", "entity_2_idx": [[213, 222]], "entity_2_idx_in_text_with_entity_marker": [226, 235], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p18", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), [E1]desmin[/E1] and alpha-smooth muscle actin ([E2]alpha-SMA[/E2]), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "desmin", "entity_1_idx": [[175, 181]], "entity_1_idx_in_text_with_entity_marker": [179, 185], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "alpha-SMA", "entity_2_idx": [[213, 222]], "entity_2_idx_in_text_with_entity_marker": [226, 235], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d423.s0_BioInfer.d423.s0.p19", "text": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, connexin 43 (Cx43), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "text_with_entity_marker": "METHODS: We have performed a detailed study of the pattern of expression of myosin heavy chain (MHC), myosin light chain (MLC), troponin I (TnI) isoforms, [E1]connexin 43[/E1] ([E2]Cx43[/E2]), desmin and alpha-smooth muscle actin (alpha-SMA), in the ventricular conduction system of normal and congenitally malformed mouse hearts (iv background) from embryonic day 14.5 to 19.5.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "connexin 43", "entity_1_idx": [[155, 166]], "entity_1_idx_in_text_with_entity_marker": [159, 170], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "Cx43", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d138.s0_BioInfer.d138.s0.p0", "text": "Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.", "text_with_entity_marker": "Characterization of [E1]MLH1[/E1] and [E2]MSH2[/E2] DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MLH1", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MSH2", "entity_2_idx": [[29, 33]], "entity_2_idx_in_text_with_entity_marker": [42, 46], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d445.s0_BioInfer.d445.s0.p0", "text": "Mutations in RAD27 cause increased rates of mitotic crossing over and are lethal in combination with mutations in RAD51 and RAD52.", "text_with_entity_marker": "Mutations in [E1]RAD27[/E1] cause increased rates of mitotic crossing over and are lethal in combination with mutations in [E2]RAD51[/E2] and RAD52.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD27", "entity_1_idx": [[13, 18]], "entity_1_idx_in_text_with_entity_marker": [17, 22], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD51", "entity_2_idx": [[114, 119]], "entity_2_idx_in_text_with_entity_marker": [127, 132], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d445.s0_BioInfer.d445.s0.p1", "text": "Mutations in RAD27 cause increased rates of mitotic crossing over and are lethal in combination with mutations in RAD51 and RAD52.", "text_with_entity_marker": "Mutations in RAD27 cause increased rates of mitotic crossing over and are lethal in combination with mutations in [E1]RAD51[/E1] and [E2]RAD52[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD51", "entity_1_idx": [[114, 119]], "entity_1_idx_in_text_with_entity_marker": [118, 123], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD52", "entity_2_idx": [[124, 129]], "entity_2_idx_in_text_with_entity_marker": [137, 142], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d445.s0_BioInfer.d445.s0.p2", "text": "Mutations in RAD27 cause increased rates of mitotic crossing over and are lethal in combination with mutations in RAD51 and RAD52.", "text_with_entity_marker": "Mutations in [E1]RAD27[/E1] cause increased rates of mitotic crossing over and are lethal in combination with mutations in RAD51 and [E2]RAD52[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD27", "entity_1_idx": [[13, 18]], "entity_1_idx_in_text_with_entity_marker": [17, 22], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD52", "entity_2_idx": [[124, 129]], "entity_2_idx_in_text_with_entity_marker": [137, 142], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p70", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), [E1]phosphoprotein[/E1] (P) and matrix (M) proteins of MV and the H, F, NP and [E2]P proteins[/E2] of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[96, 110], [130, 138]], "entity_1_idx_in_text_with_entity_marker": [100, 114], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P proteins", "entity_2_idx": [[166, 176]], "entity_2_idx_in_text_with_entity_marker": [179, 189], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p71", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, [E1]F[/E1], NP and [E2]P proteins[/E2] of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F", "entity_1_idx": [[156, 157], [168, 176]], "entity_1_idx_in_text_with_entity_marker": [160, 161], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "P proteins", "entity_2_idx": [[166, 176]], "entity_2_idx_in_text_with_entity_marker": [179, 189], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p72", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin ([E1]H[/E1]), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and [E2]P proteins[/E2] of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "H", "entity_1_idx": [[53, 54]], "entity_1_idx_in_text_with_entity_marker": [57, 58], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P proteins", "entity_2_idx": [[166, 176]], "entity_2_idx_in_text_with_entity_marker": [179, 189], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p73", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein ([E1]P[/E1]) and matrix (M) proteins of MV and the H, F, NP and [E2]P proteins[/E2] of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[112, 113]], "entity_1_idx_in_text_with_entity_marker": [116, 117], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P proteins", "entity_2_idx": [[166, 176]], "entity_2_idx_in_text_with_entity_marker": [179, 189], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p74", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein ([E1]NP[/E1]), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and [E2]P proteins[/E2] of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NP", "entity_1_idx": [[91, 93]], "entity_1_idx_in_text_with_entity_marker": [95, 97], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P proteins", "entity_2_idx": [[166, 176]], "entity_2_idx_in_text_with_entity_marker": [179, 189], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p75", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix ([E1]M[/E1]) proteins of MV and the H, F, NP and [E2]P proteins[/E2] of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[127, 128]], "entity_1_idx_in_text_with_entity_marker": [131, 132], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P proteins", "entity_2_idx": [[166, 176]], "entity_2_idx_in_text_with_entity_marker": [179, 189], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p76", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), [E1]phosphoprotein[/E1] (P) and matrix (M) proteins of MV and the H, [E2]F[/E2], NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[96, 110], [130, 138]], "entity_1_idx_in_text_with_entity_marker": [100, 114], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F", "entity_2_idx": [[156, 157], [168, 176]], "entity_2_idx_in_text_with_entity_marker": [169, 170], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p77", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin ([E1]H[/E1]), fusion (F), nucleocapsid protein (NP), [E2]phosphoprotein[/E2] (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "H", "entity_1_idx": [[53, 54]], "entity_1_idx_in_text_with_entity_marker": [57, 58], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "phosphoprotein", "entity_2_idx": [[96, 110], [130, 138]], "entity_2_idx_in_text_with_entity_marker": [109, 123], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p78", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), [E1]phosphoprotein[/E1] ([E2]P[/E2]) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[96, 110], [130, 138]], "entity_1_idx_in_text_with_entity_marker": [100, 114], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P", "entity_2_idx": [[112, 113]], "entity_2_idx_in_text_with_entity_marker": [125, 126], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d480.s0_BioInfer.d480.s0.p79", "text": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein (NP), phosphoprotein (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "text_with_entity_marker": "Panels of six to 31 MAbs against the haemagglutinin (H), fusion (F), nucleocapsid protein ([E1]NP[/E1]), [E2]phosphoprotein[/E2] (P) and matrix (M) proteins of MV and the H, F, NP and P proteins of CDV were employed.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NP", "entity_1_idx": [[91, 93]], "entity_1_idx_in_text_with_entity_marker": [95, 97], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "phosphoprotein", "entity_2_idx": [[96, 110], [130, 138]], "entity_2_idx_in_text_with_entity_marker": [109, 123], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d58.s0_BioInfer.d58.s0.p0", "text": "Analysis of the u.v. absorbance and far-u.v. circular dichroism spectra of profilin and actin did not reveal any major changes in the conformation of the proteins accompanying the modifications at the C-terminal ends.", "text_with_entity_marker": "Analysis of the u.v. absorbance and far-u.v. circular dichroism spectra of [E1]profilin[/E1] and [E2]actin[/E2] did not reveal any major changes in the conformation of the proteins accompanying the modifications at the C-terminal ends.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "profilin", "entity_1_idx": [[75, 83]], "entity_1_idx_in_text_with_entity_marker": [79, 87], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[88, 93]], "entity_2_idx_in_text_with_entity_marker": [101, 106], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d404.s0_BioInfer.d404.s0.p0", "text": "Like the spectrin alpha-chain, the major central part of the spectrin beta-chain is made up of repeat units of 106 amino-acids.", "text_with_entity_marker": "Like the [E1]spectrin alpha-chain[/E1], the major central part of the [E2]spectrin beta-chain[/E2] is made up of repeat units of 106 amino-acids.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "spectrin alpha-chain", "entity_1_idx": [[9, 29]], "entity_1_idx_in_text_with_entity_marker": [13, 33], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "spectrin beta-chain", "entity_2_idx": [[61, 80]], "entity_2_idx_in_text_with_entity_marker": [74, 93], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s0_BioInfer.d148.s0.p0", "text": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and caspase-8, and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "text_with_entity_marker": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, [E1]TRAIL[/E1], TRADD, RIP, and [E2]caspase-8[/E2], and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRAIL", "entity_1_idx": [[219, 224]], "entity_1_idx_in_text_with_entity_marker": [223, 228], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "caspase-8", "entity_2_idx": [[242, 251]], "entity_2_idx_in_text_with_entity_marker": [255, 264], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s0_BioInfer.d148.s0.p1", "text": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and caspase-8, and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "text_with_entity_marker": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and [E1]caspase-8[/E1], and an up to twofold increase for FADD and [E2]FAP[/E2], but there was little change for FAF.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "caspase-8", "entity_1_idx": [[242, 251]], "entity_1_idx_in_text_with_entity_marker": [246, 255], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FAP", "entity_2_idx": [[296, 299]], "entity_2_idx_in_text_with_entity_marker": [309, 312], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s0_BioInfer.d148.s0.p2", "text": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and caspase-8, and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "text_with_entity_marker": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, [E1]RIP[/E1], and [E2]caspase-8[/E2], and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RIP", "entity_1_idx": [[233, 236]], "entity_1_idx_in_text_with_entity_marker": [237, 240], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "caspase-8", "entity_2_idx": [[242, 251]], "entity_2_idx_in_text_with_entity_marker": [255, 264], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s0_BioInfer.d148.s0.p3", "text": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and caspase-8, and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "text_with_entity_marker": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, [E1]TNF-R1[/E1], TRAIL, TRADD, RIP, and [E2]caspase-8[/E2], and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TNF-R1", "entity_1_idx": [[211, 217]], "entity_1_idx_in_text_with_entity_marker": [215, 221], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "caspase-8", "entity_2_idx": [[242, 251]], "entity_2_idx_in_text_with_entity_marker": [255, 264], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s0_BioInfer.d148.s0.p4", "text": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and caspase-8, and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "text_with_entity_marker": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for [E1]Fas[/E1], Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and [E2]caspase-8[/E2], and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas", "entity_1_idx": [[194, 197]], "entity_1_idx_in_text_with_entity_marker": [198, 201], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "caspase-8", "entity_2_idx": [[242, 251]], "entity_2_idx_in_text_with_entity_marker": [255, 264], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s0_BioInfer.d148.s0.p5", "text": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and caspase-8, and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "text_with_entity_marker": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, [E1]TRADD[/E1], RIP, and [E2]caspase-8[/E2], and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRADD", "entity_1_idx": [[226, 231]], "entity_1_idx_in_text_with_entity_marker": [230, 235], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "caspase-8", "entity_2_idx": [[242, 251]], "entity_2_idx_in_text_with_entity_marker": [255, 264], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s0_BioInfer.d148.s0.p6", "text": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and caspase-8, and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "text_with_entity_marker": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, [E1]Fas ligand[/E1], TNF-R1, TRAIL, TRADD, RIP, and [E2]caspase-8[/E2], and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Fas ligand", "entity_1_idx": [[199, 209]], "entity_1_idx_in_text_with_entity_marker": [203, 213], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "caspase-8", "entity_2_idx": [[242, 251]], "entity_2_idx_in_text_with_entity_marker": [255, 264], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s0_BioInfer.d148.s0.p7", "text": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and caspase-8, and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "text_with_entity_marker": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and [E1]caspase-8[/E1], and an up to twofold increase for FADD and FAP, but there was little change for [E2]FAF[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "caspase-8", "entity_1_idx": [[242, 251]], "entity_1_idx_in_text_with_entity_marker": [246, 255], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FAF", "entity_2_idx": [[333, 336]], "entity_2_idx_in_text_with_entity_marker": [346, 349], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s0_BioInfer.d148.s0.p8", "text": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and caspase-8, and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "text_with_entity_marker": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and [E1]caspase-8[/E1], and an up to twofold increase for [E2]FADD[/E2] and FAP, but there was little change for FAF.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "caspase-8", "entity_1_idx": [[242, 251]], "entity_1_idx_in_text_with_entity_marker": [246, 255], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FADD", "entity_2_idx": [[287, 291]], "entity_2_idx_in_text_with_entity_marker": [300, 304], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d148.s0_BioInfer.d148.s0.p9", "text": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, TRAIL, TRADD, RIP, and caspase-8, and an up to twofold increase for FADD and FAP, but there was little change for FAF.", "text_with_entity_marker": "Compared with control and contralateral kidneys, the ligated kidneys displayed a dynamic expression of mRNAs for many apoptosis-related molecules, which included an up to threefold increase for Fas, Fas ligand, TNF-R1, [E1]TRAIL[/E1], TRADD, RIP, and caspase-8, and an up to twofold increase for FADD and [E2]FAP[/E2], but there was little change for FAF.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TRAIL", "entity_1_idx": [[219, 224]], "entity_1_idx_in_text_with_entity_marker": [223, 228], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "FAP", "entity_2_idx": [[296, 299]], "entity_2_idx_in_text_with_entity_marker": [309, 312], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d730.s0_BioInfer.d730.s0.p40", "text": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on fibronectin, whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "text_with_entity_marker": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to [E1]laminin[/E1], but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble [E2]vinculin[/E2] or paxillin-containing focal adhesions or actin stress fibers on fibronectin, whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "laminin", "entity_1_idx": [[185, 192]], "entity_1_idx_in_text_with_entity_marker": [189, 196], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "vinculin", "entity_2_idx": [[453, 461]], "entity_2_idx_in_text_with_entity_marker": [466, 474], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d730.s0_BioInfer.d730.s0.p41", "text": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on fibronectin, whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "text_with_entity_marker": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a [E1]vinculin[/E1] (-/-) ES cell mutant (e) were unable to assemble [E2]vinculin[/E2] or paxillin-containing focal adhesions or actin stress fibers on fibronectin, whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "vinculin", "entity_1_idx": [[395, 403]], "entity_1_idx_in_text_with_entity_marker": [399, 407], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "vinculin", "entity_2_idx": [[453, 461]], "entity_2_idx_in_text_with_entity_marker": [466, 474], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d730.s0_BioInfer.d730.s0.p42", "text": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on fibronectin, whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "text_with_entity_marker": "The undifferentiated cells (a) were unable to spread on gelatin or [E1]laminin[/E1] and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on [E2]fibronectin[/E2], whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "laminin", "entity_1_idx": [[67, 74]], "entity_1_idx_in_text_with_entity_marker": [71, 78], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "fibronectin", "entity_2_idx": [[527, 538]], "entity_2_idx_in_text_with_entity_marker": [540, 551], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d730.s0_BioInfer.d730.s0.p43", "text": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on fibronectin, whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "text_with_entity_marker": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not [E1]fibronectin[/E1] (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on [E2]fibronectin[/E2], whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fibronectin", "entity_1_idx": [[202, 213]], "entity_1_idx_in_text_with_entity_marker": [206, 217], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "fibronectin", "entity_2_idx": [[527, 538]], "entity_2_idx_in_text_with_entity_marker": [540, 551], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d730.s0_BioInfer.d730.s0.p44", "text": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on fibronectin, whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "text_with_entity_marker": "The undifferentiated cells (a) were unable to spread on [E1]gelatin[/E1] or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on [E2]fibronectin[/E2], whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "gelatin", "entity_1_idx": [[56, 63]], "entity_1_idx_in_text_with_entity_marker": [60, 67], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "fibronectin", "entity_2_idx": [[527, 538]], "entity_2_idx_in_text_with_entity_marker": [540, 551], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d730.s0_BioInfer.d730.s0.p45", "text": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on fibronectin, whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "text_with_entity_marker": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on [E1]fibronectin[/E1] (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on [E2]fibronectin[/E2], whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fibronectin", "entity_1_idx": [[142, 153]], "entity_1_idx_in_text_with_entity_marker": [146, 157], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "fibronectin", "entity_2_idx": [[527, 538]], "entity_2_idx_in_text_with_entity_marker": [540, 551], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d730.s0_BioInfer.d730.s0.p46", "text": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on fibronectin, whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "text_with_entity_marker": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of [E1]beta1 integrin[/E1], although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on [E2]fibronectin[/E2], whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta1 integrin", "entity_1_idx": [[251, 265]], "entity_1_idx_in_text_with_entity_marker": [255, 269], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "fibronectin", "entity_2_idx": [[527, 538]], "entity_2_idx_in_text_with_entity_marker": [540, 551], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d730.s0_BioInfer.d730.s0.p47", "text": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on fibronectin, whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "text_with_entity_marker": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or [E1]paxillin[/E1]-containing focal adhesions or actin stress fibers on [E2]fibronectin[/E2], whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "paxillin", "entity_1_idx": [[465, 473]], "entity_1_idx_in_text_with_entity_marker": [469, 477], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "fibronectin", "entity_2_idx": [[527, 538]], "entity_2_idx_in_text_with_entity_marker": [540, 551], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d730.s0_BioInfer.d730.s0.p48", "text": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on fibronectin, whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "text_with_entity_marker": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to [E1]laminin[/E1], but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on [E2]fibronectin[/E2], whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "laminin", "entity_1_idx": [[185, 192]], "entity_1_idx_in_text_with_entity_marker": [189, 196], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "fibronectin", "entity_2_idx": [[527, 538]], "entity_2_idx_in_text_with_entity_marker": [540, 551], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d730.s0_BioInfer.d730.s0.p49", "text": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a vinculin (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on fibronectin, whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "text_with_entity_marker": "The undifferentiated cells (a) were unable to spread on gelatin or laminin and grew as rounded colonies, although they were able to spread on fibronectin (b) showed reduced adhesion to laminin, but not fibronectin (c) expressed much reduced levels of beta1 integrin, although levels of alpha5 and alphaV were wild-type (d) were less polarized with increased membrane protrusions compared with a [E1]vinculin[/E1] (-/-) ES cell mutant (e) were unable to assemble vinculin or paxillin-containing focal adhesions or actin stress fibers on [E2]fibronectin[/E2], whereas vinculin (-/-) ES cells were able to assemble talin-containing focal adhesions.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "vinculin", "entity_1_idx": [[395, 403]], "entity_1_idx_in_text_with_entity_marker": [399, 407], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "fibronectin", "entity_2_idx": [[527, 538]], "entity_2_idx_in_text_with_entity_marker": [540, 551], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d316.s0_BioInfer.d316.s0.p0", "text": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, MyoD and myogenin.", "text_with_entity_marker": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, [E1]MyoD[/E1] and [E2]myogenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MyoD", "entity_1_idx": [[181, 185]], "entity_1_idx_in_text_with_entity_marker": [185, 189], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myogenin", "entity_2_idx": [[190, 198]], "entity_2_idx_in_text_with_entity_marker": [203, 211], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d316.s0_BioInfer.d316.s0.p1", "text": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, MyoD and myogenin.", "text_with_entity_marker": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, [E1]sarcomeric actin[/E1], Myf-5, [E2]MyoD[/E2] and myogenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "sarcomeric actin", "entity_1_idx": [[156, 172]], "entity_1_idx_in_text_with_entity_marker": [160, 176], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d316.s0_BioInfer.d316.s0.p2", "text": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, MyoD and myogenin.", "text_with_entity_marker": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, [E1]Myf-5[/E1], [E2]MyoD[/E2] and myogenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Myf-5", "entity_1_idx": [[174, 179]], "entity_1_idx_in_text_with_entity_marker": [178, 183], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d316.s0_BioInfer.d316.s0.p3", "text": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, MyoD and myogenin.", "text_with_entity_marker": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, [E1]nestin[/E1], myosin heavy chain, sarcomeric actin, Myf-5, [E2]MyoD[/E2] and myogenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nestin", "entity_1_idx": [[128, 134]], "entity_1_idx_in_text_with_entity_marker": [132, 138], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d316.s0_BioInfer.d316.s0.p4", "text": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, MyoD and myogenin.", "text_with_entity_marker": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, [E1]myosin heavy chain[/E1], sarcomeric actin, Myf-5, [E2]MyoD[/E2] and myogenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin heavy chain", "entity_1_idx": [[136, 154]], "entity_1_idx_in_text_with_entity_marker": [140, 158], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d316.s0_BioInfer.d316.s0.p5", "text": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, MyoD and myogenin.", "text_with_entity_marker": "In addition, we performed immunohistochemistry on sectioned Myf-5 and [E1]MyoD[/E1] mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, [E2]MyoD[/E2] and myogenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "MyoD", "entity_1_idx": [[70, 74]], "entity_1_idx_in_text_with_entity_marker": [74, 78], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d316.s0_BioInfer.d316.s0.p6", "text": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, MyoD and myogenin.", "text_with_entity_marker": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with [E1]desmin[/E1], nestin, myosin heavy chain, sarcomeric actin, Myf-5, [E2]MyoD[/E2] and myogenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "desmin", "entity_1_idx": [[120, 126]], "entity_1_idx_in_text_with_entity_marker": [124, 130], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d316.s0_BioInfer.d316.s0.p7", "text": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, MyoD and myogenin.", "text_with_entity_marker": "In addition, we performed immunohistochemistry on sectioned [E1]Myf-5[/E1] and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, [E2]MyoD[/E2] and myogenin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Myf-5", "entity_1_idx": [[60, 65]], "entity_1_idx_in_text_with_entity_marker": [64, 69], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "MyoD", "entity_2_idx": [[181, 185]], "entity_2_idx_in_text_with_entity_marker": [194, 198], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d316.s0_BioInfer.d316.s0.p8", "text": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, MyoD and myogenin.", "text_with_entity_marker": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, [E1]sarcomeric actin[/E1], Myf-5, MyoD and [E2]myogenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "sarcomeric actin", "entity_1_idx": [[156, 172]], "entity_1_idx_in_text_with_entity_marker": [160, 176], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myogenin", "entity_2_idx": [[190, 198]], "entity_2_idx_in_text_with_entity_marker": [203, 211], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d316.s0_BioInfer.d316.s0.p9", "text": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, Myf-5, MyoD and myogenin.", "text_with_entity_marker": "In addition, we performed immunohistochemistry on sectioned Myf-5 and MyoD mutant embryos with antibodies reactive with desmin, nestin, myosin heavy chain, sarcomeric actin, [E1]Myf-5[/E1], MyoD and [E2]myogenin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Myf-5", "entity_1_idx": [[174, 179]], "entity_1_idx_in_text_with_entity_marker": [178, 183], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myogenin", "entity_2_idx": [[190, 198]], "entity_2_idx_in_text_with_entity_marker": [203, 211], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d733.s0_BioInfer.d733.s0.p0", "text": "They exhibited strong synergistic increases in CAN1 duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes RAD50, RAD51, and RAD52 for viability.", "text_with_entity_marker": "They exhibited strong synergistic increases in CAN1 duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes [E1]RAD50[/E1], RAD51, and [E2]RAD52[/E2] for viability.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD50", "entity_1_idx": [[188, 193]], "entity_1_idx_in_text_with_entity_marker": [192, 197], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD52", "entity_2_idx": [[206, 211]], "entity_2_idx_in_text_with_entity_marker": [219, 224], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d733.s0_BioInfer.d733.s0.p1", "text": "They exhibited strong synergistic increases in CAN1 duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes RAD50, RAD51, and RAD52 for viability.", "text_with_entity_marker": "They exhibited strong synergistic increases in CAN1 duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes RAD50, [E1]RAD51[/E1], and [E2]RAD52[/E2] for viability.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD51", "entity_1_idx": [[195, 200]], "entity_1_idx_in_text_with_entity_marker": [199, 204], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD52", "entity_2_idx": [[206, 211]], "entity_2_idx_in_text_with_entity_marker": [219, 224], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d733.s0_BioInfer.d733.s0.p2", "text": "They exhibited strong synergistic increases in CAN1 duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes RAD50, RAD51, and RAD52 for viability.", "text_with_entity_marker": "They exhibited strong synergistic increases in [E1]CAN1[/E1] duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes RAD50, RAD51, and [E2]RAD52[/E2] for viability.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "CAN1", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD52", "entity_2_idx": [[206, 211]], "entity_2_idx_in_text_with_entity_marker": [219, 224], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d733.s0_BioInfer.d733.s0.p3", "text": "They exhibited strong synergistic increases in CAN1 duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes RAD50, RAD51, and RAD52 for viability.", "text_with_entity_marker": "They exhibited strong synergistic increases in CAN1 duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes [E1]RAD50[/E1], [E2]RAD51[/E2], and RAD52 for viability.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "RAD50", "entity_1_idx": [[188, 193]], "entity_1_idx_in_text_with_entity_marker": [192, 197], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD51", "entity_2_idx": [[195, 200]], "entity_2_idx_in_text_with_entity_marker": [208, 213], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d733.s0_BioInfer.d733.s0.p4", "text": "They exhibited strong synergistic increases in CAN1 duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes RAD50, RAD51, and RAD52 for viability.", "text_with_entity_marker": "They exhibited strong synergistic increases in [E1]CAN1[/E1] duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes [E2]RAD50[/E2], RAD51, and RAD52 for viability.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "CAN1", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD50", "entity_2_idx": [[188, 193]], "entity_2_idx_in_text_with_entity_marker": [201, 206], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d733.s0_BioInfer.d733.s0.p5", "text": "They exhibited strong synergistic increases in CAN1 duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes RAD50, RAD51, and RAD52 for viability.", "text_with_entity_marker": "They exhibited strong synergistic increases in [E1]CAN1[/E1] duplication mutations, intrachromosomal and interchromosomal recombination, and required the wild-type double-strand break repair genes RAD50, [E2]RAD51[/E2], and RAD52 for viability.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "CAN1", "entity_1_idx": [[47, 51]], "entity_1_idx_in_text_with_entity_marker": [51, 55], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "RAD51", "entity_2_idx": [[195, 200]], "entity_2_idx_in_text_with_entity_marker": [208, 213], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p0", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, [E1]P[/E1]: 1751-2190, M: 3571-4057, [E2]F[/E2]: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[259, 260]], "entity_1_idx_in_text_with_entity_marker": [263, 264], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "F", "entity_2_idx": [[287, 288]], "entity_2_idx_in_text_with_entity_marker": [300, 301], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p1", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, [E1]F[/E1]: 6621-7210, [E2]L[/E2]: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F", "entity_1_idx": [[287, 288]], "entity_1_idx_in_text_with_entity_marker": [291, 292], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "L", "entity_2_idx": [[301, 302]], "entity_2_idx_in_text_with_entity_marker": [314, 315], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p2", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein ([E1]L[/E1]) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, [E2]F[/E2]: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "L", "entity_1_idx": [[109, 110]], "entity_1_idx_in_text_with_entity_marker": [113, 114], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "F", "entity_2_idx": [[287, 288]], "entity_2_idx_in_text_with_entity_marker": [300, 301], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p3", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, [E1]M[/E1]: 3571-4057, [E2]F[/E2]: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[273, 274]], "entity_1_idx_in_text_with_entity_marker": [277, 278], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "F", "entity_2_idx": [[287, 288]], "entity_2_idx_in_text_with_entity_marker": [300, 301], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p4", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), [E1]fusion[/E1] (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, [E2]F[/E2]: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fusion", "entity_1_idx": [[78, 84], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [82, 88], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "F", "entity_2_idx": [[287, 288]], "entity_2_idx_in_text_with_entity_marker": [300, 301], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p5", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein ([E1]P[/E1]), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, [E2]F[/E2]: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[62, 63]], "entity_1_idx_in_text_with_entity_marker": [66, 67], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "F", "entity_2_idx": [[287, 288]], "entity_2_idx_in_text_with_entity_marker": [300, 301], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p6", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid ([E1]N[/E1]), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, [E2]F[/E2]: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[42, 43]], "entity_1_idx_in_text_with_entity_marker": [46, 47], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "F", "entity_2_idx": [[287, 288]], "entity_2_idx_in_text_with_entity_marker": [300, 301], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p7", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion ([E1]F[/E1]), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, [E2]F[/E2]: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F", "entity_1_idx": [[86, 87]], "entity_1_idx_in_text_with_entity_marker": [90, 91], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "F", "entity_2_idx": [[287, 288]], "entity_2_idx_in_text_with_entity_marker": [300, 301], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p8", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of [E1]nucleocapsid[/E1] (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, [E2]F[/E2]: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nucleocapsid", "entity_1_idx": [[28, 40], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [32, 44], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "F", "entity_2_idx": [[287, 288]], "entity_2_idx_in_text_with_entity_marker": [300, 301], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p9", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), [E1]matrix[/E1] (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, [E2]F[/E2]: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "matrix", "entity_1_idx": [[66, 72], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [70, 76], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "F", "entity_2_idx": [[287, 288]], "entity_2_idx_in_text_with_entity_marker": [300, 301], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p60", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein ([E1]P[/E1]), matrix (M), [E2]fusion[/E2] (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[62, 63]], "entity_1_idx_in_text_with_entity_marker": [66, 67], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "fusion", "entity_2_idx": [[78, 84], [100, 107]], "entity_2_idx_in_text_with_entity_marker": [91, 97], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p61", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid ([E1]N[/E1]), phosphoprotein (P), matrix (M), [E2]fusion[/E2] (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[42, 43]], "entity_1_idx_in_text_with_entity_marker": [46, 47], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "fusion", "entity_2_idx": [[78, 84], [100, 107]], "entity_2_idx_in_text_with_entity_marker": [91, 97], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p62", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), [E1]fusion[/E1] ([E2]F[/E2]), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fusion", "entity_1_idx": [[78, 84], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [82, 88], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "F", "entity_2_idx": [[86, 87]], "entity_2_idx_in_text_with_entity_marker": [99, 100], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p63", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of [E1]nucleocapsid[/E1] (N), phosphoprotein (P), matrix (M), [E2]fusion[/E2] (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nucleocapsid", "entity_1_idx": [[28, 40], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [32, 44], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "fusion", "entity_2_idx": [[78, 84], [100, 107]], "entity_2_idx_in_text_with_entity_marker": [91, 97], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p64", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), [E1]matrix[/E1] (M), [E2]fusion[/E2] (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "matrix", "entity_1_idx": [[66, 72], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [70, 76], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "fusion", "entity_2_idx": [[78, 84], [100, 107]], "entity_2_idx_in_text_with_entity_marker": [91, 97], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p65", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), [E1]phosphoprotein[/E1] (P), matrix (M), [E2]fusion[/E2] (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[46, 60], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [50, 64], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "fusion", "entity_2_idx": [[78, 84], [100, 107]], "entity_2_idx_in_text_with_entity_marker": [91, 97], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p66", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), [E1]fusion[/E1] (F), and [E2]large protein[/E2] (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fusion", "entity_1_idx": [[78, 84], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [82, 88], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "large protein", "entity_2_idx": [[94, 107]], "entity_2_idx_in_text_with_entity_marker": [107, 120], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p67", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix ([E1]M[/E1]), [E2]fusion[/E2] (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "M", "entity_1_idx": [[74, 75]], "entity_1_idx_in_text_with_entity_marker": [78, 79], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "fusion", "entity_2_idx": [[78, 84], [100, 107]], "entity_2_idx_in_text_with_entity_marker": [91, 97], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p68", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), [E1]fusion[/E1] (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position [E2]N[/E2]: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "fusion", "entity_1_idx": [[78, 84], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [82, 88], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "N", "entity_2_idx": [[245, 246]], "entity_2_idx_in_text_with_entity_marker": [258, 259], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p69", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid ([E1]N[/E1]), phosphoprotein ([E2]P[/E2]), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[42, 43]], "entity_1_idx_in_text_with_entity_marker": [46, 47], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "P", "entity_2_idx": [[62, 63]], "entity_2_idx_in_text_with_entity_marker": [75, 76], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p70", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein ([E1]P[/E1]), matrix (M), fusion ([E2]F[/E2]), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[62, 63]], "entity_1_idx_in_text_with_entity_marker": [66, 67], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "F", "entity_2_idx": [[86, 87]], "entity_2_idx_in_text_with_entity_marker": [99, 100], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p71", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of [E1]nucleocapsid[/E1] (N), phosphoprotein ([E2]P[/E2]), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nucleocapsid", "entity_1_idx": [[28, 40], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [32, 44], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "P", "entity_2_idx": [[62, 63]], "entity_2_idx_in_text_with_entity_marker": [75, 76], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p72", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein ([E1]P[/E1]), [E2]matrix[/E2] (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[62, 63]], "entity_1_idx_in_text_with_entity_marker": [66, 67], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "matrix", "entity_2_idx": [[66, 72], [100, 107]], "entity_2_idx_in_text_with_entity_marker": [79, 85], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p73", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), [E1]phosphoprotein[/E1] ([E2]P[/E2]), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[46, 60], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [50, 64], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "P", "entity_2_idx": [[62, 63]], "entity_2_idx_in_text_with_entity_marker": [75, 76], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p74", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein ([E1]P[/E1]), matrix (M), fusion (F), and [E2]large protein[/E2] (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[62, 63]], "entity_1_idx_in_text_with_entity_marker": [66, 67], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "large protein", "entity_2_idx": [[94, 107]], "entity_2_idx_in_text_with_entity_marker": [107, 120], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p75", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein ([E1]P[/E1]), matrix ([E2]M[/E2]), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[62, 63]], "entity_1_idx_in_text_with_entity_marker": [66, 67], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "M", "entity_2_idx": [[74, 75]], "entity_2_idx_in_text_with_entity_marker": [87, 88], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p76", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid (N), phosphoprotein ([E1]P[/E1]), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position [E2]N[/E2]: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[62, 63]], "entity_1_idx_in_text_with_entity_marker": [66, 67], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "N", "entity_2_idx": [[245, 246]], "entity_2_idx_in_text_with_entity_marker": [258, 259], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p77", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid ([E1]N[/E1]), phosphoprotein (P), matrix (M), fusion ([E2]F[/E2]), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[42, 43]], "entity_1_idx_in_text_with_entity_marker": [46, 47], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "F", "entity_2_idx": [[86, 87]], "entity_2_idx_in_text_with_entity_marker": [99, 100], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p78", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of [E1]nucleocapsid[/E1] ([E2]N[/E2]), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nucleocapsid", "entity_1_idx": [[28, 40], [100, 107]], "entity_1_idx_in_text_with_entity_marker": [32, 44], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "N", "entity_2_idx": [[42, 43]], "entity_2_idx_in_text_with_entity_marker": [55, 56], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d653.s0_BioInfer.d653.s0.p79", "text": "The nucleotide sequences of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "text_with_entity_marker": "The nucleotide sequences of nucleocapsid ([E1]N[/E1]), phosphoprotein (P), [E2]matrix[/E2] (M), fusion (F), and large protein (L) genes were partly determined for 19 wild strains of measles virus (MV) isolated over the past 10 years in Japan (nucleotide position N: 1301-1700, P: 1751-2190, M: 3571-4057, F: 6621-7210, L: 10381-11133) and also for a MV strain obtained from a patient with subacute sclerosing panencephalitis (SSPE) who had natural measles in 1980.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[42, 43]], "entity_1_idx_in_text_with_entity_marker": [46, 47], "entity_1_type": "Gene", "entity_1_type_id": 3, "entity_2": "matrix", "entity_2_idx": [[66, 72], [100, 107]], "entity_2_idx_in_text_with_entity_marker": [79, 85], "entity_2_type": "Gene", "entity_2_type_id": 3}], "directed": false, "reverse": false}
{"id": "BioInfer.d490.s0_BioInfer.d490.s0.p0", "text": "Polyacrylamide gels of platelets heated at 45 degrees C for 90 minutes showed an increase in talin incorporation into heated platelet cytoskeletons but no increase in filamentous actin.", "text_with_entity_marker": "Polyacrylamide gels of platelets heated at 45 degrees C for 90 minutes showed an increase in [E1]talin[/E1] incorporation into heated platelet cytoskeletons but no increase in filamentous [E2]actin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "talin", "entity_1_idx": [[93, 98]], "entity_1_idx_in_text_with_entity_marker": [97, 102], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[179, 184]], "entity_2_idx_in_text_with_entity_marker": [192, 197], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d821.s0_BioInfer.d821.s0.p10", "text": "We show that the HSV-1 UL5, UL8, UL29, UL30, UL42, and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "text_with_entity_marker": "We show that the HSV-1 UL5, UL8, [E1]UL29[/E1], UL30, [E2]UL42[/E2], and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UL29", "entity_1_idx": [[33, 37]], "entity_1_idx_in_text_with_entity_marker": [37, 41], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "UL42", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d821.s0_BioInfer.d821.s0.p11", "text": "We show that the HSV-1 UL5, UL8, UL29, UL30, UL42, and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "text_with_entity_marker": "We show that the HSV-1 [E1]UL5[/E1], [E2]UL8[/E2], UL29, UL30, UL42, and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UL5", "entity_1_idx": [[23, 26]], "entity_1_idx_in_text_with_entity_marker": [27, 30], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "UL8", "entity_2_idx": [[28, 31]], "entity_2_idx_in_text_with_entity_marker": [41, 44], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d821.s0_BioInfer.d821.s0.p12", "text": "We show that the HSV-1 UL5, UL8, UL29, UL30, UL42, and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "text_with_entity_marker": "We show that the HSV-1 UL5, [E1]UL8[/E1], UL29, UL30, UL42, and UL52 gene products along with the AAV [E2]Rep68[/E2] protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UL8", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "Rep68", "entity_2_idx": [[93, 98]], "entity_2_idx_in_text_with_entity_marker": [106, 111], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d821.s0_BioInfer.d821.s0.p13", "text": "We show that the HSV-1 UL5, UL8, UL29, UL30, UL42, and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "text_with_entity_marker": "We show that the HSV-1 UL5, [E1]UL8[/E1], UL29, UL30, UL42, and [E2]UL52[/E2] gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UL8", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "UL52", "entity_2_idx": [[55, 59]], "entity_2_idx_in_text_with_entity_marker": [68, 72], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d821.s0_BioInfer.d821.s0.p14", "text": "We show that the HSV-1 UL5, UL8, UL29, UL30, UL42, and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "text_with_entity_marker": "We show that the HSV-1 UL5, [E1]UL8[/E1], UL29, UL30, [E2]UL42[/E2], and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UL8", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "UL42", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d821.s0_BioInfer.d821.s0.p15", "text": "We show that the HSV-1 UL5, UL8, UL29, UL30, UL42, and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "text_with_entity_marker": "We show that the HSV-1 [E1]UL5[/E1], UL8, UL29, UL30, UL42, and UL52 gene products along with the AAV [E2]Rep68[/E2] protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UL5", "entity_1_idx": [[23, 26]], "entity_1_idx_in_text_with_entity_marker": [27, 30], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "Rep68", "entity_2_idx": [[93, 98]], "entity_2_idx_in_text_with_entity_marker": [106, 111], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d821.s0_BioInfer.d821.s0.p16", "text": "We show that the HSV-1 UL5, UL8, UL29, UL30, UL42, and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "text_with_entity_marker": "We show that the HSV-1 [E1]UL5[/E1], UL8, UL29, UL30, UL42, and [E2]UL52[/E2] gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UL5", "entity_1_idx": [[23, 26]], "entity_1_idx_in_text_with_entity_marker": [27, 30], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "UL52", "entity_2_idx": [[55, 59]], "entity_2_idx_in_text_with_entity_marker": [68, 72], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d821.s0_BioInfer.d821.s0.p17", "text": "We show that the HSV-1 UL5, UL8, UL29, UL30, UL42, and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "text_with_entity_marker": "We show that the HSV-1 [E1]UL5[/E1], UL8, UL29, UL30, [E2]UL42[/E2], and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UL5", "entity_1_idx": [[23, 26]], "entity_1_idx_in_text_with_entity_marker": [27, 30], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "UL42", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d821.s0_BioInfer.d821.s0.p18", "text": "We show that the HSV-1 UL5, UL8, UL29, UL30, UL42, and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "text_with_entity_marker": "We show that the HSV-1 UL5, UL8, UL29, UL30, UL42, and [E1]UL52[/E1] gene products along with the AAV [E2]Rep68[/E2] protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UL52", "entity_1_idx": [[55, 59]], "entity_1_idx_in_text_with_entity_marker": [59, 63], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "Rep68", "entity_2_idx": [[93, 98]], "entity_2_idx_in_text_with_entity_marker": [106, 111], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d821.s0_BioInfer.d821.s0.p19", "text": "We show that the HSV-1 UL5, UL8, UL29, UL30, UL42, and UL52 gene products along with the AAV Rep68 protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "text_with_entity_marker": "We show that the HSV-1 UL5, UL8, UL29, UL30, [E1]UL42[/E1], and UL52 gene products along with the AAV [E2]Rep68[/E2] protein are sufficient to initiate replication on duplex DNA containing the AAV origins of replication, resulting in products several hundred nucleotides in length.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UL42", "entity_1_idx": [[45, 49]], "entity_1_idx_in_text_with_entity_marker": [49, 53], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "Rep68", "entity_2_idx": [[93, 98]], "entity_2_idx_in_text_with_entity_marker": [106, 111], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d829.s0_BioInfer.d829.s0.p0", "text": "When a lyophilized Mf and AO mixture was incubated at 40 degrees C and 65% relative humidity, the conjugation of AO was confirmed at myosin heavy chain, actin, and tropomyosin.", "text_with_entity_marker": "When a lyophilized Mf and AO mixture was incubated at 40 degrees C and 65% relative humidity, the conjugation of AO was confirmed at myosin heavy chain, [E1]actin[/E1], and [E2]tropomyosin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[153, 158]], "entity_1_idx_in_text_with_entity_marker": [157, 162], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "tropomyosin", "entity_2_idx": [[164, 175]], "entity_2_idx_in_text_with_entity_marker": [177, 188], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d829.s0_BioInfer.d829.s0.p1", "text": "When a lyophilized Mf and AO mixture was incubated at 40 degrees C and 65% relative humidity, the conjugation of AO was confirmed at myosin heavy chain, actin, and tropomyosin.", "text_with_entity_marker": "When a lyophilized Mf and AO mixture was incubated at 40 degrees C and 65% relative humidity, the conjugation of AO was confirmed at [E1]myosin heavy chain[/E1], actin, and [E2]tropomyosin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin heavy chain", "entity_1_idx": [[133, 151]], "entity_1_idx_in_text_with_entity_marker": [137, 155], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "tropomyosin", "entity_2_idx": [[164, 175]], "entity_2_idx_in_text_with_entity_marker": [177, 188], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d829.s0_BioInfer.d829.s0.p2", "text": "When a lyophilized Mf and AO mixture was incubated at 40 degrees C and 65% relative humidity, the conjugation of AO was confirmed at myosin heavy chain, actin, and tropomyosin.", "text_with_entity_marker": "When a lyophilized Mf and AO mixture was incubated at 40 degrees C and 65% relative humidity, the conjugation of AO was confirmed at [E1]myosin heavy chain[/E1], [E2]actin[/E2], and tropomyosin.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "myosin heavy chain", "entity_1_idx": [[133, 151]], "entity_1_idx_in_text_with_entity_marker": [137, 155], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[153, 158]], "entity_2_idx_in_text_with_entity_marker": [166, 171], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d703.s0_BioInfer.d703.s0.p0", "text": "These proteins also compose the essential heterotrimeric splicing factor SF3a, and products of yeast pre-mRNA processing genes PRP9, PRP11, and PRP21 are their likely yeast counterparts.", "text_with_entity_marker": "These proteins also compose the essential heterotrimeric splicing factor SF3a, and products of yeast pre-mRNA processing genes [E1]PRP9[/E1], PRP11, and [E2]PRP21[/E2] are their likely yeast counterparts.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "PRP9", "entity_1_idx": [[127, 131]], "entity_1_idx_in_text_with_entity_marker": [131, 135], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "PRP21", "entity_2_idx": [[144, 149]], "entity_2_idx_in_text_with_entity_marker": [157, 162], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d703.s0_BioInfer.d703.s0.p1", "text": "These proteins also compose the essential heterotrimeric splicing factor SF3a, and products of yeast pre-mRNA processing genes PRP9, PRP11, and PRP21 are their likely yeast counterparts.", "text_with_entity_marker": "These proteins also compose the essential heterotrimeric splicing factor SF3a, and products of yeast pre-mRNA processing genes PRP9, [E1]PRP11[/E1], and [E2]PRP21[/E2] are their likely yeast counterparts.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "PRP11", "entity_1_idx": [[133, 138]], "entity_1_idx_in_text_with_entity_marker": [137, 142], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "PRP21", "entity_2_idx": [[144, 149]], "entity_2_idx_in_text_with_entity_marker": [157, 162], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d703.s0_BioInfer.d703.s0.p2", "text": "These proteins also compose the essential heterotrimeric splicing factor SF3a, and products of yeast pre-mRNA processing genes PRP9, PRP11, and PRP21 are their likely yeast counterparts.", "text_with_entity_marker": "These proteins also compose the essential heterotrimeric splicing factor [E1]SF3a[/E1], and products of yeast pre-mRNA processing genes PRP9, PRP11, and [E2]PRP21[/E2] are their likely yeast counterparts.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "SF3a", "entity_1_idx": [[73, 77]], "entity_1_idx_in_text_with_entity_marker": [77, 81], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "PRP21", "entity_2_idx": [[144, 149]], "entity_2_idx_in_text_with_entity_marker": [157, 162], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d703.s0_BioInfer.d703.s0.p3", "text": "These proteins also compose the essential heterotrimeric splicing factor SF3a, and products of yeast pre-mRNA processing genes PRP9, PRP11, and PRP21 are their likely yeast counterparts.", "text_with_entity_marker": "These proteins also compose the essential heterotrimeric splicing factor SF3a, and products of yeast pre-mRNA processing genes [E1]PRP9[/E1], [E2]PRP11[/E2], and PRP21 are their likely yeast counterparts.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "PRP9", "entity_1_idx": [[127, 131]], "entity_1_idx_in_text_with_entity_marker": [131, 135], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "PRP11", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d703.s0_BioInfer.d703.s0.p4", "text": "These proteins also compose the essential heterotrimeric splicing factor SF3a, and products of yeast pre-mRNA processing genes PRP9, PRP11, and PRP21 are their likely yeast counterparts.", "text_with_entity_marker": "These proteins also compose the essential heterotrimeric splicing factor [E1]SF3a[/E1], and products of yeast pre-mRNA processing genes [E2]PRP9[/E2], PRP11, and PRP21 are their likely yeast counterparts.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "SF3a", "entity_1_idx": [[73, 77]], "entity_1_idx_in_text_with_entity_marker": [77, 81], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "PRP9", "entity_2_idx": [[127, 131]], "entity_2_idx_in_text_with_entity_marker": [140, 144], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d703.s0_BioInfer.d703.s0.p5", "text": "These proteins also compose the essential heterotrimeric splicing factor SF3a, and products of yeast pre-mRNA processing genes PRP9, PRP11, and PRP21 are their likely yeast counterparts.", "text_with_entity_marker": "These proteins also compose the essential heterotrimeric splicing factor [E1]SF3a[/E1], and products of yeast pre-mRNA processing genes PRP9, [E2]PRP11[/E2], and PRP21 are their likely yeast counterparts.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "SF3a", "entity_1_idx": [[73, 77]], "entity_1_idx_in_text_with_entity_marker": [77, 81], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "PRP11", "entity_2_idx": [[133, 138]], "entity_2_idx_in_text_with_entity_marker": [146, 151], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d572.s0_BioInfer.d572.s0.p0", "text": "The amino acid composition of the 15-kDa protein was similar to that of mammalian profilin and it inhibited the salt-induced polymerization of rabbit skeletal muscle actin.", "text_with_entity_marker": "The amino acid composition of the 15-kDa protein was similar to that of mammalian [E1]profilin[/E1] and it inhibited the salt-induced polymerization of rabbit [E2]skeletal muscle actin[/E2].", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "profilin", "entity_1_idx": [[82, 90]], "entity_1_idx_in_text_with_entity_marker": [86, 94], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "skeletal muscle actin", "entity_2_idx": [[150, 171]], "entity_2_idx_in_text_with_entity_marker": [163, 184], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d775.s0_BioInfer.d775.s0.p10", "text": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "text_with_entity_marker": "Transfection of plasmids encoding the BRSV minigenome, [E1]nucleocapsid protein[/E1] (N), phosphoprotein ([E2]P[/E2]) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nucleocapsid protein", "entity_1_idx": [[55, 75]], "entity_1_idx_in_text_with_entity_marker": [59, 79], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P", "entity_2_idx": [[97, 98]], "entity_2_idx_in_text_with_entity_marker": [110, 111], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d775.s0_BioInfer.d775.s0.p11", "text": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "text_with_entity_marker": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein ([E1]N[/E1]), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to [E2]CAT[/E2] activity and progeny with the minigenome.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[77, 78]], "entity_1_idx_in_text_with_entity_marker": [81, 82], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "CAT", "entity_2_idx": [[254, 257]], "entity_2_idx_in_text_with_entity_marker": [267, 270], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d775.s0_BioInfer.d775.s0.p12", "text": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "text_with_entity_marker": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), [E1]phosphoprotein[/E1] (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to [E2]CAT[/E2] activity and progeny with the minigenome.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[81, 95]], "entity_1_idx_in_text_with_entity_marker": [85, 99], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "CAT", "entity_2_idx": [[254, 257]], "entity_2_idx_in_text_with_entity_marker": [267, 270], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d775.s0_BioInfer.d775.s0.p13", "text": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "text_with_entity_marker": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), phosphoprotein (P) and [E1]L[/E1] protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to [E2]CAT[/E2] activity and progeny with the minigenome.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "L", "entity_1_idx": [[104, 105]], "entity_1_idx_in_text_with_entity_marker": [108, 109], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "CAT", "entity_2_idx": [[254, 257]], "entity_2_idx_in_text_with_entity_marker": [267, 270], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d775.s0_BioInfer.d775.s0.p14", "text": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "text_with_entity_marker": "Transfection of plasmids encoding the BRSV minigenome, [E1]nucleocapsid protein[/E1] (N), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to [E2]CAT[/E2] activity and progeny with the minigenome.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nucleocapsid protein", "entity_1_idx": [[55, 75]], "entity_1_idx_in_text_with_entity_marker": [59, 79], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "CAT", "entity_2_idx": [[254, 257]], "entity_2_idx_in_text_with_entity_marker": [267, 270], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d775.s0_BioInfer.d775.s0.p15", "text": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "text_with_entity_marker": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein ([E1]N[/E1]), [E2]phosphoprotein[/E2] (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[77, 78]], "entity_1_idx_in_text_with_entity_marker": [81, 82], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "phosphoprotein", "entity_2_idx": [[81, 95]], "entity_2_idx_in_text_with_entity_marker": [94, 108], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d775.s0_BioInfer.d775.s0.p16", "text": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "text_with_entity_marker": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein ([E1]N[/E1]), phosphoprotein (P) and [E2]L[/E2] protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "N", "entity_1_idx": [[77, 78]], "entity_1_idx_in_text_with_entity_marker": [81, 82], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "L", "entity_2_idx": [[104, 105]], "entity_2_idx_in_text_with_entity_marker": [117, 118], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d775.s0_BioInfer.d775.s0.p17", "text": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "text_with_entity_marker": "Transfection of plasmids encoding the BRSV minigenome, [E1]nucleocapsid protein[/E1] ([E2]N[/E2]), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nucleocapsid protein", "entity_1_idx": [[55, 75]], "entity_1_idx_in_text_with_entity_marker": [59, 79], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "N", "entity_2_idx": [[77, 78]], "entity_2_idx_in_text_with_entity_marker": [90, 91], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d775.s0_BioInfer.d775.s0.p18", "text": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "text_with_entity_marker": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), [E1]phosphoprotein[/E1] (P) and [E2]L[/E2] protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "phosphoprotein", "entity_1_idx": [[81, 95]], "entity_1_idx_in_text_with_entity_marker": [85, 99], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "L", "entity_2_idx": [[104, 105]], "entity_2_idx_in_text_with_entity_marker": [117, 118], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d775.s0_BioInfer.d775.s0.p19", "text": "Transfection of plasmids encoding the BRSV minigenome, nucleocapsid protein (N), phosphoprotein (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "text_with_entity_marker": "Transfection of plasmids encoding the BRSV minigenome, [E1]nucleocapsid protein[/E1] (N), [E2]phosphoprotein[/E2] (P) and L protein, each under the control of T7 promoter, into cells infected with a vaccinia virus recombinant expressing the T7 RNA polymerase gave rise to CAT activity and progeny with the minigenome.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "nucleocapsid protein", "entity_1_idx": [[55, 75]], "entity_1_idx_in_text_with_entity_marker": [59, 79], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "phosphoprotein", "entity_2_idx": [[81, 95]], "entity_2_idx_in_text_with_entity_marker": [94, 108], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d354.s0_BioInfer.d354.s0.p0", "text": "Insulin-like growth factor-I, actin, and myosin heavy chain messenger RNAs in skeletal muscle after an injection of growth hormone in subjects over 60 years old.", "text_with_entity_marker": "[E1]Insulin-like growth factor-I[/E1], [E2]actin[/E2], and myosin heavy chain messenger RNAs in skeletal muscle after an injection of growth hormone in subjects over 60 years old.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Insulin-like growth factor-I", "entity_1_idx": [[0, 28]], "entity_1_idx_in_text_with_entity_marker": [4, 32], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[30, 35]], "entity_2_idx_in_text_with_entity_marker": [43, 48], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d354.s0_BioInfer.d354.s0.p1", "text": "Insulin-like growth factor-I, actin, and myosin heavy chain messenger RNAs in skeletal muscle after an injection of growth hormone in subjects over 60 years old.", "text_with_entity_marker": "Insulin-like growth factor-I, [E1]actin[/E1], and [E2]myosin heavy chain[/E2] messenger RNAs in skeletal muscle after an injection of growth hormone in subjects over 60 years old.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "actin", "entity_1_idx": [[30, 35]], "entity_1_idx_in_text_with_entity_marker": [34, 39], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosin heavy chain", "entity_2_idx": [[41, 59]], "entity_2_idx_in_text_with_entity_marker": [54, 72], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d354.s0_BioInfer.d354.s0.p2", "text": "Insulin-like growth factor-I, actin, and myosin heavy chain messenger RNAs in skeletal muscle after an injection of growth hormone in subjects over 60 years old.", "text_with_entity_marker": "[E1]Insulin-like growth factor-I[/E1], actin, and [E2]myosin heavy chain[/E2] messenger RNAs in skeletal muscle after an injection of growth hormone in subjects over 60 years old.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Insulin-like growth factor-I", "entity_1_idx": [[0, 28]], "entity_1_idx_in_text_with_entity_marker": [4, 32], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "myosin heavy chain", "entity_2_idx": [[41, 59]], "entity_2_idx_in_text_with_entity_marker": [54, 72], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p80", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein ([E1]P[/E1]), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase ([E2]HN[/E2]) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "P", "entity_1_idx": [[87, 88]], "entity_1_idx_in_text_with_entity_marker": [91, 92], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "HN", "entity_2_idx": [[204, 206]], "entity_2_idx_in_text_with_entity_marker": [217, 219], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p81", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic ([E1]SH[/E1]) protein, haemagglutinin-neuraminidase ([E2]HN[/E2]) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "SH", "entity_1_idx": [[161, 163]], "entity_1_idx_in_text_with_entity_marker": [165, 167], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "HN", "entity_2_idx": [[204, 206]], "entity_2_idx_in_text_with_entity_marker": [217, 219], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p82", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein ([E1]F[/E1]), small hydrophobic (SH) protein, haemagglutinin-neuraminidase ([E2]HN[/E2]) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "F", "entity_1_idx": [[138, 139]], "entity_1_idx_in_text_with_entity_marker": [142, 143], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "HN", "entity_2_idx": [[204, 206]], "entity_2_idx_in_text_with_entity_marker": [217, 219], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p83", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase ([E1]HN[/E1]) protein and large ([E2]L[/E2]) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "HN", "entity_1_idx": [[204, 206]], "entity_1_idx_in_text_with_entity_marker": [208, 210], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "L", "entity_2_idx": [[227, 228]], "entity_2_idx_in_text_with_entity_marker": [240, 241], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p84", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein ([E1]NP[/E1]), phosphoprotein (P), V protein, [E2]matrix protein[/E2] (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NP", "entity_1_idx": [[66, 68]], "entity_1_idx_in_text_with_entity_marker": [70, 72], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "matrix protein", "entity_2_idx": [[102, 116]], "entity_2_idx_in_text_with_entity_marker": [115, 129], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p85", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein ([E1]NP[/E1]), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, [E2]haemagglutinin-neuraminidase[/E2] (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NP", "entity_1_idx": [[66, 68]], "entity_1_idx_in_text_with_entity_marker": [70, 72], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "haemagglutinin-neuraminidase", "entity_2_idx": [[174, 202], [208, 215]], "entity_2_idx_in_text_with_entity_marker": [187, 215], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p86", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein ([E1]NP[/E1]), phosphoprotein ([E2]P[/E2]), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NP", "entity_1_idx": [[66, 68]], "entity_1_idx_in_text_with_entity_marker": [70, 72], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "P", "entity_2_idx": [[87, 88]], "entity_2_idx_in_text_with_entity_marker": [100, 101], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p87", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein ([E1]NP[/E1]), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic ([E2]SH[/E2]) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NP", "entity_1_idx": [[66, 68]], "entity_1_idx_in_text_with_entity_marker": [70, 72], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "SH", "entity_2_idx": [[161, 163]], "entity_2_idx_in_text_with_entity_marker": [174, 176], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p88", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein ([E1]NP[/E1]), phosphoprotein (P), V protein, matrix protein (M), fusion protein ([E2]F[/E2]), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NP", "entity_1_idx": [[66, 68]], "entity_1_idx_in_text_with_entity_marker": [70, 72], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "F", "entity_2_idx": [[138, 139]], "entity_2_idx_in_text_with_entity_marker": [151, 152], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d560.s0_BioInfer.d560.s0.p89", "text": "The 16236 nt genome encodes eight proteins, nucleocapsid protein (NP), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large (L) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "text_with_entity_marker": "The 16236 nt genome encodes eight proteins, nucleocapsid protein ([E1]NP[/E1]), phosphoprotein (P), V protein, matrix protein (M), fusion protein (F), small hydrophobic (SH) protein, haemagglutinin-neuraminidase (HN) protein and large ([E2]L[/E2]) protein, which are flanked by a 55 nt leader sequence and a 54 nt trailer sequence.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "NP", "entity_1_idx": [[66, 68]], "entity_1_idx_in_text_with_entity_marker": [70, 72], "entity_1_type": "Individual_protein", "entity_1_type_id": 0, "entity_2": "L", "entity_2_idx": [[227, 228]], "entity_2_idx_in_text_with_entity_marker": [240, 241], "entity_2_type": "Individual_protein", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "BioInfer.d7.s3_BioInfer.d7.s3.p0", "text": "Mechanism of action of Acanthamoeba profilin: demonstration of actin species specificity and regulation by micromolar concentrations of MgCl2.", "text_with_entity_marker": "Mechanism of action of Acanthamoeba [E1]profilin[/E1]: demonstration of [E2]actin[/E2] species specificity and regulation by micromolar concentrations of MgCl2.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "profilin", "entity_1_idx": [[36, 44]], "entity_1_idx_in_text_with_entity_marker": [40, 48], "entity_1_type": "Gene/protein/RNA", "entity_1_type_id": 2, "entity_2": "actin", "entity_2_idx": [[63, 68]], "entity_2_idx_in_text_with_entity_marker": [76, 81], "entity_2_type": "Gene/protein/RNA", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "HPRD50.d31.s0_HPRD50.d31.s0.p0", "text": "Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation", "text_with_entity_marker": "[E1]Raf1[/E1] interaction with [E2]Cdc25[/E2] phosphatase ties mitogenic signal transduction to cell cycle activation", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Raf1", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0117803", "entity_1_type_id": 112, "entity_2": "Cdc25", "entity_2_idx": [[22, 27]], "entity_2_idx_in_text_with_entity_marker": [35, 40], "entity_2_type": "pm0106635||pm0109000", "entity_2_type_id": 113}], "directed": false, "reverse": false}
{"id": "HPRD50.d31.s1_HPRD50.d31.s1.p0", "text": "We show here that Cdc25 phosphatase associates with raf1 in somatic mammalian cells and in meiotic frog oocytes", "text_with_entity_marker": "We show here that [E1]Cdc25[/E1] phosphatase associates with [E2]raf1[/E2] in somatic mammalian cells and in meiotic frog oocytes", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Cdc25", "entity_1_idx": [[18, 23]], "entity_1_idx_in_text_with_entity_marker": [22, 27], "entity_1_type": "pm0106635||pm0109000", "entity_1_type_id": 113, "entity_2": "raf1", "entity_2_idx": [[52, 56]], "entity_2_idx_in_text_with_entity_marker": [65, 69], "entity_2_type": "pm0117803", "entity_2_type_id": 112}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s0_HPRD50.d24.s0.p0", "text": "Specific interaction of Egr1 and c/EBPbeta leads to the transcriptional activation of the human low density lipoprotein receptor gene", "text_with_entity_marker": "Specific interaction of [E1]Egr1[/E1] and c/EBPbeta leads to the transcriptional activation of the human [E2]low density lipoprotein receptor[/E2] gene", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Egr1", "entity_1_idx": [[24, 28]], "entity_1_idx_in_text_with_entity_marker": [28, 32], "entity_1_type": "pm0115655", "entity_1_type_id": 87, "entity_2": "low density lipoprotein receptor", "entity_2_idx": [[96, 128]], "entity_2_idx_in_text_with_entity_marker": [109, 141], "entity_2_type": "pm0125757", "entity_2_type_id": 88}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p1", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the [E1]LDL receptor[/E1] (LDLR) promoter mediates [E2]oncostatin M[/E2] (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LDL receptor", "entity_1_idx": [[56, 68]], "entity_1_idx_in_text_with_entity_marker": [60, 72], "entity_1_type": "pm0125757", "entity_1_type_id": 88, "entity_2": "oncostatin M", "entity_2_idx": [[94, 106]], "entity_2_idx_in_text_with_entity_marker": [107, 119], "entity_2_type": "pm0100359", "entity_2_type_id": 89}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p3", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the LDL receptor ([E1]LDLR[/E1]) promoter mediates [E2]oncostatin M[/E2] (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "LDLR", "entity_1_idx": [[70, 74]], "entity_1_idx_in_text_with_entity_marker": [74, 78], "entity_1_type": "pm0125757", "entity_1_type_id": 88, "entity_2": "oncostatin M", "entity_2_idx": [[94, 106]], "entity_2_idx_in_text_with_entity_marker": [107, 119], "entity_2_type": "pm0100359", "entity_2_type_id": 89}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p5", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates [E1]oncostatin M[/E1] (OM)-induced transcription of the [E2]LDLR[/E2] gene through a cholesterol-independent pathway", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "oncostatin M", "entity_1_idx": [[94, 106]], "entity_1_idx_in_text_with_entity_marker": [98, 110], "entity_1_type": "pm0100359", "entity_1_type_id": 89, "entity_2": "LDLR", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "pm0125757", "entity_2_type_id": 88}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s0_HPRD50.d36.s0.p0", "text": "CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation", "text_with_entity_marker": "[E1]CD22[/E1] associates with [E2]protein tyrosine phosphatase 1C[/E2], Syk, and phospholipase C-gamma(1) upon B cell activation", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CD22", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "protein tyrosine phosphatase 1C", "entity_2_idx": [[21, 52]], "entity_2_idx_in_text_with_entity_marker": [34, 65], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s1_HPRD50.d36.s1.p0", "text": "These results suggest that tyrosyl-phosphorylated CD22 may be a substrate for PTP-1C regulates tyrosyl phosphorylation of CD22", "text_with_entity_marker": "These results suggest that tyrosyl-phosphorylated [E1]CD22[/E1] may be a substrate for [E2]PTP-1C[/E2] regulates tyrosyl phosphorylation of CD22", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CD22", "entity_1_idx": [[50, 54]], "entity_1_idx_in_text_with_entity_marker": [54, 58], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "PTP-1C", "entity_2_idx": [[78, 84]], "entity_2_idx_in_text_with_entity_marker": [91, 97], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s1_HPRD50.d36.s1.p2", "text": "These results suggest that tyrosyl-phosphorylated CD22 may be a substrate for PTP-1C regulates tyrosyl phosphorylation of CD22", "text_with_entity_marker": "These results suggest that tyrosyl-phosphorylated CD22 may be a substrate for [E1]PTP-1C[/E1] regulates tyrosyl phosphorylation of [E2]CD22[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "PTP-1C", "entity_1_idx": [[78, 84]], "entity_1_idx_in_text_with_entity_marker": [82, 88], "entity_1_type": "pm0105676", "entity_1_type_id": 136, "entity_2": "CD22", "entity_2_idx": [[122, 126]], "entity_2_idx_in_text_with_entity_marker": [135, 139], "entity_2_type": "pm0119833", "entity_2_type_id": 135}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s3_HPRD50.d36.s3.p0", "text": "Complexes of either CD22/PTP-1C/Syk/PLC-gamma(1) could be isolated from B cells stimulated by BCR engagement or a mixture of hydrogen peroxidase and sodium orthovanadate, respectively", "text_with_entity_marker": "Complexes of either [E1]CD22[/E1]/[E2]PTP-1C[/E2]/Syk/PLC-gamma(1) could be isolated from B cells stimulated by BCR engagement or a mixture of hydrogen peroxidase and sodium orthovanadate, respectively", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "CD22", "entity_1_idx": [[20, 24]], "entity_1_idx_in_text_with_entity_marker": [24, 28], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "PTP-1C", "entity_2_idx": [[25, 31]], "entity_2_idx_in_text_with_entity_marker": [38, 44], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s4_HPRD50.d36.s4.p2", "text": "Transient expression of CD22 and a null mutant of PTP-1C (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of CD22 and its interaction with PTP-1CM", "text_with_entity_marker": "Transient expression of CD22 and a null mutant of [E1]PTP-1C[/E1] (PTP-1CM) in COS cells resulted in an increase in tyrosyl phosphorylation of [E2]CD22[/E2] and its interaction with PTP-1CM", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "PTP-1C", "entity_1_idx": [[50, 56]], "entity_1_idx_in_text_with_entity_marker": [54, 60], "entity_1_type": "pm0105676", "entity_1_type_id": 136, "entity_2": "CD22", "entity_2_idx": [[134, 138]], "entity_2_idx_in_text_with_entity_marker": [147, 151], "entity_2_type": "pm0119833", "entity_2_type_id": 135}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s1_HPRD50.d20.s1.p0", "text": "We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins Imp3 and Imp4", "text_with_entity_marker": "We have cloned cDNAs encoding the human and mouse homologs of the yeast U3 snoRNP-associated proteins [E1]Imp3[/E1] and [E2]Imp4[/E2]", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Imp3", "entity_1_idx": [[102, 106]], "entity_1_idx_in_text_with_entity_marker": [106, 110], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "Imp4", "entity_2_idx": [[111, 115]], "entity_2_idx_in_text_with_entity_marker": [124, 128], "entity_2_type": "pm0104160||pm0117832", "entity_2_type_id": 69}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s2_HPRD50.d20.s2.p0", "text": "The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved", "text_with_entity_marker": "The results of complementation experiments show that, in contrast to mouse [E1]Imp4[/E1], mouse [E2]Imp3[/E2] can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Imp4", "entity_1_idx": [[75, 79]], "entity_1_idx_in_text_with_entity_marker": [79, 83], "entity_1_type": "pm0104160||pm0117832", "entity_1_type_id": 69, "entity_2": "Imp3", "entity_2_idx": [[87, 91]], "entity_2_idx_in_text_with_entity_marker": [100, 104], "entity_2_type": "pm0100548||pm0102353||pm0121765", "entity_2_type_id": 68}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s2_HPRD50.d20.s2.p1", "text": "The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved", "text_with_entity_marker": "The results of complementation experiments show that, in contrast to mouse [E1]Imp4[/E1], mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of [E2]Imp3[/E2] in pre-rRNA processing is evolutionarily conserved", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Imp4", "entity_1_idx": [[75, 79]], "entity_1_idx_in_text_with_entity_marker": [79, 83], "entity_1_type": "pm0104160||pm0117832", "entity_1_type_id": 69, "entity_2": "Imp3", "entity_2_idx": [[202, 206]], "entity_2_idx_in_text_with_entity_marker": [215, 219], "entity_2_type": "pm0100548||pm0102353||pm0121765", "entity_2_type_id": 68}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s2_HPRD50.d20.s2.p2", "text": "The results of complementation experiments show that, in contrast to mouse Imp4, mouse Imp3 can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of Imp3 in pre-rRNA processing is evolutionarily conserved", "text_with_entity_marker": "The results of complementation experiments show that, in contrast to mouse Imp4, mouse [E1]Imp3[/E1] can partially alleviate the growth defect of the corresponding yeast null strain, indicating that the role of [E2]Imp3[/E2] in pre-rRNA processing is evolutionarily conserved", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Imp3", "entity_1_idx": [[87, 91]], "entity_1_idx_in_text_with_entity_marker": [91, 95], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "Imp3", "entity_2_idx": [[202, 206]], "entity_2_idx_in_text_with_entity_marker": [215, 219], "entity_2_type": "pm0100548||pm0102353||pm0121765", "entity_2_type_id": 68}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s4_HPRD50.d32.s4.p0", "text": "Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in perlecan which was partially removed by pretreatment with heparitinase, but not by chondroitin ABC lyase", "text_with_entity_marker": "Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in [E1]perlecan[/E1] which was partially removed by pretreatment with heparitinase, but not by chondroitin [E2]ABC[/E2] lyase", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "perlecan", "entity_1_idx": [[178, 186]], "entity_1_idx_in_text_with_entity_marker": [182, 190], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "ABC", "entity_2_idx": [[273, 276]], "entity_2_idx_in_text_with_entity_marker": [286, 289], "entity_2_type": "pm0102466", "entity_2_type_id": 123}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s5_HPRD50.d32.s5.p0", "text": "[35S]-Sulfate labeled proteoglycans (PGs) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine serum albumin", "text_with_entity_marker": "[35S]-Sulfate labeled proteoglycans ([E1]PGs[/E1]) derived from cultured ECs and SMCs bound to affinity columns containing A beta (1-28) or (1-40), with virtually no binding to A beta (40-1) (reverse peptide), beta-amyloid precursor protein (410-429), or bovine [E2]serum albumin[/E2]", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "PGs", "entity_1_idx": [[37, 40]], "entity_1_idx_in_text_with_entity_marker": [41, 44], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "serum albumin", "entity_2_idx": [[253, 266]], "entity_2_idx_in_text_with_entity_marker": [266, 279], "entity_2_type": "pm0103143", "entity_2_type_id": 124}], "directed": false, "reverse": false}
{"id": "HPRD50.d0.s0_HPRD50.d0.s0.p0", "text": "Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III", "text_with_entity_marker": "Cloning and characterization of two evolutionarily conserved subunits ([E1]TFIIIC102[/E1] and [E2]TFIIIC63[/E2]) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TFIIIC102", "entity_1_idx": [[71, 80]], "entity_1_idx_in_text_with_entity_marker": [75, 84], "entity_1_type": "pm0125479", "entity_1_type_id": 0, "entity_2": "TFIIIC63", "entity_2_idx": [[85, 93]], "entity_2_idx_in_text_with_entity_marker": [98, 106], "entity_2_type": "pm0100174", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "HPRD50.d0.s0_HPRD50.d0.s0.p1", "text": "Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III", "text_with_entity_marker": "Cloning and characterization of two evolutionarily conserved subunits ([E1]TFIIIC102[/E1] and TFIIIC63) of human [E2]TFIIIC[/E2] and their involvement in functional interactions with TFIIIB and RNA polymerase III", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TFIIIC102", "entity_1_idx": [[71, 80]], "entity_1_idx_in_text_with_entity_marker": [75, 84], "entity_1_type": "pm0125479", "entity_1_type_id": 0, "entity_2": "TFIIIC", "entity_2_idx": [[104, 110]], "entity_2_idx_in_text_with_entity_marker": [117, 123], "entity_2_type": "pm0120026", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "HPRD50.d0.s0_HPRD50.d0.s0.p2", "text": "Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and TFIIIC63) of human TFIIIC and their involvement in functional interactions with TFIIIB and RNA polymerase III", "text_with_entity_marker": "Cloning and characterization of two evolutionarily conserved subunits (TFIIIC102 and [E1]TFIIIC63[/E1]) of human [E2]TFIIIC[/E2] and their involvement in functional interactions with TFIIIB and RNA polymerase III", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "TFIIIC63", "entity_1_idx": [[85, 93]], "entity_1_idx_in_text_with_entity_marker": [89, 97], "entity_1_type": "pm0100174", "entity_1_type_id": 1, "entity_2": "TFIIIC", "entity_2_idx": [[104, 110]], "entity_2_idx_in_text_with_entity_marker": [117, 123], "entity_2_type": "pm0120026", "entity_2_type_id": 2}], "directed": false, "reverse": false}
{"id": "IEPA.d90.s213_IEPA.d90.s213.p0", "text": "DNase1 footprints suggest the involvement of at least three types of transcription factors in the regulation of alpha-Amy2/A by gibberellin", "text_with_entity_marker": "DNase1 footprints suggest the involvement of at least three types of transcription factors in the regulation of [E1]alpha-Amy2/A[/E1] by [E2]gibberellin[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "alpha-Amy2/A", "entity_1_idx": [[112, 124]], "entity_1_idx_in_text_with_entity_marker": [116, 128], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "gibberellin", "entity_2_idx": [[128, 139]], "entity_2_idx_in_text_with_entity_marker": [141, 152], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d90.s214_IEPA.d90.s214.p0", "text": "The regulation of alpha-Amy2 genes by GA therefore involves an interplay of at least three different types of transcription factor", "text_with_entity_marker": "The regulation of [E1]alpha-Amy2[/E1] genes by [E2]GA[/E2] therefore involves an interplay of at least three different types of transcription factor", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "alpha-Amy2", "entity_1_idx": [[18, 28]], "entity_1_idx_in_text_with_entity_marker": [22, 32], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "GA", "entity_2_idx": [[38, 40]], "entity_2_idx_in_text_with_entity_marker": [51, 53], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d137.s325_IEPA.d137.s325.p0", "text": "We previously showed that arginine vasopressin (AVP) stimulates heat shock protein 27 (HSP27) induction through protein kinase C activation in aortic smooth muscle A10 cells", "text_with_entity_marker": "We previously showed that [E1]arginine vasopressin[/E1] (AVP) stimulates heat shock protein 27 (HSP27) induction through [E2]protein kinase C[/E2] activation in aortic smooth muscle A10 cells", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "arginine vasopressin", "entity_1_idx": [[26, 46]], "entity_1_idx_in_text_with_entity_marker": [30, 50], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[112, 128]], "entity_2_idx_in_text_with_entity_marker": [125, 141], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d137.s326_IEPA.d137.s326.p0", "text": "Calphostin C and ET-18-OCH(3), inhibitors of protein kinase C, reduced the phosphorylation of p38 MAP kinase by AVP", "text_with_entity_marker": "Calphostin C and ET-18-OCH(3), inhibitors of [E1]protein kinase C[/E1], reduced the phosphorylation of p38 MAP kinase by [E2]AVP[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "protein kinase C", "entity_1_idx": [[45, 61]], "entity_1_idx_in_text_with_entity_marker": [49, 65], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "AVP", "entity_2_idx": [[112, 115]], "entity_2_idx_in_text_with_entity_marker": [125, 128], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d55.s140_IEPA.d55.s140.p0", "text": "The effect of AVP was also inhibited in the presence of the protein kinase C inhibitor calphostin C", "text_with_entity_marker": "The effect of [E1]AVP[/E1] was also inhibited in the presence of the [E2]protein kinase C[/E2] inhibitor calphostin C", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "AVP", "entity_1_idx": [[14, 17]], "entity_1_idx_in_text_with_entity_marker": [18, 21], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[60, 76]], "entity_2_idx_in_text_with_entity_marker": [73, 89], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d55.s141_IEPA.d55.s141.p0", "text": "The addition of AVP increased protein kinase C activity in cardiac myocytes, and its effect was significantly inhibited in the presence of calphostin C", "text_with_entity_marker": "The addition of [E1]AVP[/E1] increased [E2]protein kinase C[/E2] activity in cardiac myocytes, and its effect was significantly inhibited in the presence of calphostin C", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "AVP", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[30, 46]], "entity_2_idx_in_text_with_entity_marker": [43, 59], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d55.s142_IEPA.d55.s142.p2", "text": "These results support the hypothesis that the heart may be a target organ for AVP and that AVP modulates IL-1beta-induced iNOS expression in myocytes through the V1a receptor, which is mediated at least partially via activation of protein kinase C", "text_with_entity_marker": "These results support the hypothesis that the heart may be a target organ for AVP and that [E1]AVP[/E1] modulates IL-1beta-induced iNOS expression in myocytes through the V1a receptor, which is mediated at least partially via activation of [E2]protein kinase C[/E2]", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "AVP", "entity_1_idx": [[91, 94]], "entity_1_idx_in_text_with_entity_marker": [95, 98], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[231, 247]], "entity_2_idx_in_text_with_entity_marker": [244, 260], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d110.s264_IEPA.d110.s264.p0", "text": "Signal transduction of arginine vasopressin-induced arachidonic acid release in H9c2 cardiac myoblasts: role of Ca2+ and the protein kinase C-dependent activation of p42 mitogen-activated protein kinase", "text_with_entity_marker": "Signal transduction of [E1]arginine vasopressin[/E1]-induced arachidonic acid release in H9c2 cardiac myoblasts: role of Ca2+ and the [E2]protein kinase C[/E2]-dependent activation of p42 mitogen-activated protein kinase", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "arginine vasopressin", "entity_1_idx": [[23, 43]], "entity_1_idx_in_text_with_entity_marker": [27, 47], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[125, 141]], "entity_2_idx_in_text_with_entity_marker": [138, 154], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d110.s267_IEPA.d110.s267.p0", "text": "AVP- or TPA-induced activation and tyrosine phosphorylation of p42 MAPK were completely blocked by down-regulation of PKCalpha, betaI, epsilon, and delta, but still occurred, together with the cytosolic PLA2 mobility shift, in the absence of external Ca2+", "text_with_entity_marker": "[E1]AVP[/E1]- or TPA-induced activation and tyrosine phosphorylation of p42 MAPK were completely blocked by down-regulation of [E2]PKCalpha[/E2], betaI, epsilon, and delta, but still occurred, together with the cytosolic PLA2 mobility shift, in the absence of external Ca2+", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "AVP", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PKCalpha", "entity_2_idx": [[118, 126]], "entity_2_idx_in_text_with_entity_marker": [131, 139], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d110.s268_IEPA.d110.s268.p0", "text": "These results show that AVP-induced AA release in H9c2 cells is secondary to activation of the V1 receptor/Gq protein/PLCP pathway, leading to an influx of extracellular Ca2+ and activation of PKCalpha, betaI, epsilon, and delta", "text_with_entity_marker": "These results show that [E1]AVP[/E1]-induced AA release in H9c2 cells is secondary to activation of the V1 receptor/Gq protein/PLCP pathway, leading to an influx of extracellular Ca2+ and activation of [E2]PKCalpha[/E2], betaI, epsilon, and delta", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "AVP", "entity_1_idx": [[24, 27]], "entity_1_idx_in_text_with_entity_marker": [28, 31], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PKCalpha", "entity_2_idx": [[193, 201]], "entity_2_idx_in_text_with_entity_marker": [206, 214], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d177.s426_IEPA.d177.s426.p0", "text": "As expected, in fusion of NPY alone (18 microg/day) augmented food intake (191.6% over the initial control, P < 0.05) and produced a 25.1% weight gain in conjunction with a 10-fold increase in serum leptin concentrations at the end of the 7-day period", "text_with_entity_marker": "As expected, in fusion of [E1]NPY[/E1] alone (18 microg/day) augmented food intake (191.6% over the initial control, P < 0.05) and produced a 25.1% weight gain in conjunction with a 10-fold increase in serum [E2]leptin[/E2] concentrations at the end of the 7-day period", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "NPY", "entity_1_idx": [[26, 29]], "entity_1_idx_in_text_with_entity_marker": [30, 33], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[199, 205]], "entity_2_idx_in_text_with_entity_marker": [212, 218], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d177.s427_IEPA.d177.s427.p0", "text": "Interestingly, coinfusion of this regimen of NPY with the highly effective anorectic and body reducing effects of CNTF (5.0 microg/day) not only prevented the CNTF-induced anorexia and weight loss, but also normalized serum leptin concentrations and hypothalamic NPY gene expression", "text_with_entity_marker": "Interestingly, coinfusion of this regimen of [E1]NPY[/E1] with the highly effective anorectic and body reducing effects of CNTF (5.0 microg/day) not only prevented the CNTF-induced anorexia and weight loss, but also normalized serum [E2]leptin[/E2] concentrations and hypothalamic NPY gene expression", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "NPY", "entity_1_idx": [[45, 48]], "entity_1_idx_in_text_with_entity_marker": [49, 52], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[224, 230]], "entity_2_idx_in_text_with_entity_marker": [237, 243], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d191.s459_IEPA.d191.s459.p0", "text": "Similarly, central leptin treatment also had a greater effect in suppressing hypothalamic NPY mRNA expression in young (-23+/-4%) than in old (-8+/-4%) rats compared with their age-matched pair-fed treated rats", "text_with_entity_marker": "Similarly, central [E1]leptin[/E1] treatment also had a greater effect in suppressing hypothalamic [E2]NPY[/E2] mRNA expression in young (-23+/-4%) than in old (-8+/-4%) rats compared with their age-matched pair-fed treated rats", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "leptin", "entity_1_idx": [[19, 25]], "entity_1_idx_in_text_with_entity_marker": [23, 29], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "NPY", "entity_2_idx": [[90, 93]], "entity_2_idx_in_text_with_entity_marker": [103, 106], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d135.s323_IEPA.d135.s323.p0", "text": "These results suggest that, in isolated white adipocytes, the released adenosine acts as a helper and/or a positive regulator for insulin in the release of leptin via an activation of adenosine A1 receptors that involves the PLC-PKC pathway.", "text_with_entity_marker": "These results suggest that, in isolated white adipocytes, the released adenosine acts as a helper and/or a positive regulator for [E1]insulin[/E1] in the release of leptin via an activation of adenosine A1 receptors that involves the [E2]PLC[/E2]-PKC pathway.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "insulin", "entity_1_idx": [[130, 137]], "entity_1_idx_in_text_with_entity_marker": [134, 141], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PLC", "entity_2_idx": [[225, 228]], "entity_2_idx_in_text_with_entity_marker": [238, 241], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d84.s199_IEPA.d84.s199.p0", "text": "Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycaemia in insulin-dependent diabetics", "text_with_entity_marker": "Effect of residual endogenous [E1]insulin[/E1] secretion on the abnormal [E2]oxytocin[/E2] response to hypoglycaemia in insulin-dependent diabetics", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "insulin", "entity_1_idx": [[30, 37]], "entity_1_idx_in_text_with_entity_marker": [34, 41], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "oxytocin", "entity_2_idx": [[64, 72]], "entity_2_idx_in_text_with_entity_marker": [77, 85], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d84.s200_IEPA.d84.s200.p0", "text": "Since previous studies showed that AVP secretion is influenced by the persistence of residual endogenous insulin secretion, we wondered whether this factor also regulates OT secretion", "text_with_entity_marker": "Since previous studies showed that AVP secretion is influenced by the persistence of residual endogenous [E1]insulin[/E1] secretion, we wondered whether this factor also regulates [E2]OT[/E2] secretion", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "insulin", "entity_1_idx": [[105, 112]], "entity_1_idx_in_text_with_entity_marker": [109, 116], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "OT", "entity_2_idx": [[171, 173]], "entity_2_idx_in_text_with_entity_marker": [184, 186], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d84.s201_IEPA.d84.s201.p0", "text": "DESIGN: Case-control study: the OT response to insulin-induced hypoglycaemia was measured in normal and diabetic patients with or without residual endogenous insulin secretion", "text_with_entity_marker": "DESIGN: Case-control study: the [E1]OT[/E1] response to [E2]insulin[/E2]-induced hypoglycaemia was measured in normal and diabetic patients with or without residual endogenous insulin secretion", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "OT", "entity_1_idx": [[32, 34]], "entity_1_idx_in_text_with_entity_marker": [36, 38], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[47, 54]], "entity_2_idx_in_text_with_entity_marker": [60, 67], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d84.s203_IEPA.d84.s203.p0", "text": "CONCLUSIONS: These data indicate that a residual endogenous insulin secretion exerts a partial protective action against the hypothalamic-pituitary disorder affecting the OT secretory system in IDDM", "text_with_entity_marker": "CONCLUSIONS: These data indicate that a residual endogenous [E1]insulin[/E1] secretion exerts a partial protective action against the hypothalamic-pituitary disorder affecting the [E2]OT[/E2] secretory system in IDDM", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "insulin", "entity_1_idx": [[60, 67]], "entity_1_idx_in_text_with_entity_marker": [64, 71], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "OT", "entity_2_idx": [[171, 173]], "entity_2_idx_in_text_with_entity_marker": [184, 186], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d131.s316_IEPA.d131.s316.p0", "text": "Vasopressin stimulates tyrosine phosphorylation by activation of PKC in the rat smooth muscle cell line, A-10", "text_with_entity_marker": "[E1]Vasopressin[/E1] stimulates tyrosine phosphorylation by activation of [E2]PKC[/E2] in the rat smooth muscle cell line, A-10", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "Vasopressin", "entity_1_idx": [[0, 11]], "entity_1_idx_in_text_with_entity_marker": [4, 15], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[65, 68]], "entity_2_idx_in_text_with_entity_marker": [78, 81], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d131.s317_IEPA.d131.s317.p0", "text": "The protein kinase C (PKC) inhibitors: staurosporine, H7 and GF109203X are able to block the AVP-stimulated phosphorylation", "text_with_entity_marker": "The [E1]protein kinase C[/E1] (PKC) inhibitors: staurosporine, H7 and GF109203X are able to block the [E2]AVP[/E2]-stimulated phosphorylation", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "protein kinase C", "entity_1_idx": [[4, 20]], "entity_1_idx_in_text_with_entity_marker": [8, 24], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "AVP", "entity_2_idx": [[93, 96]], "entity_2_idx_in_text_with_entity_marker": [106, 109], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d131.s318_IEPA.d131.s318.p0", "text": "These results indicate that PKC is upstream of the phosphorylation, a motion which is supported by the fact that the AVP-stimulated phosphorylation was downregulated by phorbol esters", "text_with_entity_marker": "These results indicate that [E1]PKC[/E1] is upstream of the phosphorylation, a motion which is supported by the fact that the [E2]AVP[/E2]-stimulated phosphorylation was downregulated by phorbol esters", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "PKC", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "AVP", "entity_2_idx": [[117, 120]], "entity_2_idx_in_text_with_entity_marker": [130, 133], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d198.s483_IEPA.d198.s483.p0", "text": "Arcuate nucleus NPY mRNA increased in rats given protein-free diet, correlating with leptin rather than decreased feeding", "text_with_entity_marker": "Arcuate nucleus [E1]NPY[/E1] mRNA increased in rats given protein-free diet, correlating with [E2]leptin[/E2] rather than decreased feeding", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "NPY", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[85, 91]], "entity_2_idx_in_text_with_entity_marker": [98, 104], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d58.s150_IEPA.d58.s150.p0", "text": "We have recently shown that AVP causes a protein kinase C (PKC)-dependent increase in ACTH release and biosynthesis in ovine anterior pituitary cells", "text_with_entity_marker": "We have recently shown that [E1]AVP[/E1] causes a [E2]protein kinase C[/E2] (PKC)-dependent increase in ACTH release and biosynthesis in ovine anterior pituitary cells", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "AVP", "entity_1_idx": [[28, 31]], "entity_1_idx_in_text_with_entity_marker": [32, 35], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase C", "entity_2_idx": [[41, 57]], "entity_2_idx_in_text_with_entity_marker": [54, 70], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d58.s151_IEPA.d58.s151.p0", "text": "In these cells, AVP also causes the translocation of PKC from the cytosol to the cell membrane which is maximal at 5 min, but the intracellular events distal to protein kinase C activation that underlie ACTH secretion have not been well characterized to date", "text_with_entity_marker": "In these cells, [E1]AVP[/E1] also causes the translocation of [E2]PKC[/E2] from the cytosol to the cell membrane which is maximal at 5 min, but the intracellular events distal to protein kinase C activation that underlie ACTH secretion have not been well characterized to date", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "AVP", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PKC", "entity_2_idx": [[53, 56]], "entity_2_idx_in_text_with_entity_marker": [66, 69], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d105.s244_IEPA.d105.s244.p0", "text": "The deduced consensus closely resembled gibberellin response elements in alpha-amylase promoters", "text_with_entity_marker": "The deduced consensus closely resembled [E1]gibberellin[/E1] response elements in [E2]alpha-amylase[/E2] promoters", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "gibberellin", "entity_1_idx": [[40, 51]], "entity_1_idx_in_text_with_entity_marker": [44, 55], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "alpha-amylase", "entity_2_idx": [[73, 86]], "entity_2_idx_in_text_with_entity_marker": [86, 99], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d129.s307_IEPA.d129.s307.p0", "text": "Sympathetic inhibition, leptin, and uncoupling protein subtype expression in normal fasting rats", "text_with_entity_marker": "Sympathetic inhibition, [E1]leptin[/E1], and [E2]uncoupling protein[/E2] subtype expression in normal fasting rats", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[24, 30]], "entity_1_idx_in_text_with_entity_marker": [28, 34], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "uncoupling protein", "entity_2_idx": [[36, 54]], "entity_2_idx_in_text_with_entity_marker": [49, 67], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d129.s308_IEPA.d129.s308.p0", "text": "To further investigate neural effects on leptin and uncoupling proteins (UCPs), we studied in vivo perturbations intended to block adrenergic input to peripheral tissues", "text_with_entity_marker": "To further investigate neural effects on [E1]leptin[/E1] and [E2]uncoupling proteins[/E2] (UCPs), we studied in vivo perturbations intended to block adrenergic input to peripheral tissues", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[41, 47]], "entity_1_idx_in_text_with_entity_marker": [45, 51], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "uncoupling proteins", "entity_2_idx": [[52, 71]], "entity_2_idx_in_text_with_entity_marker": [65, 84], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d129.s309_IEPA.d129.s309.p0", "text": "We examined plasma leptin, leptin mRNA, and adipose and muscle UCP subtype mRNA in rats treated with alpha-methyl-p-tyrosine methyl ester (AMPT-ME), which inhibits catecholamine synthesis and 6-hydroxydopamine (6HDA), which is toxic to catecholinergic nerve terminals but, unlike AMPT-ME, does not enter the central nervous system", "text_with_entity_marker": "We examined plasma [E1]leptin[/E1], [E2]leptin[/E2] mRNA, and adipose and muscle UCP subtype mRNA in rats treated with alpha-methyl-p-tyrosine methyl ester (AMPT-ME), which inhibits catecholamine synthesis and 6-hydroxydopamine (6HDA), which is toxic to catecholinergic nerve terminals but, unlike AMPT-ME, does not enter the central nervous system", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[19, 25]], "entity_1_idx_in_text_with_entity_marker": [23, 29], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[27, 33]], "entity_2_idx_in_text_with_entity_marker": [40, 46], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d129.s309_IEPA.d129.s309.p1", "text": "We examined plasma leptin, leptin mRNA, and adipose and muscle UCP subtype mRNA in rats treated with alpha-methyl-p-tyrosine methyl ester (AMPT-ME), which inhibits catecholamine synthesis and 6-hydroxydopamine (6HDA), which is toxic to catecholinergic nerve terminals but, unlike AMPT-ME, does not enter the central nervous system", "text_with_entity_marker": "We examined plasma leptin, [E1]leptin[/E1] mRNA, and adipose and muscle [E2]UCP[/E2] subtype mRNA in rats treated with alpha-methyl-p-tyrosine methyl ester (AMPT-ME), which inhibits catecholamine synthesis and 6-hydroxydopamine (6HDA), which is toxic to catecholinergic nerve terminals but, unlike AMPT-ME, does not enter the central nervous system", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[27, 33]], "entity_1_idx_in_text_with_entity_marker": [31, 37], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP", "entity_2_idx": [[63, 66]], "entity_2_idx_in_text_with_entity_marker": [76, 79], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d129.s309_IEPA.d129.s309.p2", "text": "We examined plasma leptin, leptin mRNA, and adipose and muscle UCP subtype mRNA in rats treated with alpha-methyl-p-tyrosine methyl ester (AMPT-ME), which inhibits catecholamine synthesis and 6-hydroxydopamine (6HDA), which is toxic to catecholinergic nerve terminals but, unlike AMPT-ME, does not enter the central nervous system", "text_with_entity_marker": "We examined plasma [E1]leptin[/E1], leptin mRNA, and adipose and muscle [E2]UCP[/E2] subtype mRNA in rats treated with alpha-methyl-p-tyrosine methyl ester (AMPT-ME), which inhibits catecholamine synthesis and 6-hydroxydopamine (6HDA), which is toxic to catecholinergic nerve terminals but, unlike AMPT-ME, does not enter the central nervous system", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[19, 25]], "entity_1_idx_in_text_with_entity_marker": [23, 29], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP", "entity_2_idx": [[63, 66]], "entity_2_idx_in_text_with_entity_marker": [76, 79], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d129.s310_IEPA.d129.s310.p0", "text": "Intraperitoneal 6HDA, 100 mg/kg, as a single dose at 1800, increased plasma leptin approximately twofold after 18-20 h, increased IBAT (but not epididymal fat) leptin mRNA by two- to threefold, and decreased IBAT UCP-3 mRNA to 30-40% of control", "text_with_entity_marker": "Intraperitoneal 6HDA, 100 mg/kg, as a single dose at 1800, increased plasma [E1]leptin[/E1] approximately twofold after 18-20 h, increased IBAT (but not epididymal fat) [E2]leptin[/E2] mRNA by two- to threefold, and decreased IBAT UCP-3 mRNA to 30-40% of control", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[76, 82]], "entity_1_idx_in_text_with_entity_marker": [80, 86], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[160, 166]], "entity_2_idx_in_text_with_entity_marker": [173, 179], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d129.s310_IEPA.d129.s310.p1", "text": "Intraperitoneal 6HDA, 100 mg/kg, as a single dose at 1800, increased plasma leptin approximately twofold after 18-20 h, increased IBAT (but not epididymal fat) leptin mRNA by two- to threefold, and decreased IBAT UCP-3 mRNA to 30-40% of control", "text_with_entity_marker": "Intraperitoneal 6HDA, 100 mg/kg, as a single dose at 1800, increased plasma [E1]leptin[/E1] approximately twofold after 18-20 h, increased IBAT (but not epididymal fat) leptin mRNA by two- to threefold, and decreased IBAT [E2]UCP-3[/E2] mRNA to 30-40% of control", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[76, 82]], "entity_1_idx_in_text_with_entity_marker": [80, 86], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP-3", "entity_2_idx": [[213, 218]], "entity_2_idx_in_text_with_entity_marker": [226, 231], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d129.s310_IEPA.d129.s310.p2", "text": "Intraperitoneal 6HDA, 100 mg/kg, as a single dose at 1800, increased plasma leptin approximately twofold after 18-20 h, increased IBAT (but not epididymal fat) leptin mRNA by two- to threefold, and decreased IBAT UCP-3 mRNA to 30-40% of control", "text_with_entity_marker": "Intraperitoneal 6HDA, 100 mg/kg, as a single dose at 1800, increased plasma leptin approximately twofold after 18-20 h, increased IBAT (but not epididymal fat) [E1]leptin[/E1] mRNA by two- to threefold, and decreased IBAT [E2]UCP-3[/E2] mRNA to 30-40% of control", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[160, 166]], "entity_1_idx_in_text_with_entity_marker": [164, 170], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCP-3", "entity_2_idx": [[213, 218]], "entity_2_idx_in_text_with_entity_marker": [226, 231], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d129.s311_IEPA.d129.s311.p0", "text": "However, the in vivo modulation of leptin and UCPs appears complex and, beyond a causal effect of SNA per se, may depend on concurrent changes in plasma insulin, glucose, and circulatory hemodynamics", "text_with_entity_marker": "However, the in vivo modulation of [E1]leptin[/E1] and [E2]UCPs[/E2] appears complex and, beyond a causal effect of SNA per se, may depend on concurrent changes in plasma insulin, glucose, and circulatory hemodynamics", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[35, 41]], "entity_1_idx_in_text_with_entity_marker": [39, 45], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "UCPs", "entity_2_idx": [[46, 50]], "entity_2_idx_in_text_with_entity_marker": [59, 63], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d184.s441_IEPA.d184.s441.p0", "text": "These results suggest that T3 may increase UCP family expression independent of leptin action", "text_with_entity_marker": "These results suggest that T3 may increase [E1]UCP[/E1] family expression independent of [E2]leptin[/E2] action", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "UCP", "entity_1_idx": [[43, 46]], "entity_1_idx_in_text_with_entity_marker": [47, 50], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "leptin", "entity_2_idx": [[80, 86]], "entity_2_idx_in_text_with_entity_marker": [93, 99], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d75.s179_IEPA.d75.s179.p0", "text": "Concurrent decrease of vasopressin and protein kinase Calpha immunoreactivity during the light phase in the vole suprachiasmatic nucleus", "text_with_entity_marker": "Concurrent decrease of [E1]vasopressin[/E1] and [E2]protein kinase Calpha[/E2] immunoreactivity during the light phase in the vole suprachiasmatic nucleus", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "vasopressin", "entity_1_idx": [[23, 34]], "entity_1_idx_in_text_with_entity_marker": [27, 38], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase Calpha", "entity_2_idx": [[39, 60]], "entity_2_idx_in_text_with_entity_marker": [52, 73], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d75.s180_IEPA.d75.s180.p0", "text": "Mean numbers of AVP- and protein kinase Calpha-immunoreactive neurons were determined in the suprachiasmatic nucleus of common voles, entrained to a 12:12 h light-dark (LD) cycle, at the beginning of the light period (zeitgeber time zero) and 6 h later (zeitgeber time six)", "text_with_entity_marker": "Mean numbers of [E1]AVP[/E1]- and [E2]protein kinase Calpha[/E2]-immunoreactive neurons were determined in the suprachiasmatic nucleus of common voles, entrained to a 12:12 h light-dark (LD) cycle, at the beginning of the light period (zeitgeber time zero) and 6 h later (zeitgeber time six)", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AVP", "entity_1_idx": [[16, 19]], "entity_1_idx_in_text_with_entity_marker": [20, 23], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase Calpha", "entity_2_idx": [[25, 46]], "entity_2_idx_in_text_with_entity_marker": [38, 59], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d75.s181_IEPA.d75.s181.p0", "text": "At zeitgeber time zero, mean numbers of AVP- and protein kinase Calpha- immunoreactive neurons were 2194 and 9897, respectively", "text_with_entity_marker": "At zeitgeber time zero, mean numbers of [E1]AVP[/E1]- and [E2]protein kinase Calpha[/E2]- immunoreactive neurons were 2194 and 9897, respectively", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "AVP", "entity_1_idx": [[40, 43]], "entity_1_idx_in_text_with_entity_marker": [44, 47], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "protein kinase Calpha", "entity_2_idx": [[49, 70]], "entity_2_idx_in_text_with_entity_marker": [62, 83], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d145.s347_IEPA.d145.s347.p0", "text": "The effects of full-length amyloid beta protein, A(beta) (1-40), on phosphoinositide-specific phospholipase C (PLC) were investigated in synaptic plasma membranes (SPM) and cytosol prepared from the cerebral cortex of adult rats", "text_with_entity_marker": "The effects of full-length [E1]amyloid[/E1] beta protein, A(beta) (1-40), on phosphoinositide-specific [E2]phospholipase C[/E2] (PLC) were investigated in synaptic plasma membranes (SPM) and cytosol prepared from the cerebral cortex of adult rats", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "amyloid", "entity_1_idx": [[27, 34]], "entity_1_idx_in_text_with_entity_marker": [31, 38], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "phospholipase C", "entity_2_idx": [[94, 109]], "entity_2_idx_in_text_with_entity_marker": [107, 122], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d145.s348_IEPA.d145.s348.p0", "text": "Aggregated A(beta) also decreased significantly the level of diacylglycerol, the product of PLC", "text_with_entity_marker": "Aggregated [E1]A(beta)[/E1] also decreased significantly the level of diacylglycerol, the product of [E2]PLC[/E2]", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "A(beta)", "entity_1_idx": [[11, 18]], "entity_1_idx_in_text_with_entity_marker": [15, 22], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "PLC", "entity_2_idx": [[92, 95]], "entity_2_idx_in_text_with_entity_marker": [105, 108], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d138.s327_IEPA.d138.s327.p0", "text": "Insulin-like signaling in yeast: modulation of protein phosphatase 2A, protein kinase A, cAMP-specific phosphodiesterase, and glycosyl-phosphatidylinositol-specific phospholipase C activities", "text_with_entity_marker": "[E1]Insulin[/E1]-like signaling in yeast: modulation of protein phosphatase 2A, protein kinase A, cAMP-specific phosphodiesterase, and glycosyl-phosphatidylinositol-specific [E2]phospholipase C[/E2] activities", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "Insulin", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "phospholipase C", "entity_2_idx": [[165, 180]], "entity_2_idx_in_text_with_entity_marker": [178, 193], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d138.s330_IEPA.d138.s330.p0", "text": "As the GPI-PLC reaction is rate limiting, the efficiency of the two-step anchor cleavage was significantly increased when insulin was present together with glucose as compared to glucose alone", "text_with_entity_marker": "As the [E1]GPI-PLC[/E1] reaction is rate limiting, the efficiency of the two-step anchor cleavage was significantly increased when [E2]insulin[/E2] was present together with glucose as compared to glucose alone", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "GPI-PLC", "entity_1_idx": [[7, 14]], "entity_1_idx_in_text_with_entity_marker": [11, 18], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[122, 129]], "entity_2_idx_in_text_with_entity_marker": [135, 142], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d165.s398_IEPA.d165.s398.p0", "text": "The aim of the current investigations was focused on the study of the involvement of leptin and neuropeptide Y in lipid mobilization", "text_with_entity_marker": "The aim of the current investigations was focused on the study of the involvement of [E1]leptin[/E1] and [E2]neuropeptide Y[/E2] in lipid mobilization", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[85, 91]], "entity_1_idx_in_text_with_entity_marker": [89, 95], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "neuropeptide Y", "entity_2_idx": [[96, 110]], "entity_2_idx_in_text_with_entity_marker": [109, 123], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d165.s399_IEPA.d165.s399.p0", "text": "The lipolytic rate was assessed through glycerol release after incubation with leptin and NPY at concentrations ranging from 10(-6) to 10(-12) M in isolated adipocytes obtained from female rats", "text_with_entity_marker": "The lipolytic rate was assessed through glycerol release after incubation with [E1]leptin[/E1] and [E2]NPY[/E2] at concentrations ranging from 10(-6) to 10(-12) M in isolated adipocytes obtained from female rats", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[79, 85]], "entity_1_idx_in_text_with_entity_marker": [83, 89], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "NPY", "entity_2_idx": [[90, 93]], "entity_2_idx_in_text_with_entity_marker": [103, 106], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d165.s400_IEPA.d165.s400.p0", "text": "At equimolar concentrations of leptin and NPY (10(-12) to 10(-6) M) the observed lipolytic activity is comparable to the basal lipolytic activity, except at a concentration of 10(-9) M where upon a significant increase in lipolysis is observed", "text_with_entity_marker": "At equimolar concentrations of [E1]leptin[/E1] and [E2]NPY[/E2] (10(-12) to 10(-6) M) the observed lipolytic activity is comparable to the basal lipolytic activity, except at a concentration of 10(-9) M where upon a significant increase in lipolysis is observed", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "leptin", "entity_1_idx": [[31, 37]], "entity_1_idx_in_text_with_entity_marker": [35, 41], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "NPY", "entity_2_idx": [[42, 45]], "entity_2_idx_in_text_with_entity_marker": [55, 58], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d101.s240_IEPA.d101.s240.p0", "text": "The two groups were similar in their morning thyroxin, triiodothyronine, TSH, estradiol, cortisol, gastrin, cholecystokinin, somatostatin, oxytocin, insulin and IGF-1 levels", "text_with_entity_marker": "The two groups were similar in their morning thyroxin, triiodothyronine, TSH, estradiol, cortisol, gastrin, cholecystokinin, somatostatin, [E1]oxytocin[/E1], [E2]insulin[/E2] and IGF-1 levels", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "oxytocin", "entity_1_idx": [[139, 147]], "entity_1_idx_in_text_with_entity_marker": [143, 151], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "insulin", "entity_2_idx": [[149, 156]], "entity_2_idx_in_text_with_entity_marker": [162, 169], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d104.s243_IEPA.d104.s243.p0", "text": "In addition, abscisic acid-mediated inhibition of gibberellin-stimulated responses seems to depend on the activation of a phospholipase D during induction of alpha-amylase in barley aleurone cells as well as on a putative acetyltransferase involved in elongation growth.", "text_with_entity_marker": "In addition, abscisic acid-mediated inhibition of [E1]gibberellin[/E1]-stimulated responses seems to depend on the activation of a phospholipase D during induction of [E2]alpha-amylase[/E2] in barley aleurone cells as well as on a putative acetyltransferase involved in elongation growth.", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "gibberellin", "entity_1_idx": [[50, 61]], "entity_1_idx_in_text_with_entity_marker": [54, 65], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "alpha-amylase", "entity_2_idx": [[158, 171]], "entity_2_idx_in_text_with_entity_marker": [171, 184], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "IEPA.d29.s61_IEPA.d29.s61.p0", "text": "This action of beta-amyloid 25-35 is not altered by pretreatment with the calcium channel blockers nifedipine or cobalt, with the depleter of intracellular calcium stores cyclopiazonic acid, or with the phospholipase C inhibitor neomycin", "text_with_entity_marker": "This action of [E1]beta-amyloid[/E1] 25-35 is not altered by pretreatment with the calcium channel blockers nifedipine or cobalt, with the depleter of intracellular calcium stores cyclopiazonic acid, or with the [E2]phospholipase C[/E2] inhibitor neomycin", "relation": [{"relation_type": "negative", "relation_id": 2, "entity_1": "beta-amyloid", "entity_1_idx": [[15, 27]], "entity_1_idx_in_text_with_entity_marker": [19, 31], "entity_1_type": "no-type", "entity_1_type_id": 0, "entity_2": "phospholipase C", "entity_2_idx": [[203, 218]], "entity_2_idx_in_text_with_entity_marker": [216, 231], "entity_2_type": "no-type", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "LLL.d28.s0_LLL.d28.s0.p0", "text": "Primer extension experiments and Northern blot analysis show that an active sigmaA-dependent promoter precedes kdgR and transcription is terminated at the putative p-independent terminator downstream of kdgT.", "text_with_entity_marker": "Primer extension experiments and Northern blot analysis show that an active [E1]sigmaA[/E1]-dependent promoter precedes [E2]kdgR[/E2] and transcription is terminated at the putative p-independent terminator downstream of kdgT.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sigmaA", "entity_1_idx": [[76, 82]], "entity_1_idx_in_text_with_entity_marker": [80, 86], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "kdgR", "entity_2_idx": [[111, 115]], "entity_2_idx_in_text_with_entity_marker": [124, 128], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d19.s0_LLL.d19.s0.p0", "text": "sspG transcription also requires the DNA binding protein GerE.", "text_with_entity_marker": "[E1]sspG[/E1] transcription also requires the DNA binding protein [E2]GerE[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sspG", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "target", "entity_1_type_id": 1, "entity_2": "GerE", "entity_2_idx": [[57, 61]], "entity_2_idx_in_text_with_entity_marker": [70, 74], "entity_2_type": "agent", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "LLL.d19.s1_LLL.d19.s1.p0", "text": "In contrast, sspJ is transcribed in the forespore compartment by RNA polymerase with the forespore-specific sigmaG and appears to give a monocistronic transcript.", "text_with_entity_marker": "In contrast, [E1]sspJ[/E1] is transcribed in the forespore compartment by RNA polymerase with the forespore-specific [E2]sigmaG[/E2] and appears to give a monocistronic transcript.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sspJ", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "target", "entity_1_type_id": 1, "entity_2": "sigmaG", "entity_2_idx": [[108, 114]], "entity_2_idx_in_text_with_entity_marker": [121, 127], "entity_2_type": "agent", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "LLL.d16.s0_LLL.d16.s0.p0", "text": "(i) The finding that the bmrUR operon is under sigmaB control indicates that the elimination of multidrug compounds might be a new function in multiple stress resistance.", "text_with_entity_marker": "(i) The finding that the [E1]bmrUR[/E1] operon is under [E2]sigmaB[/E2] control indicates that the elimination of multidrug compounds might be a new function in multiple stress resistance.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "bmrUR", "entity_1_idx": [[25, 30]], "entity_1_idx_in_text_with_entity_marker": [29, 34], "entity_1_type": "target", "entity_1_type_id": 1, "entity_2": "sigmaB", "entity_2_idx": [[47, 53]], "entity_2_idx_in_text_with_entity_marker": [60, 66], "entity_2_type": "agent", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "LLL.d16.s1_LLL.d16.s1.p0", "text": "The ydaP gene might belong to the increasing number of sigmaB-dependent genes whose orthologues are under the control of sigmas in Escherichia coli, indicating that both regulons may fulfil similar functions.", "text_with_entity_marker": "The [E1]ydaP[/E1] gene might belong to the increasing number of [E2]sigmaB[/E2]-dependent genes whose orthologues are under the control of sigmas in Escherichia coli, indicating that both regulons may fulfil similar functions.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "ydaP", "entity_1_idx": [[4, 8]], "entity_1_idx_in_text_with_entity_marker": [8, 12], "entity_1_type": "target", "entity_1_type_id": 1, "entity_2": "sigmaB", "entity_2_idx": [[55, 61]], "entity_2_idx_in_text_with_entity_marker": [68, 74], "entity_2_type": "agent", "entity_2_type_id": 0}], "directed": false, "reverse": false}
{"id": "LLL.d16.s2_LLL.d16.s2.p0", "text": "Three new sigmaB-dependent genes (ydaE, ydaG and yfkM) encoding proteins with still unknown functions were also described.", "text_with_entity_marker": "Three new [E1]sigmaB[/E1]-dependent genes ([E2]ydaE[/E2], ydaG and yfkM) encoding proteins with still unknown functions were also described.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sigmaB", "entity_1_idx": [[10, 16]], "entity_1_idx_in_text_with_entity_marker": [14, 20], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "ydaE", "entity_2_idx": [[34, 38]], "entity_2_idx_in_text_with_entity_marker": [47, 51], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d16.s2_LLL.d16.s2.p1", "text": "Three new sigmaB-dependent genes (ydaE, ydaG and yfkM) encoding proteins with still unknown functions were also described.", "text_with_entity_marker": "Three new [E1]sigmaB[/E1]-dependent genes (ydaE, [E2]ydaG[/E2] and yfkM) encoding proteins with still unknown functions were also described.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sigmaB", "entity_1_idx": [[10, 16]], "entity_1_idx_in_text_with_entity_marker": [14, 20], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "ydaG", "entity_2_idx": [[40, 44]], "entity_2_idx_in_text_with_entity_marker": [53, 57], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d16.s2_LLL.d16.s2.p2", "text": "Three new sigmaB-dependent genes (ydaE, ydaG and yfkM) encoding proteins with still unknown functions were also described.", "text_with_entity_marker": "Three new [E1]sigmaB[/E1]-dependent genes (ydaE, ydaG and [E2]yfkM[/E2]) encoding proteins with still unknown functions were also described.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sigmaB", "entity_1_idx": [[10, 16]], "entity_1_idx_in_text_with_entity_marker": [14, 20], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "yfkM", "entity_2_idx": [[49, 53]], "entity_2_idx_in_text_with_entity_marker": [62, 66], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d44.s0_LLL.d44.s0.p0", "text": "The sigma W regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase (YteI), flotillin (YuaG), ABC transporters (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "text_with_entity_marker": "The [E1]sigma W[/E1] regulon includes a penicillin binding protein ([E2]PBP4*[/E2]) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase (YteI), flotillin (YuaG), ABC transporters (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sigma W", "entity_1_idx": [[4, 11]], "entity_1_idx_in_text_with_entity_marker": [8, 15], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "PBP4*", "entity_2_idx": [[59, 64]], "entity_2_idx_in_text_with_entity_marker": [72, 77], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d44.s0_LLL.d44.s0.p1", "text": "The sigma W regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase (YteI), flotillin (YuaG), ABC transporters (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "text_with_entity_marker": "The [E1]sigma W[/E1] regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase ([E2]RacX[/E2]), homologues of signal peptide peptidase (YteI), flotillin (YuaG), ABC transporters (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sigma W", "entity_1_idx": [[4, 11]], "entity_1_idx_in_text_with_entity_marker": [8, 15], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "RacX", "entity_2_idx": [[108, 112]], "entity_2_idx_in_text_with_entity_marker": [121, 125], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d44.s0_LLL.d44.s0.p2", "text": "The sigma W regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase (YteI), flotillin (YuaG), ABC transporters (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "text_with_entity_marker": "The [E1]sigma W[/E1] regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase ([E2]YteI[/E2]), flotillin (YuaG), ABC transporters (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sigma W", "entity_1_idx": [[4, 11]], "entity_1_idx_in_text_with_entity_marker": [8, 15], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "YteI", "entity_2_idx": [[155, 159]], "entity_2_idx_in_text_with_entity_marker": [168, 172], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d44.s0_LLL.d44.s0.p3", "text": "The sigma W regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase (YteI), flotillin (YuaG), ABC transporters (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "text_with_entity_marker": "The [E1]sigma W[/E1] regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase (YteI), flotillin ([E2]YuaG[/E2]), ABC transporters (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sigma W", "entity_1_idx": [[4, 11]], "entity_1_idx_in_text_with_entity_marker": [8, 15], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "YuaG", "entity_2_idx": [[173, 177]], "entity_2_idx_in_text_with_entity_marker": [186, 190], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d44.s0_LLL.d44.s0.p4", "text": "The sigma W regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase (YteI), flotillin (YuaG), ABC transporters (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "text_with_entity_marker": "The [E1]sigma W[/E1] regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase (YteI), flotillin (YuaG), ABC transporters ([E2]YknXYZ[/E2]), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sigma W", "entity_1_idx": [[4, 11]], "entity_1_idx_in_text_with_entity_marker": [8, 15], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "YknXYZ", "entity_2_idx": [[198, 204]], "entity_2_idx_in_text_with_entity_marker": [211, 217], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d44.s0_LLL.d44.s0.p5", "text": "The sigma W regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase (YteI), flotillin (YuaG), ABC transporters (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "text_with_entity_marker": "The [E1]sigma W[/E1] regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase (YteI), flotillin (YuaG), ABC transporters (YknXYZ), non-haem bromoperoxidase ([E2]YdjP[/E2]), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sigma W", "entity_1_idx": [[4, 11]], "entity_1_idx_in_text_with_entity_marker": [8, 15], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "YdjP", "entity_2_idx": [[233, 237]], "entity_2_idx_in_text_with_entity_marker": [246, 250], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d44.s0_LLL.d44.s0.p6", "text": "The sigma W regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase (YteI), flotillin (YuaG), ABC transporters (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "text_with_entity_marker": "The [E1]sigma W[/E1] regulon includes a penicillin binding protein (PBP4*) and a co-transcribed amino acid racemase (RacX), homologues of signal peptide peptidase (YteI), flotillin (YuaG), ABC transporters (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase ([E2]YfhM[/E2]) and three small peptides with structural similarities to bacteriocin precursor polypeptides.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sigma W", "entity_1_idx": [[4, 11]], "entity_1_idx_in_text_with_entity_marker": [8, 15], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "YfhM", "entity_2_idx": [[259, 263]], "entity_2_idx_in_text_with_entity_marker": [272, 276], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d7.s0_LLL.d7.s0.p1", "text": "Expression of the sigma(K)-dependent cwlH gene depended on gerE.", "text_with_entity_marker": "Expression of the [E1]sigma(K)[/E1]-dependent [E2]cwlH[/E2] gene depended on gerE.", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "sigma(K)", "entity_1_idx": [[18, 26]], "entity_1_idx_in_text_with_entity_marker": [22, 30], "entity_1_type": "agent", "entity_1_type_id": 0, "entity_2": "cwlH", "entity_2_idx": [[37, 41]], "entity_2_idx_in_text_with_entity_marker": [50, 54], "entity_2_type": "target", "entity_2_type_id": 1}], "directed": false, "reverse": false}
{"id": "LLL.d7.s0_LLL.d7.s0.p2", "text": "Expression of the sigma(K)-dependent cwlH gene depended on gerE.", "text_with_entity_marker": "Expression of the sigma(K)-dependent [E1]cwlH[/E1] gene depended on [E2]gerE[/E2].", "relation": [{"relation_type": "enzyme", "relation_id": 0, "entity_1": "cwlH", "entity_1_idx": [[37, 41]], "entity_1_idx_in_text_with_entity_marker": [41, 45], "entity_1_type": "target", "entity_1_type_id": 1, "entity_2": "gerE", "entity_2_idx": [[59, 63]], "entity_2_idx_in_text_with_entity_marker": [72, 76], "entity_2_type": "agent", "entity_2_type_id": 0}], "directed": false, "reverse": false}
